Compositions with improved SPF and UVA photoprotection

Abstract

The present invention relates to sunscreen products, cosmetic and pharmaceutical formulations or home care products with UVA and / or UVB protection comprising an organic UV filter and certain mycosporine-like amino acid compounds. The products and formulations provide improved SPF performance and UVA photoprotection. In addition, the products and formulations according to the invention provide a broad spectrum of photoprotection against UV radiation. In addition, the present invention relates to the use of such mycosporine-like amino acid compounds for promoting SPF and UVA photoprotection of sunscreen products, cosmetic or pharmaceutical formulations or home care products comprising organic UV filters. Furthermore, the present invention relates to a method of enhancing the SPF and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical formulation or a home care product comprising an organic UV filter by adding a certain kind of mycosporine amino acid compounds. Finally, the invention relates to a method for providing anti-aging benefits to the skin, whitening the skin or preventing the blackening of the skin, improving the appearance of the skin, reducing the visible signs of skin aging and improving the gloss and compactness of the skin by topically applying the sunscreen product or cosmetic or pharmaceutical formulation according to the invention to the skin.

Description

Technical Field

[0001] The present invention relates to sunscreen products, cosmetic and pharmaceutical preparations or home care products with UVA and / or UVB protection, which contain organic UV filters and certain mycosporin-like amino acid compounds. The products and preparations provide improved SPF performance and UVA light protection. In addition, the products and preparations according to the present invention provide broad-spectrum light protection against UV radiation. In addition, the present invention relates to the use of such mycosporin-like amino acid compounds for boosting the SPF and UVA light protection of sunscreen products, cosmetic or pharmaceutical preparations or home care products containing organic UV filters. In addition, the present invention relates to a method for enhancing the SPF and UVA light protection of sunscreen products, cosmetic or pharmaceutical preparations or home care products containing organic UV filters by adding certain mycosporin-like amino acid compounds. Finally, the present invention relates to a method for providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin by topically applying the sunscreen product or cosmetic or pharmaceutical preparation according to the present invention to the skin. Background Art

[0002] The negative effects of exposure to UV light are well known. Prolonged exposure to sunlight can cause damage to the skin, such as sun spots, and dry out hair, making it brittle. When the skin is exposed to UV light with a wavelength of 290nm to 400nm, long-term damage can lead to serious conditions such as skin cancer, and the type of damage depends on the wavelength of the radiation.

[0003] Sunlight includes two types of UV rays: long-wave ultraviolet A (UVA: wavelength 320nm to 400nm) and short-wave ultraviolet B (UVB: wavelength 280nm to 320nm). UVA is further divided into two wavelength ranges, namely UVA1 (340nm to 400nm) and UVA2 (320nm to 340nm).

[0004] UVA rays make up the majority (95%) of UV radiation. They have a longer wavelength than UVB and UVC rays, which means they have less energy (shorter wavelengths have more energy than longer wavelengths). Due to their longer wavelengths, they can penetrate into the dermis, which is primarily made up of collagen. When UVA rays are absorbed by the skin, they produce free radicals that can damage cells and DNA and break down collagen. This is why UVA rays are highly associated with premature aging. Skin damage caused by UVA radiation accelerates the appearance of aging, such as loss of skin elasticity and the appearance of wrinkles. This process is often referred to as photoaging. As the skin ages, the outer skin layer (epidermis) becomes thinner, even though the number of cells remains largely unchanged. However, the number of pigment-containing cells (melanocytes) decreases. As a result, the skin looks pale and translucent. Large pigment spots (age spots, liver spots, or freckles) may appear in areas exposed to the sun. Changes in connective tissue reduce the strength and elasticity of the skin, which becomes more noticeable in areas exposed to the sun (solar elastosis). Elastosis produces the leathery, weathered appearance common to farmers and sailors who spend a lot of time outdoors. In addition, UVA radiation can trigger phototoxic or photoallergic skin reactions.

[0005] UVB rays make up less than 5% of UV radiation and, due to their shorter wavelength, can only penetrate the epidermis. Here they are directly absorbed by DNA and melamine and can cause genetic mutations which, if not corrected by the cells' natural defenses, can lead to rapid proliferation of mutated cells and ultimately skin cancer. The damage caused by UVB rays can be seen almost immediately in the form of sun spots, which are an inflammatory response to skin damage.

[0006] UVC rays are by far the most damaging of the three types of UV rays. However, due to their short wavelength, they are completely absorbed by the atmosphere and therefore cannot reach our skin.

[0007] In order to attenuate these negative effects of UV radiation, ie for the purpose of protecting the skin and keratin materials from UV radiation, use is generally made of sunscreen compositions which contain screening agents active in the UVA range and in the UVB range, ie over the entire range from 280 nm to 400 nm.

[0008] UV filters are compounds with a pronounced absorption capacity for ultraviolet radiation. They are used, inter alia, in sunscreen products, cosmetic, dermatological or pharmacological preparations or household care products, but also for improving the light fastness of industrial products such as paints, varnishes, plastics, textiles, polymers such as, for example, polymers and copolymers of mono- and diolefins, polystyrenes, polyurethanes, polyamides, polyesters, polyureas and polycarbonates, packaging materials and rubbers.

[0009] UV filters are divided into UVA filters and UVB filters depending on the position of their absorption maximum; if a UV filter absorbs both UVA and UVB, it is called a UVA / UVB broadband absorber or UVA / UVB broadband filter.

[0010] In order to achieve the desired maximum protection against UV radiation, sunscreen products or cosmetics, especially dermatological and pharmacological preparations, are formulated as mixtures containing UV filters with different concentrations, and the choice of the UV filters used is determined by the regulations in the country or economic region. For example, UV filters that can be used to protect the skin are regulated in the United States by the US FDA via its OTC monograph system and in the European Union by cosmetic regulations. Regulations covering the use of UV filters also exist in other countries and regions. These regulations not only specify the filters that can be used, but also determine the maximum use level of each UV filter.

[0011] In order to achieve broad-spectrum UV protection, sunscreen formulations usually contain a combination of several organic UV filters, which may be supplemented with inorganic UV filters in order to increase the efficacy.

[0012] However, the use of organic UV filters is subject to increasing concern, since they are suspected to be a possible cause of skin irritation and allergies in sensitive persons as well as their potential harmful effects on the environment. Furthermore, some organic UV filters suffer from photostability.

[0013] The number of known UVA filters and specifically approved UVA filters is small, and therefore products are limited in the UVA filters that can be used to provide broad spectrum protection.

[0014] Therefore, there is still a continuing need to provide further substances which improve the SPF properties and UVA photoprotection of sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising organic UV filters.

[0015] It is therefore an object of the present invention to provide sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising organic UV filters with UVA and / or UVB protection, which exhibit improved SPF performance as well as improved UVA photoprotection. Ideally, the sunscreen products, cosmetic or pharmaceutical preparations or home care products provide improved UV filter performance, in particular UVA photoprotection, and thus may allow a reduction in the amount of organic UV filters without affecting the envisaged SPF.

[0016] Another object of the present invention is to provide the use of substances for boosting SPF performance and UVA photoprotection in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising organic UV filters.

[0017] It is a further object of the present invention to provide a method for enhancing or boosting the SPF performance and UVA photoprotection in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising organic UV filters.

[0018] It is a further object of the present invention to provide a method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin via a sunscreen product or a cosmetic or pharmaceutical formulation comprising organic UV filters.

[0019] Surprisingly, it has been found that the SPF performance and UVA photoprotection in sunscreen products, cosmetic or pharmaceutical preparations or home care products with UVA and / or UVB protection can be significantly improved by adding certain mycosporin-like amino acid compounds.

[0020] This problem is solved by the subject matter of the independent patent claims. However, further aspects of the invention are also apparent from the wording of the dependent patent claims, from the following detailed description in conjunction with the accompanying examples and drawings. Summary of the invention

[0021] In order to achieve the above problems, the present invention provides a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product in a first aspect, which comprises or consists of the following:

[0022] (a) at least one primary organic UV filter;

[0023] (b) at least one mycosporine-like amino acid compound,

[0024] It is represented by the general formula (V)

[0025]

[0026] as defined herein, or a tautomer or stereoisomer or salt thereof;

[0027] or

[0028] Represented by the general formula (VI)

[0029]

[0030] as defined herein, or a tautomer or stereoisomer or salt thereof;

[0031] or any mixture of the above compounds.

[0032] In a second aspect, the present invention provides the use of at least one mycosporine-like amino acid compound as defined herein, or a mixture thereof, for boosting the SPF performance and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising at least one organic UV filter.

[0033] In yet another aspect, the present invention relates to a method for enhancing or boosting the SPF performance and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising at least one organic UV filter, said method comprising adding to said sunscreen product, cosmetic or pharmaceutical preparation or home care product an effective amount of a mycosporin-like amino acid compound or a mixture thereof as defined herein.

[0034] Finally, the present invention relates to a method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin by topically applying a sunscreen product or a cosmetic or pharmaceutical formulation according to the present invention to the skin or hair.

[0035] The invention is specified in the appended claims. However, the invention itself as well as its preferred variations, other objects and advantages will also be apparent from the following detailed description taken in conjunction with the accompanying examples. DETAILED DESCRIPTION

[0036] In the context of the present invention, the following general meanings apply:

[0037] As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cosmetic preparation", "the cosmetic preparation" or "a cosmetic preparation" also includes a plurality of cosmetic preparations.

[0038] The terms "comprising," "including," and "containing" should be understood as open-ended terms, and mean that the named components following the term are essential but not "limited to," and other components may be added and still be encompassed by the invention.

[0039] The term "consisting of" as used according to the present invention means that the total amount of components (a) and (b) adds up to 100 wt.-%, based on the total weight of the sunscreen product or cosmetic or pharmaceutical formulation, and indicates that the subject matter is closed and may include only the explicitly listed limitations.

[0040] Whenever "comprising" is mentioned, it is intended to encompass both meanings as alternatives, ie the meaning may be "including" or "consisting of", unless the context indicates otherwise.

[0041] The term "optionally" means that the subsequently described compound may but need not be present in the composition, and that the description includes variations in which the compound is included and variations in which the compound is not present.

[0042] The terms "or" or "and / or" are used as function words to indicate that two words or phrases are to be taken together or separately.

[0043] All range endpoints directed to the same component or property are inclusive and independently combinable.

[0044] The term "compound" or "compound of the present invention" refers to all compounds covered by structural formula (V) and / or formula (VI) and / or formula (VII) and / or formula (XIII) and / or formula (IX) and / or formula (X) and / or formula (A) and their subformulae disclosed herein, and includes each subgenus and all specific compounds whose structures are within the formulae disclosed herein.

[0045] Compounds can be identified by their chemical structure and / or chemical name. When the chemical structure and chemical name conflict, the chemical structure determines the identity of the compound.

[0046] The term "at least one ... compound" means that the food or cosmetic or pharmaceutical preparation according to the invention, in particular a sunscreen product or a home care product may contain any one of the subsequently described individual compounds or a mixture of two, three, four, five, six or even more different subsequently described compounds.

[0047] The term "effective amount of a compound" refers to an amount of a compound sufficient to achieve the desired effect or improvement.

[0048] The term "cosmetic or pharmaceutical preparation" in the context of the present invention is a composition for cosmetic or pharmaceutical purposes, which contains UV filters to protect the skin or hair from UV radiation. In addition to providing photoprotection, the cosmetic or pharmaceutical preparation according to the present invention can also be used in a method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin.

[0049] The term "sunscreen composition" or "sunscreen" or "skin care product", also known as "sun blocker", "sun cream" or "sunscreen milk", refers to any topical product that reflects and / or absorbs a certain portion of UV radiation and thus helps prevent sun spots and, most importantly, skin cancer. Therefore, the term "sunscreen composition" is to be understood as including not only sunscreen compositions, but also any cosmetic composition that provides UV protection. According to the present invention, the sunscreen composition may contain one or more active agents, such as organic UV filters, and other ingredients or additives, such as emulsifiers, emollients, viscosity regulators, stabilizers, preservatives or fragrances. Sunscreens come in the form of lotions, sprays, gels, foams (such as expanding foam lotions or whipping lotions), sticks, powders and other topical products. UV absorbing compounds are used not only in sunscreens, but also in other personal care products, such as lipsticks, shampoos, hair sprays, body washes, soaps and insect repellents.

[0050] The sunscreen product, cosmetic or pharmaceutical preparation or home care product of the present invention provides enhanced SPF performance and UVA photoprotection, as well as broad-spectrum photoprotection against UV radiation.

[0051] In the context of the present invention, the term "home care products" are necessities used in the home for daily care and cleaning purposes. They are used to maintain hygiene and a good atmosphere in the home. Home care products typically include laundry detergents (powders, liquids and tablets), fabric conditioners, dishwashing detergents (liquids and tablets), hard floor and surface cleaners, glass cleaners, carpet cleaners, oven cleaners, air fresheners, disinfectants, detergents, car wash products. These products are typically manufactured in the form of liquids, powders, sprays, granules, etc. Sunscreen-containing formulations prevent premature photodamage and photobleaching of surfaces and the home care formulations themselves.

[0052] As used herein, the term "light stabilizer" is a compound suitable for protecting body care agents and household cleaning and treatment agents from photolytic degradation.

[0053] The term "photostability" refers to the ability of a UV filter or any other molecule exposed to sunlight to remain stable under irradiation. In particular, this means that the compound does not undergo degradation processes under UV radiation.

[0054] Sun protection factor (SPF) indicates the ability of sunscreen, cosmetic or pharmaceutical preparation or home care product to prevent UVB rays, but does not fully specify the extent (if any) of sunscreen composition to prevent UVA radiation. SPF is a measure of the amount of solar energy (UV radiation) required to produce sunburn on protected skin (i.e., in the presence of sunscreen) relative to the amount of solar energy required to produce sunburn on unprotected skin. As the SPF value increases, sunburn protection increases. With and without sunscreen, an artificial UV source is used to irradiate the skin until there is erythema (minimum erythema dose-MED). Then the SPF is calculated by dividing the MED of the protected skin by the MED of the unprotected skin, i.e., how long does it take for the skin to be sunburned with and without sunscreen. In theory, this means that a sunscreen with an SPF of 50 means that it can be exposed to UV radiation 50 times longer before sunburn.

[0055] UVA photoprotection is expressed as UVA protection factor (UVA-PF). UVA-PF is similar to SPF in that it is a measure of the extent to which a sunscreen protects the skin from UVA radiation. This is done in a similar manner by irradiating the skin with UVA. This can be done in vivo with human skin or in vitro by applying the sunscreen to a PMMA plate (polymethyl methacrylate plate) and measuring how much UVA passes through a glass slide with or without the sunscreen. In order to characterize protection against UVA radiation, the PPD (persistent pigment darkening) method is used, which measures the skin color observed 2 to 4 hours after the skin is exposed to UVA radiation. The PPD method appears to correlate well with the in vitro UVA-PF test.

[0056] UVA-PF based on persistent pigmentation (PPD) is designated as “UVA PPD PF" and is mathematically represented by the ratio of the dose of UVA radiation necessary to reach the pigmentation threshold with the use of UV screeners (MPPDp) to the dose of UVA radiation necessary to reach the pigmentation threshold without the use of UV screeners (MPPDnp), as shown below:

[0057]

[0058] UVA in sunscreen products, cosmetic or pharmaceutical preparations or household care products PPD PF is usually at least 4. Use UVA PPD Skin properly treated with a cosmetic composition with a PF of 4 means that it takes about 4 times longer for the skin to darken (ie reach the threshold level of melanin) than skin not treated with a sunscreen product, cosmetic or pharmaceutical preparation or home care product.

[0059] The term "broad spectrum photoprotection" means photoprotection against both UVA and UVB radiation. Broad spectrum is based on the breadth of protection a sunscreen provides in both the UVA and UVB spectra. In order for a sunscreen to be considered broad spectrum, it must achieve a critical wavelength of at least 370 nm, meaning that 10% of the protection provided by the sunscreen must be for wavelengths above 370 nm. A critical wavelength of >370 nm is the strict minimum that a sunscreen product should achieve to be labeled "broad spectrum."

[0060] The term "critical wavelength" is defined as the wavelength at which the area under the UV protection curve (% protection vs. wavelength) accounts for 90% of the total area under the curve in the UV region (280 nm-400 nm). For example, a critical wavelength of 370 nm indicates that the protection of the sunscreen composition is not limited to wavelengths of UV-B, i.e. wavelengths of 280 nm-320 nm, but extends to 370 nm in such a way that 90% of the total area under the protection curve in the UV region is reached at 370 nm. The higher the critical wavelength, the better the protection against UV radiation.

[0061] To calculate the critical wavelength The measured spectral absorption from 190nm to 400nm is mathematically integrated to calculate the area under the absorbance curve. The critical wavelength value is based on the inherent shape and width of the absorbance curve, not its amplitude. The critical wavelength is the wavelength below which 90% of the area under the absorbance curve lies. The critical wavelength of a UVB sunscreen is smaller than that of a sunscreen that protects against both UVB and UVA. A higher critical wavelength ensures more UV protection, especially protection from longer wavelength UVA rays. For example, a sunscreen with a critical wavelength of 370nm provides more protection against UVA rays than a sunscreen with a critical wavelength of 350nm.

[0062] The combination of in vivo SPF rating and critical wavelength provides a complete description of the photoprotective properties of a product.

[0063] According to the invention, the main object of the invention is solved by a sunscreen product, a cosmetic, in particular a dermatological or pharmaceutical preparation or a home care product, which comprises or consists of:

[0064] (a) at least one primary organic UV filter; and

[0065] (b) at least one mycosporine-like amino acid compound,

[0066] It is represented by the general formula (V)

[0067]

[0068] in

[0069] -Z is selected from the group consisting of O-R2' or amide';

[0070] -R1' is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), CR7'R8', C=O, halogen, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), and unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro;

[0071] -R2' is selected from the group consisting of H, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl;

[0072] -amide' is selected from the group consisting of NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10', unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid);

[0073] -R3' is selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9'R10', and unsubstituted or substituted C-spiro;

[0074] - the substituents R4', R5' and R6', which may be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, -S(=O)2OH, sulfonyl, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9'R10', and unsubstituted or substituted C-spiro;

[0075] - R7' and R8', which may be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10';

[0076] - R9' and R10', which may be the same or different, are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, and unsubstituted or substituted heteroaryl;

[0077] -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and -R is unsubstituted or substituted alkyl;

[0078] or a tautomer or stereoisomer or salt of the above compounds;

[0079] Or represented by general formula (VI)

[0080]

[0081] in

[0082] -R1" is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, halogen, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro;

[0083] -R2" is selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -C(=O)-amide", unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted hetero Aryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro;

[0084] -X is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl),

[0085] --CR7 "R8", C=O, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro;

[0086] - the substituents R4", R5" and R6", which may be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, -S(=O)2OH, sulfonyl, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro;

[0087] - R7" and R8", which may be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9"R10";

[0088] -amide" is selected from the group consisting of NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid);

[0089] - R9" and R10", which may be the same or different, are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, and unsubstituted or substituted heteroaryl;

[0090] -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and

[0091] -R is unsubstituted or substituted alkyl;

[0092] or a tautomer or stereoisomer or salt of the above compounds;

[0093] or any mixture of the above compounds.

[0094] The sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention contain at least one primary organic UV filter (a) which provides protection against UVA and / or UVB radiation.

[0095] Organic UV filters are compounds or mixtures of compounds that block or absorb ultraviolet (UV) light. UV classification includes UVA (320nm to 400nm), UVB (290nm to 320nm) and UVC (200nm to 280nm). UV absorbing compounds are not only used in sunscreens, but also in other personal care products, such as lipsticks, shampoos, hair sprays, bath agents, soaps and insect repellents. Chemical filters prevent UV radiation by absorption, reflection or scattering. In contrast, reflection and scattering are achieved by inorganic physical UV filters, such as titanium dioxide (TiO2) and zinc oxide (ZnO). Mainly, the absorption of UVB is carried out by organic UV filters, which are called chemical UV filters.

[0096] Non-limiting examples of organic UV filters include:

[0097] (i) Sparingly soluble UV filters (not appreciably soluble in water or oil), such as methylenebis-benzotriazolyltetramethylbutylphenol, tris-biphenyltriazine, ketone, 1,1'-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl-]phenyl];

[0098] (ii) oil-soluble organic UV filters (at least partially soluble in oil or organic solvents), such as bis-ethylhexyloxyphenol methoxyphenyl triazine, butyl methoxydibenzoylmethane (BMBM), oxybenzone, sulisobenzone, diethylhexyl butyramido triazone (DBT), drometrizole trisiloxane, ethylhexyl methoxycinnamate (EHMC), ethylhexyl salicylate (EHS), ethylhexyl triazone (EHT), homosalate, isoamyl p-methoxycinnamate, 4-methylbenzylidene camphor, octocrylene (OCR), polysilicone-15 and diethylaminohydroxybenzoyl hexyl benzoate (DHHB); and

[0099] (iii) water-soluble UV filters such as phenylbenzimidazole sulfonic acid (PBSA), sulfisobenzone-sodium salt, benzadiene camphor sulfonic acid, camphor benzalkonium methylsulfate, cinoxate, disodium phenyldibenzylimidazole tetrasulfonate, terephthalylidene dicamphor sulfonic acid, PABA and PEG-25PAB; and any mixtures thereof.

[0100] According to the invention, many different organic compounds can be used as UV filters. They are divided into several structural classes:

[0101] (1) Benzophenone

[0102] a. Benzophenone-3 (BP3)

[0103] b. Benzophenone-4 (BP4)

[0104] (2) Salicylate

[0105] a. Homosalate (HMS)

[0106] b. 2-Ethylhexyl salicylate (EHS)

[0107] (3) p-Aminobenzoic acid and its derivatives

[0108] a. Dimethyl PABA ethylhexyl ester (OD-PABA)

[0109] b.4-para-aminobenzoic acid (PABA)

[0110] (4) Benzimidazole derivatives

[0111] a. Phenylbenzimidazole sulfonic acid (PMDSA)

[0112] b. Bisdisulizoledisodium

[0113] (5) Triazine

[0114] a. Ethylhexyl triazone (OT)

[0115] b. Diethylhexyl butyramido triazone (DBT)

[0116] c. Bis-ethylhexyloxyphenol methoxyphenyl triazine (EMT)

[0117] (6) Benzotriazole

[0118] a. Dromtriazole trisiloxane (DRT)

[0119] b. Methylene bis-benzotriazolyl tetramethylbutylphenol (MBP, biscotrizole)

[0120] (7) Dibenzoylmethane derivatives

[0121] a.4-tert-Butyl-4'-methoxydibenzoylmethane (BM-DBM, avobenzone)

[0122] (8) Cinnamate

[0123] a. Ethylhexyl methoxycinnamate (OMC)

[0124] b. Isoamyl p-methoxycinnamate (IMC, amiloride)

[0125] (9) Camphor derivatives

[0126] a. Terephthalidene dicamphor sulfonic acid (PDSA)

[0127] b.3-Benzalcamphor (3BC)

[0128] c. Benzylidene camphorsulfonic acid (BCSA)

[0129] d.4-Methylbenzylidene camphor (4-MBC)

[0130] e. Polyacrylamide methylbenzylidene camphor (PBC)

[0131] (10) Camphor benzalkonium methyl sulfate (CBM).

[0132] At least one primary organic UV filter (a) is selected from the group consisting of: camphor benzalkonium methylsulfate, homosalate, benzophenone-3, phenylbenzimidazole sulfonic acid, terephthalylidene dicamphor sulfonic acid, butyl methoxydibenzoylmethane, benzylidene camphor sulfonic acid, octocrylene, polyacrylamidomethyl benzylidene camphor, ethylhexyl methoxycinnamate, PEG-25 PABA, isoamyl p-methoxycinnamate, ethylhexyl triazone, drometrizole trisiloxane, diethylhexyl butamido triazone, 4-methylbenzylidene camphor, ethylhexyl salicylate, ethylhexyl dimethyl PABA, diphenylmethane Benzophenone-4, benzophenone-5, methylene bis-benzotriazolyl tetramethylbutylphenol (nano), disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, polysilicone-15, diethylamino hydroxybenzoyl hexyl benzoate, tris-biphenyl triazine (nano), phenylene bis-diphenyl triazine, methoxypropylaminocyclohexenylene ethoxyethyl cyanoacetate, bis-(diethylamino hydroxybenzoyl benzoyl) piperazine, TEA-salicylate, benzophenone-8, PABA, dimethyl PABA ethylhexyl ester, menthyl anthranilate, and any mixture thereof.

[0133] More preferably, at least one primary organic UV filter (a) is selected from the group consisting of camphor benzalkonium methylsulfate, benzophenone-3, terephthalylidene dicamphor sulfonic acid, benzylidene camphor sulfonic acid, polyacrylamide methyl benzylidene camphor, PEG-25 PABA, drometrizole trisiloxane, dimethyl PABA ethylhexyl ester, benzophenone-4, benzophenone-5, methylene bis-benzotriazolyl tetramethylbutylphenol, polysilicone-15, titanium dioxide (nano), tris-biphenyl triazine (nano), phenylene bis-diphenyl triazine, methoxypropylaminocyclohexenylene ethoxyethyl cyanoacetic acid Ester, bis-(diethylaminohydroxybenzoylbenzoyl)piperazine, benzophenone-8, ethylhexyl dimethyl PABA, homosalate, phenylbenzimidazole sulfonic acid, butyl methoxydibenzoylmethane, octocrylene, ethylhexyl methoxycinnamate, isoamyl p-methoxycinnamate, ethylhexyl triazone, diethylhexyl butamido triazone, 4-methylbenzylidene camphor, ethylhexyl salicylate, disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylaminohydroxybenzoyl hexyl benzoate, menthyl anthranilate, and any mixture thereof.

[0134] Most preferably, the at least one primary organic UV filter (a) is selected from the group consisting of homosalate, phenylbenzimidazole sulfonic acid, butyl methoxydibenzoylmethane, octocrylene, ethylhexyl methoxycinnamate, isoamyl p-methoxycinnamate, ethylhexyl triazone, diethylhexyl butyramido triazone, 4-methylbenzylidene camphor, ethylhexyl salicylate, disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylaminohydroxybenzoyl hexyl benzoate, menthyl anthranilate, and any mixtures thereof.

[0135] The aforementioned primary organic UV filters which can be used in the context of the present invention are preferred but are naturally not restrictive.

[0136] The aforementioned primary organic UV filters are used in sunscreens, cosmetic or pharmaceutical preparations or home care products as single component or in mixtures with two, three, four or more of said UV filters as specified above.

[0137] In order to optimize the SPF, i.e. to obtain a high SPF in the range of 6 to 100, preferably in the range of 6 to 70, and to cover a wide UVA and UVB range, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises at least two, more preferably at least three, most preferably at least four or even more different organic UV filters. Advantageously, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises at least one organic UVA filter and at least one organic UVB filter. Such a sunscreen product or cosmetic or pharmaceutical preparation according to the invention provides broad-spectrum photoprotection, i.e. protection against UVA and UVB.

[0138] In a preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises in combination with one or more broadband filters selected from the group consisting of 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, ethyl-2-cyano-3,3'-diphenylacrylate, dihydroxy-4-methoxybenzophenone, 2,4-dihydroxybenzophenone, tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, 2-hydroxy-4-n-octyloxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, sodium hydroxymethoxybenzophenone sulfonate, disodium 2,2'-dihydroxy-4,4'-dimethoxy-5,5 '-Disulfobenzophenone, phenol, 2-(2H-benzotriazol-2-yl)-4-methyl-6-(2-methyl-3(1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy)dimethylsiloxy)propyl), 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-1,1,3,3-tetramethylbutyl)phenol)(methylene-bis-benzotriazolyltetramethylbutylphenol), 2,4-bis-[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-1,3,5-triazine, 2,4-bis-[{(4-(2-ethylhexyloxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Aniso Triazine), 2,4-bis-[{(4-(3-sulfonic acid)-2-hydroxypropoxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine sodium salt, 2,4-bis-[{(3-(2-propoxy)-2-hydroxypropoxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}phenyl]-6-[4-(2-methoxyethylcarbonyl)phenylamino]-1,3,5-triazine, 2,4-bis-[{4-(3-(2-propoxy)-2-hydroxypropoxy)-2-hydroxy}phenyl]-6-[4-(2-ethylcarboxyl)phenylamino]-1, 3,5-triazine, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}phenyl]-6-(1-methylpyrrol-2-yl)-1,3,5-triazine, 2,4-bis-[{4-tris-(trimethylsiloxysilylpropoxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis-[{4-(2"-methylpropenyloxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis-[{4-(1',1',1',3',5',5'-heptamethylsilyloxy-2"-methylpropoxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, dioctylbutylamide triazone (INCI: Dioctylbutamidotriazone), 2,4-bis-[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)-imino]-6-(2-ethylhexyl)-imino-1,3,5-triazine, 4,4',4"-(1,3,5-triazine-2,4,6-triimino)tris-benzoic acid-tri(2-ethylhexyl) (also known as: 2,4,6-tris[anilino(p-carbon-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Octyl Triazone), 2,4,6-terphenyl-4-yl-1,3,5-triazine, 2-ethylhexyl 4-methoxycinnamate (ethylhexyl methoxycinnamate), benzoic acid, 2-hydroxy-3,3,5-trimethylcyclohexyl ester (homosalate), 2-ethylhexyl salicylate (ethylhexyl salicylate), 2-ethylhexyl 4-(dimethylamino)benzoate (dimethyl PABA ethylhexyl ester), N,N,N-trimethyl-4-(2-oxoboron-3-ylidenemethyl)aniline methylsulfate (camphor benzalkonium methylsulfate), dimethyl behenyl benzaldehyde malonate (polysilicone-15) and any mixture thereof.

[0139] Component (b) in the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the present invention is at least one mycosporin-like amino acid compound represented by the general formula (V):

[0140]

[0141] As defined herein;

[0142] Or represented by general formula (VI)

[0143]

[0144] As defined herein.

[0145] Mycosporin-like amino acids (MAAs) are small secondary metabolites produced by organisms living in environments with a lot of sunlight, usually marine environments. MAAs are imine derivatives of mycosporins and contain an aminocyclohexene imine ring attached to an amino acid, amino alcohol, or amino group. The compounds are capable of electron delocalization. In addition, the compounds exhibit antioxidant properties.

[0146] Unless otherwise indicated, in the context of the present invention, in particular for the definition of mycosporin-like amino acid compounds represented by any of the general formulae, the following general meanings apply:

[0147] According to the present invention, the term "halogen" residue / moiety or group alone or as part of another substituent refers to F, Cl, Br or I.

[0148] According to the present invention, the term "alkyl" alone or as part of another substituent refers to a saturated or monounsaturated or polyunsaturated straight or branched chain monovalent hydrocarbon radical obtained by removing a hydrogen atom from a single carbon atom of the corresponding parent alkane.

[0149] In preferred variations, the term "alkyl" also includes any alkyl moiety in radicals derived therefrom, such as alkoxy, alkylthio, alkylsulfonyl saturated straight or branched chain hydrocarbon radicals having 1 to 10, 1 to 8, 1 to 6 or 1 to 4 carbon atoms.

[0150] If the alkyl radical is further bonded to another atom, it becomes an alkylene radical or an alkylene group. In other words, the term "alkylene" also refers to a divalent straight or branched chain alkyl group. For example, -CH2CH3 is an ethyl group, while -CH2CH2- is an ethylene group.

[0151] The term "alkylene" by itself or as part of another substituent refers to a saturated straight or branched chain divalent hydrocarbon radical derived by removing two hydrogen atoms from a single carbon atom or from two different carbon atoms of a starting alkane.

[0152] In a preferred variant according to the invention, the straight-chain or branched alkyl or alkylene group contains 1 to 10 carbon atoms. In other further more preferred variants, the straight-chain or branched alkyl or alkylene group contains 1 to 6 carbon atoms.

[0153] More preferred according to the invention are saturated straight chain or branched C1-C6 alkyl groups or saturated straight chain or branched C1-C6 alkylene groups.

[0154] Most preferred are straight-chain or branched alkyl or alkylene groups having 1 to 4 carbon atoms.

[0155] Preferred alkyl radicals / moieties or alkyl groups include, but are not limited to, C1 to C6 alkyl groups including methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.

[0156] In a preferred variation, the alkyl radical / moiety is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably from the group consisting of methyl and ethyl.

[0157] The alkyl or alkylene groups as defined above may be further substituted.

[0158] The term "alkyl" or "alkylene" also includes radicals or groups with any degree of saturation, i.e., groups having only carbon-carbon single bonds ("alkyl" or "alkylene"), groups having one or more carbon-carbon double bonds ("alkenyl"), radicals having one or more carbon-carbon triple bonds ("alkynyl"), and groups having mixtures of carbon-carbon single, double and / or triple bonds.

[0159] According to the present invention, the term "alkenyl" alone or as part of another substituent refers to an unsaturated straight or branched monovalent hydrocarbon radical having at least one carbon-carbon double bond (C=C double bond). The radical can be in a cis or trans conformation around the double bond. The term "alkenyl" therefore also includes the corresponding cis / trans isomers.

[0160] In a preferred variant according to the invention, the straight-chain or branched alkenyl group contains 2 to 10 carbon atoms. In a further preferred variant, the straight-chain or branched alkenyl group contains 2 to 6 carbon atoms.

[0161] In a still further preferred variant, the straight-chain or branched alkenyl group contains 2 to 4 carbon atoms.

[0162] Preferred according to the invention are monounsaturated or diunsaturated straight-chain or branched C1 to C6 alkenyl groups.

[0163] Typical alkenyl radicals or alkenyl groups include, but are not limited to, vinyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl, cycloprop-2-en-1-yl; butenyl, such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, and the like.

[0164] Alkenyl groups as defined above may be further substituted.

[0165] According to the present invention, the term "alkynyl" alone or as part of another substituent refers to an unsaturated straight or branched chain monovalent hydrocarbon radical having at least one carbon-carbon triple bond (C≡C triple bond).

[0166] In a preferred embodiment according to the invention, the straight or branched alkynyl group contains 2 to 10 carbon atoms. In other preferred embodiments, the alkynyl group contains 2 to 6 carbon atoms. In a further preferred embodiment, the alkynyl group contains 2 to 4 carbon atoms.

[0167] Most preferred according to the invention are monounsaturated or diunsaturated straight or branched C1 to C6 alkynyl groups.

[0168] Typical alkynyl radicals / moieties or alkynyl groups include, but are not limited to, ethynyl; propynyl such as prop-1-yn-1-yl, prop-2-yn-1-yl, and the like; butynyl such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, and the like.

[0169] An alkynyl group as defined above may be further substituted. An alkyl group or an alkylene group as defined above may be further substituted.

[0170] The term "alkoxy" according to the present invention alone or as part of another substituent refers to a straight or branched chain radical of the formula -OR, wherein R is alkyl or substituted alkyl as defined herein.

[0171] In a preferred embodiment according to the invention, the straight-chain or branched alkoxy group contains 2 to 10 carbon atoms. In other preferred embodiments, the straight-chain or branched alkoxy group contains 2 to 6 carbon atoms. In a further preferred embodiment, the straight-chain or branched alkoxy group contains 2 to 4 carbon atoms.

[0172] Most preferred according to the invention are straight-chain or branched C1 to C6 alkoxy groups.

[0173] Typical alkoxy radicals / moieties or alkoxy groups include C1 to C6 alkoxy, including C1 to C4 alkoxy such as methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1,1-dimethylethoxy; and pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy The invention also includes the following: 1-methylpentyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 4-methylpentyloxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy or 1-ethyl-2-methylpropoxy.

[0174] In a preferred variant, the alkoxy radical or alkoxy group is selected from the group consisting of methoxy (-O-methyl), ethoxy (-O-ethyl), propoxy (-O-propyl) and butoxy (-O-butyl), more preferably from the group consisting of methoxy (-O-methyl) and ethoxy (-O-ethyl).

[0175] The alkoxy groups or alkylene groups as defined above may be further substituted.

[0176] The term "alkylthio" or "thioalkoxy" according to the present invention alone or as part of another substituent refers to a radical of formula -SR, wherein R is alkyl or substituted alkyl as defined herein.

[0177] According to the present invention, the term "alkyl" or "alkylene" also includes heteroalkyl radicals or heteroalkyl groups. The term "heteroalkyl" itself or as a part of other substituents refers to an alkyl group in which one or more carbon atoms in the carbon atom are independently replaced by the same or another heteroatom or by the same or another heteroatom group. Typical heteroatoms or heteroatom groups of alternative carbon atoms include but are not limited to-O-,-S-,-N-,-Si-,-NH-,-S(O)-,-S(O)2-,-S(O)NH-,-S(O)2NH-, etc. and combinations thereof. Heteroatoms or heteroatom groups may be located at any internal position of the alkyl group.

[0178] Typical heteroatom groups that may be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -OS-, -NRR-, =NN=, -N=N-, -N=N-NRR, -PR-, -P(O)2-, -POR-, -OP(O)2-, -SO-, -SO2-, -SR2OR-, and the like, where R is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl, as defined herein.

[0179] The alkyl or alkylene groups as defined above may be further substituted.

[0180] The term "acyl" or "alkanoyl" by itself or as part of another substituent according to the present invention refers to the radical R(C=O)-, wherein R is hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, arylalkyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted heteroarylalkyl, as defined herein.

[0181] Representative examples include, but are not limited to, formyl, acetyl, propionyl, butyryl, valeryl, benzoyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzylcarbonyl, and the like.

[0182] According to the present invention, the term "cycloalkyl" alone or as part of another substituent refers to a saturated or mono- or poly-unsaturated non-aromatic cyclic monovalent hydrocarbon radical in which the carbon atoms are ring-linked and which has no heteroatoms.

[0183] The carbocycle may exist as a monocyclic compound having only a single ring, or as a polycyclic compound having two or more rings.

[0184] In a preferred variation, the term "cycloalkyl" includes a three-membered to ten-membered monocyclic cycloalkyl radical or cycloalkyl group or a nine-membered to ten-membered polycyclic cycloalkyl radical or cycloalkyl group. In other more preferred variations, the cycloalkyl moiety comprises a five-membered, six-membered or seven-membered monocyclic cycloalkyl moiety or a nine-membered to twelve-membered bicyclic cycloalkyl moiety.

[0185] In a preferred embodiment according to the present invention, the cycloalkyl radical or group comprises 3 to 20 carbon atoms. In an even more preferred embodiment, the cycloalkyl radical comprises 6 to 15 carbon atoms. In a most preferred embodiment, the cycloalkyl radical comprises 6 to 10 carbon atoms. Most preferably, a monocyclic C3 to C7 cycloalkyl group.

[0186] Typical cycloalkyl radicals or cycloalkyl groups include, but are not limited to, saturated carbocyclic radicals having 3 to 20 carbon atoms, such as C3 to C12 carbocyclic radicals, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl; cyclopentyl, cyclohexyl, cycloheptyl, as well as cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclobutyl-ethyl, cyclopentyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl, or C3 to C7-carbocyclic radicals, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, 3-dien-1-yl, etc.

[0187] Preferred polycyclic cycloalkyl radicals or cycloalkyl groups according to the present invention include, but are not limited to, naphthyl, indenyl groups, and the like.

[0188] According to the invention, the term "cycloalkyl" also includes cycloalkenyl, i.e. an unsaturated cyclic hydrocarbon radical containing a C=C double bond between two carbon atoms of the ring molecule. In a broader sense, cycloalkenyl is a compound with one, two or more double bonds, wherein the number of the most conjugated double bonds possible in the molecule depends on the ring size.

[0189] Typical cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, cyclopentadienyl, and the like.

[0190] According to the invention, the term "cycloalkyl" also includes cycloalkynyl groups containing a cyclic hydrocarbon radical, ie an unsaturated -C≡C- triple bond between two carbon atoms of the ring molecule, which triple bond depends on the ring size for reasons of ring strain.

[0191] Typical cycloalkynyl groups include cyclooctynyl.

[0192] The cycloalkyl, cycloalkenyl or cycloalkynyl moieties or groups as defined above may be further substituted.

[0193] According to the present invention, the term "aryl" by itself or as part of another substituent refers to a monovalent aromatic hydrocarbon radical derived by removing a hydrogen atom from a single carbon atom of an aromatic ring system.

[0194] In a preferred variation, the term "aryl" includes a three- to ten-membered monocyclic aryl radical or aryl group or a nine- to ten-membered polycyclic aryl radical or aryl group. In other more preferred variations, the carboaryl radical comprises a five-, six- or seven-membered monocyclic carboaryl radical or a nine- to twelve-membered bicyclic carboaryl radical.

[0195] In a preferred embodiment according to the invention, the aryl radical comprises 3 to 20 carbon atoms. In a preferred variant, the aryl moiety comprises 6 to 15 ring atoms. In an even more preferred embodiment, the aryl radical comprises 6 to 10 carbon atoms.

[0196] Most preferred according to the invention are monocyclic C3 to C10 aryl groups.Most preferred are monocyclic C3 to C7 aryl groups.

[0197] Typical aryl radicals include, but are not limited to, benzene, phenyl, biphenyl, naphthyl such as 1- or 2-naphthyl, tetrahydronaphthyl, fluorenyl, indenyl, and phenanthrenyl. Typical carboaryl moieties also include, but are not limited to, groups derived from aceanthrene, acenaphthylene, acephenanthren, anthracene, azulene, benzene, Coronene, fluoranthene, fluorene, hexacene, hexylene, cyclohexadiene, asymmetric indacene, symmetric indacene, indane, indene, naphthalene, octacene, octacene, cyclooctadiene, ovalene, penta-2,4-diene, pentacene, cyclopentadiene, pentaphene, perylene, phenalene, phenanthrene, phenanthrene, septaene, pyrene, pyranthrene, rubrocene, triphenylene, and ternaphthalene, etc.

[0198] Preferred aromatic polycyclic aryl radicals or aryl groups according to the present invention include, but are not limited to, naphthalene, biphenyl and the like.

[0199] The aryl moieties or groups as defined above may be further substituted.

[0200] According to the present invention, the term "arylalkyl" as a part of another substituent refers to a non-cyclic alkyl group, wherein one hydrogen atom in the hydrogen atom attached to a carbon atom (usually a terminal or sp carbon atom) is replaced by an aryl group as defined herein. In other words, arylalkyl can also be considered as an alkyl substituted with aryl. Typical arylalkyl groups include but are not limited to benzyl, 2-phenylethane-1-yl, 2-phenylethylene-1-yl, naphthylmethyl, 2-naphthylethane-1-yl, 2-naphthylethylene-1-yl, naphthobenzyl, 2-naphthophenylethane-1-yl etc.

[0201] The term "heteroarylalkyl" alone or as part of another substituent refers to a cyclic alkyl group in which one of the hydrogen atoms attached to the carbon atom is replaced by a heteroaryl group. In a preferred embodiment according to the present invention, the heteroarylalkyl group is a 6- to 20-membered heteroarylalkyl, for example, the alkyl, alkenyl or alkynyl group of the heteroarylalkyl is a C1 to C6 alkyl and the heteroaryl group is a 5- to 15-membered heteroaryl group. In other embodiments, the heteroarylalkyl is a 6- to 13-membered heteroarylalkyl, for example, the alkyl, alkenyl or alkynyl group is a C1 to C3 alkyl and the heteroaryl group is a 5- to 10-membered heteroaryl.

[0202] According to the present invention, the term "heterocycloalkyl" alone or as part of another substituent refers to a saturated or monounsaturated or polyunsaturated non-aromatic cyclic monovalent hydrocarbon radical in which one or more carbon atoms are independently replaced by the same or different heteroatoms. Typical heteroatoms replacing carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Typical heterocycloalkyl groups include, but are not limited to, groups derived from epoxides, aziridines, thiirane, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidone, quinuclidine, etc.

[0203] In a preferred embodiment according to the invention, the heterocycloalkyl moiety or group comprises 3 to 20 ring atoms. In a preferred variant, the heterocycloalkyl moiety comprises 6 to 15 ring atoms. In an even more preferred embodiment, the heterocycloalkyl moiety comprises 6 to 10 carbon atoms.

[0204] The heterocycloalkyl moiety may exist as a monocyclic compound having only a single ring, or as a polycyclic compound having two or more rings, such as a bicyclic, tricyclic, or spirocyclic ring.

[0205] Preferably, the term "heterocycloalkyl" includes a three- to seven-membered saturated or mono- or poly-unsaturated heterocycloalkyl moiety containing one, two, three or four heteroatoms selected from the group consisting of O, N and S. One or more heteroatoms may occupy any position in the heterocycloalkyl ring.

[0206] In a preferred variation, the term "heterocycloalkyl" includes a three-membered to ten-membered monocyclic heterocycloalkyl radical or a nine-membered to twelve-membered polycyclic heterocycloalkyl radical. In other more preferred variations, the heterocycloalkyl moiety comprises a five-membered, six-membered or seven-membered monocyclic heterocycloalkyl moiety or a nine-membered to twelve-membered bicyclic heterocycloalkyl moiety.

[0207] Most preferred according to the invention are monocyclic heterocycloalkyl radicals containing 3 to 12 carbon atoms.Most preferred are monocyclic heterocycloalkyl radicals having 5 to 7 ring atoms.

[0208] Typical heterocycloalkyl moieties include, but are not limited to, five-membered or six-membered saturated or monounsaturated heterocycloalkyl groups containing one or two nitrogen atoms and / or one oxygen or sulfur atom or one or two oxygen and / or sulfur atoms as ring members, including 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 3-pyrazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 2-oxazolidinyl, 3-pyrazolidinyl, 3-pyrazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazoli ... 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1,3-dioxane-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, etc.

[0209] The heterocycloalkyl moieties or groups as defined above may be further substituted.

[0210] According to the present invention, the term "heteroaryl" by itself or as part of another substituent refers to a monovalent heteroaromatic radical obtained by removing a hydrogen atom from a single atom of a heteroaromatic ring system. Typical heteroaryl radicals or heteroaryl groups include, but are not limited to, those derived from acridine, β-carboline, chroman, cinnoline, furan, imidazole, indazole, indole, dihydroindole, indolizine, isobenzofuran, isochromium, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phenanthridine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazole, xanthene, etc.

[0211] The heteroaryl moiety may exist as a monocyclic compound having only a single ring, or as a polycyclic compound having two or more rings.

[0212] In a preferred variation, the term "heteroaryl" includes a three- to ten-membered monocyclic heteroaryl radical or a nine- to twelve-membered polycyclic heteroaryl radical. In other more preferred variations, the heteroaryl moiety comprises a five-, six- or seven-membered monocyclic heteroaryl moiety or a nine- to twelve-membered bicyclic heteroaryl moiety.

[0213] Preferably, the term "heteroaryl" includes three- to seven-membered monocyclic heteroaryl radicals containing one, two, three or four heteroatoms selected from the group consisting of O, N and S. One or more heteroatoms may occupy any position in the heteroaryl ring.

[0214] In a preferred embodiment according to the invention, the heteroaryl moiety or group comprises 3 to 20 ring atoms. In an even more preferred variation, the heteroaryl moiety comprises 6 to 15 ring atoms. In a most preferred embodiment, the heteroaryl group comprises 6 to 10 ring atoms. Most preferred according to the invention is a monocyclic C3 to C7 heteroaryl group.

[0215] Particularly preferred heteroaryl moieties or groups include, but are not limited to, those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole and pyrazine.

[0216] Five-membered aromatic heteroaryl radicals which contain, in addition to carbon atoms, one, two or three nitrogen atoms or one or two nitrogen atoms and one sulfur or oxygen atom as ring atoms include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl and 1,3,4-triazol-2-yl.

[0217] Five-membered aromatic heteroaryl radicals containing one, two, three or four nitrogen atoms as ring atoms include 1-, 2- or 3-pyrrolyl, 1-, 3- or 4-pyrazolyl, 1-, 2- or 4-imidazolyl, 1,2,3-[1H]-triazol-1-yl, 1,2,3-[2H]-triazol-2-yl, 1,2,3-[1H]-triazol-4-yl, 1,2,3-[1H]-triazol-5-yl, 1,2,3-[ 2H]-triazol-4-yl, 1,2,4-[1H]-triazol-1-yl, 1,2,4-[1H]-triazol-3-yl, 1,2,4-[1H]-triazol-5-yl, 1,2,4-[4H]-triazol-4-yl, 1,2,4-[4H]-triazol-3-yl, [1H]-tetrazole-1-yl, [1H]-tetrazole-5-yl, [2H]-tetrazole-2-yl, [2H]-tetrazole-5-yl, and the like.

[0218] Five-membered aromatic heteroaryl radicals containing as ring atoms a heteroatom selected from oxygen or sulfur and optionally one, two or three nitrogen atoms include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 3- or 4-isoxazolyl, 3- or 4-isothiazolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,3,4-oxadiazol-2-yl.

[0219] Six-membered heteroaryl radicals which contain, in addition to carbon atoms, one or two or one, two or three nitrogen atoms as ring atoms and include, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1,2,4-triazin-3-yl; 1,2,4-triazin-5-yl, 1,2,4-triazin-6-yl and 1,3,5-triazin-2-yl.

[0220] The heteroaryl moieties or groups as defined above may be further substituted.

[0221] In the context of the present application, the term "C-spiro" means a compound having at least two molecular rings with only one common atom. The simplest spiro compound is a bicyclic (having only two rings) or has a bicyclic moiety as part of a larger ring system, in either case, the two rings are connected by a single common atom defined. A common atom connected to the participating ring distinguishes spiro compounds from other bicyclic rings, the bicyclic ring: from a ring compound without a connection atom such as biphenyl, from a fused ring compound with two rings connected by two adjacent atoms such as decalin, and from a bridged ring compound with two rings connected by two non-adjacent atoms such as norbornane. Spiro compounds can be completely carbocyclic (all carbon) or heterocyclic (with one or more non-carbon atoms, such as N, O and S). The common atom connecting two (or sometimes three) rings is called a spiral atom. Preferably, a spiral atom is a carbon atom. More preferably, C-spiro compounds mean a compound of a complete carbocyclic (all carbon).

[0222] In the context of the present invention, the term "substituted" means that one or more hydrogen atoms of the indicated free radical or group are independently replaced by the same or different substituents. In addition, the term "substituted" particularly provides one or more (i.e. two, three, four, five, six or more) substituents commonly used in the art. However, it is generally known that substituents should be selected so that they do not adversely affect the usable properties or functions of the compound.

[0223] Suitable substituents in the context of the present invention preferably include halogen, perfluoroalkyl groups, perfluoroalkoxy groups, alkyl groups, alkenyl groups, alkynyl groups, hydroxyl groups, oxo groups, mercapto groups, alkylthio groups, alkoxy groups, aryl or heteroaryl groups, aryloxy groups or heteroaryloxy groups, arylalkyl or heteroarylalkyl groups, arylalkoxy or heteroarylalkoxy groups, amino groups, alkyl and dialkylamino groups, carbamoyl groups, alkylcarbonyl groups, carboxyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups, dialkylaminocarbonyl groups, arylcarbonyl groups, aryloxycarbonyl groups, alkylsulfonyl groups, arylsulfonyl groups, cycloalkyl groups, cyano groups, C1 to C6 alkylthio groups, C36 arylthiol groups, nitro groups, keto groups, acyl groups, borate or boryl groups, phosphate or phosphonyl groups, sulfamoyl groups, sulfonyl groups, sulfinyl groups and combinations thereof.

[0224] Substituents or substituent groups for replacing saturated carbon atoms in the indicated groups or radicals more preferably include, but are not limited to, halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, -NH2, amino (primary, secondary or tertiary), nitro, thiol, thioether, imine, cyano, amido, phosphonato, phosphine, carboxyl, thiocarbonyl, sulfonyl, sulfonamide, ketone, aldehyde, ester, acetyl, acetoxy, carbamoyl, oxygen (O); haloalkyl (e.g., trifluoromethyl); aminoacyl and aminoalkyl, carbocyclic cycloalkyl, which can be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl); or heterocycloalkyl, which It can be monocyclic or fused or non-fused polycyclic (for example, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiazinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aromatic (for example, phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridyl, quinolyl, isoquinolyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothienyl or benzofuranyl); -CO2CH3, -CONH2, -OCH2CONH2; -SO2NH2, -OCHF2, -CF3, -OCF3.

[0225] According to the present invention, the substituents used to replace a particular free radical or radicals may in turn be further substituted, typically by one or more of the same or different free radicals selected from the various groups noted above and defined in detail above. In the case of substituted combinations such as substituted arylalkyl, either the aryl group or the alkyl group may be substituted, or both the aryl group and the alkyl group may be substituted by one or more substituents.

[0226] In a preferred variant, Z in the general formula (V) is -O-R2' or amide'.

[0227] In a further preferred variant, R1' in the general formula (V) is CH2.

[0228] In a further preferred variant, R1' in the general formula (V) is C(alkyl)2.

[0229] In a further preferred variant, R1′ in the general formula (V) is O.

[0230] In a further preferred variant, R1′ in the general formula (V) is S.

[0231] In a further preferred variant, R1' in the general formula (V) is SO.

[0232] In a further preferred variant, R1' in the general formula (V) is SO2.

[0233] In a further preferred variant, R1' in the general formula (V) is NH.

[0234] In a further preferred variant, R1' in the general formula (V) is N(alkyl).

[0235] Most preferably, R1' in formula (V) is CH2 or C(alkyl)2.

[0236] In a preferred variant, R2' in general formula (V) is H.

[0237] In a further preferred variant, R2' in the general formula (V) is methyl.

[0238] In a further preferred variant, R2' in the general formula (V) is ethyl.

[0239] In a further preferred variant, R2' in the general formula (V) is propyl.

[0240] In a further preferred variant, R2' in the general formula (V) is isopropyl.

[0241] In a further preferred variant, R2′ in the general formula (V) is butyl.

[0242] In a further preferred variant, R2′ in the general formula (V) is isobutyl.

[0243] In a further preferred variant, R2′ in the general formula (V) is tert-butyl.

[0244] In a further preferred variant, R2' in the general formula (V) is

[0245] In a further preferred variant, R2' in the general formula (V) is

[0246] In a preferred variation, R2' in the general formula (V) is (2-ethyl-hexyl).

[0247] In a further preferred variant, R2' in the general formula (V) is phenyl.

[0248] Most preferably, R2' in the general formula (V) is H, or ethyl, or isopropyl, or 2-ethylhexyl, or phenyl.

[0249] In a preferred variant, amide' in general formula (V) is NH2.

[0250] In a further preferred variant, the amide' in the general formula (V) is NH(alkyl), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0251] In a further preferred variant, the amide' in the general formula (V) is N(alkyl)2, wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0252] In a further preferred variant, the amide' in the general formula (V) is -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0253] In a further preferred variant, the amide' in the general formula (V) is -N(OH)(H)(hydroxamic acid).

[0254] Most preferably, the amide' in formula (V) is NH2, N(methyl)2 or N(ethyl)2 or -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, or -N(OH)(H)(hydroxamic acid).

[0255] In a preferred variant, R3' in general formula (V) is H.

[0256] In a further preferred variant, R3' in the general formula (V) is methyl.

[0257] In a further preferred variant, R3' in the general formula (V) is ethyl.

[0258] In a further preferred variant, R3' in the general formula (V) is -O-methyl.

[0259] In a further preferred variant, R3' in the general formula (V) is -C(=O)-OH.

[0260] In a further preferred variant, R3' in the general formula (V) is -C(=O)-CH3.

[0261] In a further preferred variant, R3' in the general formula (V) is -C(=O)-C3H7.

[0262] In a further preferred variant, R3' in the general formula (V) is -C(=O)-O-methyl.

[0263] Most preferably, R3' in the general formula (V) is H or methyl or -O-methyl.

[0264] Such mycosporin-like amino acid compounds change the UV absorption curve of sunscreen products, cosmetic or pharmaceutical preparations or home care products and broaden the UV absorption spectrum of the formulation over the UV radiation spectrum.

[0265] In a preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an acid compound or an ester compound represented by general formula (VII):

[0266]

[0267] wherein R1′, R2′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0268] In a preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (V) is an acid compound represented by the general formula (VII-acid):

[0269]

[0270] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0271] The mycosporin-like amino acid compounds according to the general formula (VII-acid) are particularly light-stable and temperature-stable compounds and show stability in pH solutions or in different emulsion types and do not degrade.

[0272] In particular, mycosporin-like amino acid compounds having an acid group have better pH stability in a wider pH range than their corresponding hydrolyzed ester compounds, and are therefore unstable in alkaline solutions above pH 9.

[0273] In addition, the mycosporin-like amino acid compounds also have better water solubility than their corresponding ester compounds. Due to their better solubility in water, the mycosporin-like amino acid compounds can be incorporated into the aqueous phase of the emulsion at a higher concentration, resulting in an improved SPF performance boosting effect and thus producing better UVA light protection in sunscreen products, cosmetic or pharmaceutical preparations or home care products.

[0274] In a preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an ester compound represented by general formula (VII-ester):

[0275]

[0276] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0277] Preferably, the alkyl residue in formula (VII-ester) is methyl, or ethyl, or propyl, or isopropyl, or butyl, or isobutyl, or tert-butyl. Most preferably, the alkyl residue in formula (VII-ester) is methyl. Such ester compounds are particularly stable.

[0278] In an alternative preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an amide compound represented by general formula (VIII)

[0279]

[0280] wherein R1′, Amide′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0281] In a more preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an amide compound represented by general formula (VIII-amide):

[0282]

[0283] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V), and R11′ and R12′ are independently selected from the group consisting of H, OH and alkyl.

[0284] In a preferred variant according to the first aspect of the present invention, in the general formula (VIII-amide), R11′ and / or R12′ is H.

[0285] In a further preferred variant, R11′alkyl and R12′alkyl in the general formula (VIII-amide) are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0286] Preferably, R11′ and / or R12′ in the general formula (VIII-amide) are each H or are each methyl.

[0287] In a still more preferred variation, the mycosporin-like amino acid compound (b) of general formula (V) is a Weinreb amide compound represented by general formula (VIII-Weinreb amide)

[0288]

[0289] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0290] In a preferred variant, the alkyl residue in the general formula (VIII-Weinreb amide) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl residue is methyl.

[0291] Alternatively, in a still more preferred variation, the mycosporin-like amino acid compound (b) of general formula (V) is a hydroxamic acid compound represented by general formula (VIII-hydroxamic acid derivative)

[0292]

[0293] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0294] Alternatively, in a further preferred variation, the mycosporin-like amino acid compound (b) of general formula (V) is an alkylated hydroxamic acid compound represented by general formula (VIII-alkylated hydroxamic acid derivative):

[0295]

[0296] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0297] In a preferred variant, the alkyl residue in the general formula (VIII - alkylated hydroxamic acid derivative) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl group is methyl.

[0298] In a preferred alternative, the mycosporin-like amino acid compound (b) is represented by the general formula (A):

[0299]

[0300] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0301] In the present invention, the same preferred variations as defined herein for the mycosporin-like amino acid compounds according to formula (V) apply analogously to the mycosporin-like amino acid compounds according to formula (VII) or (VIII) and variations thereof or formula (A).

[0302] In a further preferred variant, R1″ in the general formula (VI) is CH2.

[0303] In a further preferred variant, R1″ in the general formula (VI) is C(alkyl)2.

[0304] In a further preferred variant, R1″ in the general formula (VI) is O.

[0305] In a further preferred variant, R1″ in the general formula (VI) is S.

[0306] In a further preferred variant, R1″ in the general formula (VI) is SO.

[0307] In a further preferred variant, R1″ in the general formula (VI) is SO 2.

[0308] In a further preferred variant, R1″ in the general formula (VI) is NH.

[0309] In a further preferred variant, R1″ in the general formula (VI) is N(alkyl).

[0310] Most preferably, R1" in formula (VI) is CH2 or C(alkyl)2.

[0311] In a preferred variant, R2" in the general formula (VI) is -CH2-OH.

[0312] In a further preferred variant, R2″ in the general formula (VI) is —C(═O)—OY.

[0313] In a further preferred variant, R2" in the general formula (VI) is -C(=O)-amide".

[0314] Most preferably, R2" in the general formula (VI) is -C(=O)-OY or -C(=O)-amide".

[0315] In a further preferred variant, X in the general formula (VI) is CH2.

[0316] In a further preferred variant, X in the general formula (VI) is C═O.

[0317] In a further preferred variant, X in the general formula (VI) is O.

[0318] In a further preferred variant, X in the general formula (VI) is S.

[0319] In a further preferred variant, X in the general formula (VI) is SO.

[0320] In a further preferred variant, X in the general formula (VI) is SO2.

[0321] In a further preferred variant, X in the general formula (VI) is NH.

[0322] In a further preferred variant, X in the general formula (VI) is N(alkyl), wherein alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0323] Most preferably, X in formula (VI) is S, SO or SO2.

[0324] In a preferred variant, Y in the general formula (VI) is H.

[0325] In a further preferred variant, Y in the general formula (VI) is methyl.

[0326] In a further preferred variant, Y in the general formula (VI) is ethyl.

[0327] In a further preferred variant, Y in the general formula (VI) is propyl.

[0328] In a further preferred variant, Y in the general formula (VI) is isopropyl.

[0329] In a further preferred variant, Y in the general formula (VI) is butyl.

[0330] In a further preferred variant, Y in the general formula (VI) is isobutyl.

[0331] In a further preferred variant, Y in the general formula (VI) is tert-butyl.

[0332] In a further preferred variant, Y in the general formula (VI) is

[0333] In a further preferred variant, Y in the general formula (VI) is

[0334] In a preferred variant, Y in the general formula (VI) is (2-ethyl-hexyl).

[0335] In a further preferred variant, Y in the general formula (VI) is phenyl.

[0336] Most preferably, Y in the general formula (VI) is H, or ethyl, or isopropyl, or 2-ethylhexyl, or phenyl.

[0337] In a preferred variant, the "amide" in the general formula (VI) is NH2.

[0338] In a further preferred variant, the "amide" in the general formula (VI) is NH(alkyl), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0339] In a further preferred variant, the "amide" in the general formula (VI) is N(alkyl)2, wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0340] In a further preferred variant, the "amide" in the general formula (VI) is -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0341] In a further preferred variant, the "amide" in the general formula (V) is -N(OH)(H)(hydroxamic acid).

[0342] Most preferably, the "amide" in general formula (V) is NH2, N(methyl)2 or N(ethyl)2 or -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, or -N(OH)(H)(hydroxamic acid).

[0343] In a more preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) is an alcohol compound represented by the general formula (IX-alcohol):

[0344]

[0345] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for the general formula (VI).

[0346] Alternatively, in a more preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an acid compound represented by the general formula (IX-acid):

[0347]

[0348] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for the general formula (VI).

[0349] Alternatively, in a more preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an ester compound represented by the general formula (VII-ester):

[0350]

[0351] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for the general formula (VI).

[0352] Preferably, the alkyl residue in the general formula (VII-ester) is methyl, ethyl, propyl, isobutyl, butyl, isobutyl or tert-butyl, more preferably, the alkyl residue is methyl.

[0353] In an alternative more preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an amide compound represented by the general formula (X):

[0354]

[0355]

[0356] wherein R1", amide", X, R4", R5" and R6" have the same meanings as defined herein for the general formula (VI).

[0357] In a more preferred alternative variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an amide compound represented by the general formula (X-amide):

[0358]

[0359] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for formula (VI), and R11" and R12" are independently selected from the group consisting of H, OH and alkyl.

[0360] In a preferred variant according to the first aspect of the present invention, in the general formula (X-amide), R11″ and / or R12″ is H.

[0361] Preferably, R11"alkyl and R12"alkyl in the general formula (X-amide) are methyl, or ethyl, or propyl, or isopropyl, or butyl, or isobutyl, or tert-butyl.

[0362] Preferably, R11" and / or R12" in the general formula (X-amide) are each H or are each methyl.

[0363] In a still more preferred variation, the mycosporin-like amino acid compound (b) of formula (VI) is a Weinreb amide compound represented by the formula (X-Weinreb amide):

[0364]

[0365] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for formula (VI).

[0366] In a preferred variant, the alkyl residue in the general formula (X-Weinreb amide) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl residue is methyl.

[0367] Alternatively, in a still more preferred variation, the mycosporin-like amino acid compound (b) of the general formula (VI) is a hydroxamic acid compound represented by the general formula (X-hydroxamic acid derivative):

[0368]

[0369] wherein R1", X, R4", R5" and R6" have the same meanings as defined above for the general formula (VI).

[0370] Alternatively, in a further preferred variation, the mycosporin-like amino acid compound (b) of the general formula (VI) is an alkylated hydroxamic acid compound represented by the general formula (VIII-alkylated hydroxamic acid derivative):

[0371]

[0372] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for formula (VI).

[0373] In a preferred variation, the alkyl residue in the general formula (X-alkylated hydroxamic acid derivative) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl residue is methyl.

[0374] In the present invention, the same preferred variants as defined herein for the mycosporin-like amino acid compounds according to general formula (VI) apply analogously to the mycosporin-like amino acid compounds according to general formula (IX) or (X) and variants thereof.

[0375] In the following and throughout the specification, the term "according to the general formula YZ and variations thereof" includes any subformula (e) of said general formula as disclosed herein. Thus, variations of the general formulas (V) and (VI) as defined herein include formulas (VII), (VIII), (IX) and (X) as defined herein. Variations of the general formulas (VII) and (VIII) as defined herein include subformulas (VII-acid), (VII-ester), (VIII-amide), (VIII-Weinreb amide), (VIII-hydroxamic acid derivative) and (VIII-alkylated hydroxamic acid derivative) as defined herein. Variations of the general formulas (IX) and (X) as defined herein include formulas (IX-acid), (IX-ester), (X-amide), (X-Weinreb amide), (X-hydroxamic acid derivative) and (X-alkylated hydroxamic acid derivative) as defined herein.

[0376] In further preferred variations, in the general formula (VI), (IX), (X) and variations thereof, X is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), ), unsubstituted or substituted CH(heteroaryl), -CR7 "R8", C=O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro.

[0377] In a further preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (V), wherein

[0378] -Z is -O-R2' or amide'; and / or

[0379] - R1' is selected from the group consisting of CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or

[0380] -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethyl-hexyl) and phenyl; or

[0381] -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0382] -R3' is selected from the group consisting of H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or

[0383] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0384] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0385] In another preferred variant of the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VII) or (VIII), wherein

[0386] - R1' is selected from the group consisting of CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or

[0387] -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethyl-hexyl) and phenyl; or

[0388] -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0389] -R3' is selected from the group consisting of H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or

[0390] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0391] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0392] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VI), wherein

[0393] -R1" is selected from the group consisting of CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or

[0394] -R2" is selected from the group consisting of -CH2-OH, -C(=O)-OY and -C(=O)-amide"; and / or

[0395] -X is selected from the group consisting of CH2, C=O, O, S, SO, SO2, NH and N(alkyl); and / or

[0396] -Y is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethyl-hexyl) and phenyl; and / or

[0397] -amide" is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0398] - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI);

[0399] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0400] In a further preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (V), wherein

[0401] -Z is -O-R2' or amide'; and / or

[0402] - R1' is selected from the group consisting of CH2 and C(methyl)2; and / or

[0403] -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethyl-hexyl) and phenyl; or

[0404] -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0405] -R3' is selected from the group consisting of H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or

[0406] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0407] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0408] In another preferred variant of the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VII) or (VIII), wherein

[0409] - R1' is selected from the group consisting of CH2 and C(methyl)2; and / or

[0410] -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethyl-hexyl) and phenyl; or

[0411] -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0412] -R3' is selected from the group consisting of H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or

[0413] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0414] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0415] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VI), wherein

[0416] -R1" is selected from the group consisting of CH2 and C(methyl)2; and / or

[0417] -R2" is selected from the group consisting of -CH2-OH, -C(=O)-OY and -C(=O)-amide"; and / or

[0418] -X is selected from the group consisting of CH2, C=O, O, S, SO, SO2, NH and N(alkyl); and / or

[0419] -Y is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethyl-hexyl) and phenyl; and / or

[0420] -amide" is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0421] - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI);

[0422] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0423] In a still more preferred variant according to the invention, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises at least one mycosporin-like amino acid compound selected from the group consisting of the following compounds I-1 to I-128 according to the general formula (V) and compounds II-1 to II-192 according to the general formula (VI):

[0424] Table 1:

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433] or tautomers or stereoisomers or salts of the above compounds, or any mixtures of the above compounds.

[0434] In the mycosporin-like amino acid compounds of Table 1, the benzene ring may be unsubstituted or substituted. The substituents R4', R5', R6', R4", R5", R6", amide', Y, amide" and alkyl have the same meanings as defined for the mycosporin-like amino acid compounds according to the aforementioned general formula (V) or (VI).

[0435] Particularly preferred are those mycosporin-like amino acid compounds wherein in the general formula (V), R1' is CH2 or C(methyl)2, or wherein in the general formula (VI), R1' is CH2 or C(methyl)2:

[0436] Table 2:

[0437]

[0438]

[0439]

[0440]

[0441] or tautomers or stereoisomers or salts of the above compounds, or any mixtures of the above compounds.

[0442] In the mycosporin-like amino acid compounds of Table 2, the benzene ring may be unsubstituted or substituted. The substituents R4', R5', R6', R4", R5", R6", amide', Y, amide" and alkyl have the same meanings as defined for the mycosporin-like amino acid compounds according to the aforementioned general formula (V) or (VI).

[0443] Preferably, in the mycosporin-like amino acid compounds according to general formula (V) or formula (VI) and specified in Table 1 and Table 2

[0444] -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-Ethylhexyl)

[0445] and phenyl group;

[0446] -amide' is selected from NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)

[0447] (Weinreb amide) and -N(OH)(H)(hydroxamic acid);

[0448] -Y is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-Ethylhexyl)

[0449] and phenyl group;

[0450] -amide" is selected from NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)

[0451] (Weinreb amide) and -N(OH)(H)(hydroxamic acid); and

[0452] - Alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0453] In the most preferred variant of the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (V) and its variants or formula (VI) and its variants, wherein R1' or R1" is CH2. Such mycosporin-like amino acid compounds have particularly good water solubility.

[0454] In a further preferred variant of the first aspect according to the present invention, the mycosporin-like amino acid compound is a compound according to the general formula (VI), (IX), (X) and variations thereof, wherein X is selected from the group consisting of S, SO and SO2.

[0455] Such mycosporin-like amino acid compounds change the UV absorption curve of sunscreen products or cosmetic or pharmaceutical preparations and broaden the UV absorption spectrum of the formulation over the UV radiation spectrum.

[0456] In still more preferred variations of the first aspect according to the invention, the mycosporin-like amino acid compound is a compound according to general formula (VI), (IX), (X) and variations thereof, wherein X is S. However, the S atom in said compound is susceptible to oxidation.

[0457] In the most preferred variants according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to the general formula (VI), (IX), (X) and variations thereof, wherein X is SO or SO2. Such mycosporin-like amino acid compounds are particularly stable due to their oxidation state.

[0458] In a further preferred variant according to the invention, in the general formulae (V) to (X) and their variants, n is 1.

[0459] In a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (V), wherein

[0460] -Z is -O-R2' or amide'; and / or

[0461] - R1' is CH2 or C(methyl)2; and / or

[0462] - R2' is H, or ethyl, or isopropyl, or 2-ethylhexyl, or phenyl; or

[0463] -amide' is NH2, or N(methyl)2, or N(ethyl)2, or -N(O-alkyl)(alkyl)(Weinreb amide), or -N(OH)(H)(hydroxamic acid); and / or

[0464] -R3' is H, or -O-methyl, or -C(=O)-OH, or -C(=O)-CH3, or -C(=O)-O-methyl; and / or

[0465] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0466] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0467] In a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VII) or (VIII), wherein

[0468] - R1' is CH2 or C(methyl)2; and / or

[0469] - R2' is H, or ethyl, or isopropyl, or 2-ethylhexyl, or phenyl; or

[0470] -amide' is NH2, or N(methyl)2, or N(ethyl)2, or -N(O-alkyl)(alkyl)(Weinreb amide), or -N(OH)(H)(hydroxamic acid); and / or

[0471] -R3' is H, or -O-methyl, or -C(=O)-OH, or -C(=O)-CH3, or -C(=O)-O-methyl; and / or

[0472] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0473] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0474] In a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VI), wherein

[0475] -R1" is CH2 or C(methyl)2; and / or

[0476] -R2" is -C(=O)-OY or -C(=O)-amide"; and / or

[0477] -X is S, SO or SO2; and / or

[0478] -Y is H, or ethyl, or isopropyl, or 2-ethylhexyl, or phenyl; or

[0479] -amide" is NH2, or N(methyl)2, or N(ethyl)2, or -N(O-alkyl)(alkyl)(Weinreb amide), or -N(OH)(H)(hydroxamic acid); and / or

[0480] - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI);

[0481] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and butyl.

[0482] The benzene ring in the mycosporin-like amino acid compounds according to general formula (V) to (X) and variations thereof may be unsubstituted or substituted.

[0483] In a preferred embodiment, the benzene ring in the mycosporin-like amino acid compounds according to the general formulae (V) to (X) is unsubstituted, i.e., the substituents R4′, R5′ and R6′ on the benzene ring in the general formula (V) are H; or the substituents R4″, R5″ and R6″ on the benzene ring in the general formula (VI) are H.

[0484] In a further preferred variant, the benzene ring in the mycosporin-like amino acid compounds according to the general formulae (V) to (X) and variants thereof is substituted.

[0485] Most preferably, the benzene ring in the mycosporin-like amino acid compound according to formula (V), (VII), (VIII) and variations thereof is unsubstituted, i.e., the substituents R4', R5' and R6' are each H. Alternatively, most preferably, the benzene ring in the mycosporin-like amino acid compound according to formula (VI), (IX), (X) and variations thereof is unsubstituted, i.e., the substituents R4", R5" and R6" are each H. The mycosporin-like amino acid compound has improved water solubility.

[0486] Preferably, the benzene ring in the mycosporin-like amino acid compounds according to general formula (V) to (X) and variations thereof is mono-substituted, di-substituted or tri-substituted.

[0487] In yet more preferred variations according to the first aspect of the invention, the mycosporin-like amino acid is a compound according to the general formula (V), (VII), (VIII) and variations thereof, wherein the substituents R4', R5' and R6' may be identical or different and are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl.

[0488] Still more preferably, the substituents R4', R5' and R6' in the general formula (V), (VII), (VIII) and their variations may be the same or different and independently selected from the group consisting of H, OH, methyl, O-methyl, -S(=O)2OH and sulfonyl.

[0489] Alternatively, the mycosporin-like amino acid compound is a compound according to the general formula (VI), (IX), (X) and variations thereof, wherein the substituents R4", R5" and R6" may be the same or different and are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl.

[0490] Still more preferably, the substituents R4", R5" and R6" in the general formula (VI), (IX), (X) and their variations may be the same or different and independently selected from the group consisting of H, OH, methyl, O-methyl, -S(=O)2OH and sulfonyl.

[0491] In the general formulae (V) to (X) and their variants, the following substitution patterns are particularly preferred:

[0492] R4′=H and R5′=H and R6′=H; or

[0493] R4'=H and R5'=H and R6'=OH; or

[0494] R4'=H and R5'=H and R6'=methyl; or

[0495] R4′=H and R5′=H and R6′=O-methyl; or

[0496] R4′=H and R5′=H and R6′=-S(=O)2OH; or

[0497] R4'=H and R5'=H and R6'=sulfonyl; or

[0498] R4'=H and R5'=OH and R6'=H; or

[0499] R4'=H and R5'=OH and R6'=OH; or

[0500] R4'=H and R5'=OH and R6'=methyl; or

[0501] R4'=H and R5'=OH and R6'=O-methyl; or

[0502] R4'=H and R5'=OH and R6'=-S(=O)2OH; or

[0503] R4'=H and R5'=OH and R6'=sulfonyl; or

[0504] R4'=H and R5'=methyl and R6'=H; or

[0505] R4'=H and R5'=methyl and R6'=OH; or

[0506] R4'=H and R5'=methyl and R6'=methyl; or

[0507] R4'=H and R5'=methyl and R6'=O-methyl; or

[0508] R4'=H and R5'=methyl and R6'=-S(=O)2OH; or

[0509] R4'=H and R5'=methyl and R6'=sulfonyl; or

[0510] R4′=H and R5′=O-methyl and R6′=H; or

[0511] R4'=H and R5'=O-methyl and R6'=OH; or

[0512] R4'=H and R5'=O-methyl and R6'=methyl; or

[0513] R4′=H and R5′=O-methyl and R6′=O-methyl; or

[0514] R4'=H and R5'=O-methyl and R6'=-S(=O)2OH; or

[0515] R4'=H and R5'=O-methyl and R6'=sulfonyl; or

[0516] R4'=H and R5'=-S(=O)2OH and R6'=H; or

[0517] R4'=H and R5'=-S(=O)2OH and R6'=OH; or

[0518] R4'=H and R5'=-S(=O)2OH and R6'=methyl; or

[0519] R4'=H and R5'=-S(=O)2OH and R6'=O-methyl; or

[0520] R4′=H and R5′=-S(=O)2OH and R6′=-S(=O)2OH; or

[0521] R4'=H and R5'=-S(=O)2OH and R6'=sulfonyl; or

[0522] R4'=H and R5'=sulfonyl and R6'=H; or

[0523] R4'=H and R5'=sulfonyl and R6'=OH; or

[0524] R4'=H and R5'=sulfonyl and R6'=methyl; or

[0525] R4'=H and R5'=sulfonyl and R6'=O-methyl; or

[0526] R4'=H and R5'=sulfonyl and R6'=-S(=O)2OH; or

[0527] R4'=H and R5'=sulfonyl and R6'=sulfonyl; or

[0528] R4′=OH and R5′=H and R6′=H; or

[0529] R4'=OH and R5'=H and R6'=OH; or

[0530] R4'=OH and R5'=H and R6'=methyl; or

[0531] R4'=OH and R5'=H and R6'=O-methyl; or

[0532] R4'=OH and R5'=H and R6'=-S(=O)2OH; or

[0533] R4'=OH and R5'=H and R6'=sulfonyl; or

[0534] R4′=OH and R5′=OH and R6′=H; or

[0535] R4′=OH and R5′=OH and R6′=OH; or

[0536] R4'=OH and R5'=OH and R6'=methyl; or

[0537] R4′=OH and R5′=OH and R6′=O-methyl; or

[0538] R4′=OH and R5′=OH and R6′=-S(=O)2OH; or

[0539] R4'=OH and R5'=OH and R6'=sulfonyl; or

[0540] R4'=OH and R5'=methyl and R6'=H; or

[0541] R4'=OH and R5'=methyl and R6'=OH; or

[0542] R4'=OH and R5'=methyl and R6'=methyl; or

[0543] R4'=OH and R5'=methyl and R6'=O-methyl; or

[0544] R4'=OH and R5'=methyl and R6'=-S(=O)2OH; or

[0545] R4'=OH and R5'=methyl and R6'=sulfonyl; or

[0546] R4'=OH and R5'=O-methyl and R6'=H; or

[0547] R4'=OH and R5'=O-methyl and R6'=OH; or

[0548] R4'=OH and R5'=O-methyl and R6'=methyl; or

[0549] R4'=OH and R5'=O-methyl and R6'=O-methyl; or

[0550] R4'=OH and R5'=O-methyl and R6'=-S(=O)2OH; or

[0551] R4'=OH and R5'=O-methyl and R6'=sulfonyl; or

[0552] R4'=OH and R5'=-S(=O)2OH and R6'=H; or

[0553] R4'=OH and R5'=-S(=O)2OH and R6'=OH; or

[0554] R4'=OH and R5'=-S(=O)2OH and R6'=methyl; or

[0555] R4'=OH and R5'=-S(=O)2OH and R6'=O-methyl; or

[0556] R4′=OH and R5′=-S(=O)2OH and R6′=-S(=O)2OH; or

[0557] R4'=OH and R5'=-S(=O)2OH and R6'=sulfonyl; or

[0558] R4'=OH and R5'=sulfonyl and R6'=H; or

[0559] R4'=OH and R5'=sulfonyl and R6'=OH; or

[0560] R4'=OH and R5'=sulfonyl and R6'=methyl; or

[0561] R4'=OH and R5'=sulfonyl and R6'=O-methyl; or

[0562] R4'=OH and R5'=sulfonyl and R6'=-S(=O)2OH; or

[0563] R4'=OH and R5'=sulfonyl and R6'=sulfonyl; or

[0564] R4'=methyl and R5'=H and R6'=H; or

[0565] R4'=methyl and R5'=H and R6'=OH; or

[0566] R4'=methyl and R5'=H and R6'=methyl; or

[0567] R4'=methyl and R5'=H and R6'=O-methyl; or

[0568] R4'=methyl and R5'=H and R6'=-S(=O)2OH; or

[0569] R4'=methyl and R5'=H and R6'=sulfonyl; or

[0570] R4'=methyl and R5'=OH and R6'=H; or

[0571] R4'=methyl and R5'=OH and R6'=OH; or

[0572] R4'=methyl and R5'=OH and R6'=methyl; or

[0573] R4'=methyl and R5'=OH and R6'=O-methyl; or

[0574] R4'=methyl and R5'=OH and R6'=-S(=O)2OH; or

[0575] R4'=methyl and R5'=OH and R6'=sulfonyl; or

[0576] R4'=methyl and R5'=methyl and R6'=H; or

[0577] R4'=methyl and R5'=methyl and R6'=OH; or

[0578] R4'=methyl and R5'=methyl and R6'=methyl; or

[0579] R4'=methyl and R5'=methyl and R6'=O-methyl; or

[0580] R4'=methyl and R5'=methyl and R6'=-S(=O)2OH; or

[0581] R4'=methyl and R5'=methyl and R6'=sulfonyl; or

[0582] R4'=methyl and R5'=O-methyl and R6'=H; or

[0583] R4'=methyl and R5'=O-methyl and R6'=OH; or

[0584] R4'=methyl and R5'=O-methyl and R6'=methyl; or

[0585] R4'=methyl and R5'=O-methyl and R6'=O-methyl; or

[0586] R4'=methyl and R5'=O-methyl and R6'=-S(=O)2OH; or

[0587] R4'=methyl and R5'=O-methyl and R6'=sulfonyl; or

[0588] R4'=methyl and R5'=-S(=O)2OH and R6'=H; or

[0589] R4'=methyl and R5'=-S(=O)2OH and R6'=OH; or

[0590] R4'=methyl and R5'=-S(=O)2OH and R6'=methyl; or

[0591] R4'=methyl and R5'=-S(=O)2OH and R6'=O-methyl; or

[0592] R4'=methyl and R5'=-S(=O)2OH and R6'=-S(=O)2OH; or

[0593] R4'=methyl and R5'=-S(=O)2OH and R6'=sulfonyl; or

[0594] R4'=methyl and R5'=sulfonyl and R6'=H; or

[0595] R4'=methyl and R5'=sulfonyl and R6'=OH; or

[0596] R4'=methyl and R5'=sulfonyl and R6'=methyl; or

[0597] R4'=methyl and R5'=sulfonyl and R6'=O-methyl; or

[0598] R4'=methyl and R5'=sulfonyl and R6'=-S(=O)2OH; or

[0599] R4'=methyl and R5'=sulfonyl and R6'=sulfonyl; or

[0600] R4'=O-methyl and R5'=H and R6'=H; or

[0601] R4'=O-methyl and R5'=H and R6'=OH; or

[0602] R4'=O-methyl and R5'=H and R6'=methyl; or

[0603] R4'=O-methyl and R5'=H and R6'=O-methyl; or

[0604] R4'=O-methyl and R5'=H and R6'=-S(=O)2OH; or

[0605] R4'=O-methyl and R5'=H and R6'=sulfonyl; or

[0606] R4'=O-methyl and R5'=OH and R6'=H; or

[0607] R4'=O-methyl and R5'=OH and R6'=OH; or

[0608] R4'=O-methyl and R5'=OH and R6'=methyl; or

[0609] R4'=O-methyl and R5'=OH and R6'=O-methyl; or

[0610] R4'=O-methyl and R5'=OH and R6'=-S(=O)2OH; or

[0611] R4'=O-methyl and R5'=OH and R6'=sulfonyl; or

[0612] R4'=O-methyl and R5'=methyl and R6'=H; or

[0613] R4'=O-methyl and R5'=methyl and R6'=OH; or

[0614] R4'=O-methyl and R5'=methyl and R6'=methyl; or

[0615] R4'=O-methyl and R5'=methyl and R6'=O-methyl; or

[0616] R4'=O-methyl and R5'=methyl and R6'=-S(=O)2OH; or

[0617] R4'=O-methyl and R5'=methyl and R6'=sulfonyl; or

[0618] R4'=O-methyl and R5'=O-methyl and R6'=H; or

[0619] R4'=O-methyl and R5'=O-methyl and R6'=OH; or

[0620] R4'=O-methyl and R5'=O-methyl and R6'=methyl; or

[0621] R4'=O-methyl and R5'=O-methyl and R6'=O-methyl; or

[0622] R4'=O-methyl and R5'=O-methyl and R6'=-S(=O)2OH; or

[0623] R4'=O-methyl and R5'=O-methyl and R6'=sulfonyl; or

[0624] R4'=O-methyl and R5'=-S(=O)2OH and R6'=H; or

[0625] R4'=O-methyl and R5'=-S(=O)2OH and R6'=OH; or

[0626] R4'=O-methyl and R5'=-S(=O)2OH and R6'=methyl; or

[0627] R4'=O-methyl and R5'=-S(=O)2OH and R6'=O-methyl; or

[0628] R4′=O-methyl and R5′=-S(=O)2OH and R6′=-S(=O)2OH; or

[0629] R4'=O-methyl and R5'=-S(=O)2OH and R6'=sulfonyl; or

[0630] R4'=O-methyl and R5'=sulfonyl and R6'=H; or

[0631] R4'=O-methyl and R5'=sulfonyl and R6'=OH; or

[0632] R4'=O-methyl and R5'=sulfonyl and R6'=methyl; or

[0633] R4'=O-methyl and R5'=sulfonyl and R6'=O-methyl; or

[0634] R4'=O-methyl and R5'=sulfonyl and R6'=-S(=O)2OH; or

[0635] R4'=O-methyl and R5'=sulfonyl and R6'=sulfonyl; or

[0636] R4′=-S(=O)2OH and R5′=H and R6′=H; or

[0637] R4′=-S(=O)2OH and R5′=H and R6′=OH; or

[0638] R4'=-S(=O)2OH and R5'=H and R6'=methyl; or

[0639] R4'=-S(=O)2OH and R5'=H and R6'=O-methyl; or

[0640] R4′=-S(=O)2OH and R5′=H and R6′=-S(=O)2OH; or

[0641] R4'=-S(=O)2OH and R5'=H and R6'=sulfonyl; or

[0642] R4′=-S(=O)2OH and R5′=OH and R6′=H; or

[0643] R4′=-S(=O)2OH and R5′=OH and R6′=OH; or

[0644] R4'=-S(=O)2OH and R5'=OH and R6'=methyl; or

[0645] R4'=-S(=O)2OH and R5'=OH and R6'=O-methyl; or

[0646] R4′=-S(=O)2OH and R5′=OH and R6′=-S(=O)2OH; or

[0647] R4'=-S(=O)2OH and R5'=OH and R6'=sulfonyl; or

[0648] R4'=-S(=O)2OH and R5'=methyl and R6'=H; or

[0649] R4'=-S(=O)2OH and R5'=methyl and R6'=OH; or

[0650] R4'=-S(=O)2OH and R5'=methyl and R6'=methyl; or

[0651] R4'=-S(=O)2OH and R5'=methyl and R6'=O-methyl; or

[0652] R4′=-S(=O)2OH and R5′=methyl and R6′=-S(=O)2OH; or

[0653] R4'=-S(=O)2OH and R5'=methyl and R6'=sulfonyl; or

[0654] R4'=-S(=O)2OH and R5'=O-methyl and R6'=H; or

[0655] R4'=-S(=O)2OH and R5'=O-methyl and R6'=OH; or

[0656] R4'=-S(=O)2OH and R5'=O-methyl and R6'=methyl; or

[0657] R4'=-S(=O)2OH and R5'=O-methyl and R6'=O-methyl; or

[0658] R4′=-S(=O)2OH and R5′=O-methyl and R6′=-S(=O)2OH; or

[0659] R4'=-S(=O)2OH and R5'=O-methyl and R6'=sulfonyl; or

[0660] R4'=-S(=O)2OH and R5'=-S(=O)2OH= and R6'=H; or

[0661] R4'=-S(=O)2OH and R5'=-S(=O)2OH and R6'=OH; or

[0662] R4'=-S(=O)2OH and R5'=-S(=O)2OH and R6'=methyl; or

[0663] R4'=-S(=O)2OH and R5'=-S(=O)2OH and R6'=O-methyl; or

[0664] R4'=-S(=O)2OH and R5'=sulfonyl and R6'=H; or

[0665] R4'=-S(=O)2OH and R5'=sulfonyl and R6'=OH; or

[0666] R4'=-S(=O)2OH and R5'=sulfonyl and R6'=methyl; or

[0667] R4'=-S(=O)2OH and R5'=sulfonyl and R6'=O-methyl; or

[0668] R4'=sulfonyl and R5'=H and R6'=H; or

[0669] R4'=sulfonyl and R5'=H and R6'=OH; or

[0670] R4'=sulfonyl and R5'=H and R6'=methyl; or

[0671] R4'=-sulfonyl and R5'=H and R6'=O-methyl; or

[0672] R4'=sulfonyl and R5'=H and R6'=-S(=O)2OH; or

[0673] R4'=sulfonyl and R5'=H and R6'=sulfonyl; or

[0674] R4'=sulfonyl and R5'=OH and R6'=H; or

[0675] R4'=sulfonyl and R5'=OH and R6'=OH; or

[0676] R4'=sulfonyl and R5'=OH and R6'=methyl; or

[0677] R4'=sulfonyl and R5'=OH and R6'=O-methyl; or

[0678] R4'=sulfonyl and R5'=OH and R6'=-S(=O)2OH; or

[0679] R4'=sulfonyl and R5'=OH and R6'=sulfonyl; or

[0680] R4'=sulfonyl and R5'=methyl and R6'=H; or

[0681] R4'=sulfonyl and R5'=methyl and R6'=OH; or

[0682] R4'=sulfonyl and R5'=methyl and R6'=methyl; or

[0683] R4'=sulfonyl and R5'=methyl and R6'=O-methyl; or

[0684] R4'=sulfonyl and R5'=methyl and R6'=-S(=O)2OH; or

[0685] R4'=sulfonyl and R5'=methyl and R6'=sulfonyl; or

[0686] R4'=sulfonyl and R5'=O-methyl and R6'=H; or

[0687] R4'=sulfonyl and R5'=O-methyl and R6'=OH; or

[0688] R4'=sulfonyl and R5'=O-methyl and R6'=methyl; or

[0689] R4'=sulfonyl and R5'=O-methyl and R6'=O-methyl; or

[0690] R4'=sulfonyl and R5'=O-methyl and R6'=-S(=O)2OH; or

[0691] R4'=sulfonyl and R5'=O-methyl and R6'=sulfonyl; or

[0692] R4'=sulfonyl and R5'=-S(=O)2OH and R6'=H; or

[0693] R4'=sulfonyl and R5'=-S(=O)2OH and R6'=OH; or

[0694] R4'=sulfonyl and R5'=-S(=O)2OH and R6'=methyl; or

[0695] R4'=sulfonyl and R5'=-S(=O)2OH and R6'=O-methyl; or

[0696] R4'=sulfonyl and R5'=sulfonyl and R6'=H; or

[0697] R4'=sulfonyl and R5'=sulfonyl and R6'=OH; or

[0698] R4'=sulfonyl and R5'=sulfonyl and R6'=methyl; or

[0699] R4'=sulfonyl and R5'=sulfonyl and R6'=O-methyl; or

[0700] R4"=H and R5"=H and R6"=H; or

[0701] R4"=H and R5"=H and R6"=OH; or

[0702] R4"=H and R5"=H and R6"=methyl; or

[0703] R4"=H and R5"=H and R6"=O-methyl; or

[0704] R4"=H and R5"=H and R6"=-S(=O)2OH; or

[0705] R4"=H and R5"=H and R6"=sulfonyl; or

[0706] R4"=H and R5"=OH and R6"=H; or

[0707] R4"=H and R5"=OH and R6"=OH; or

[0708] R4" = H and R5" = OH and R6" = methyl; or

[0709] R4"=H and R5"=OH and R6"=O-methyl; or

[0710] R4"=H and R5"=OH and R6"=-S(=O)2OH; or

[0711] R4"=H and R5"=OH and R6"=sulfonyl; or

[0712] R4"=H and R5"=methyl and R6"=H; or

[0713] R4"=H and R5"=methyl and R6"=OH; or

[0714] R4"=H and R5"=methyl and R6"=methyl; or

[0715] R4"=H and R5"=methyl and R6"=O-methyl; or

[0716] R4"=H and R5"=methyl and R6"=-S(=O)2OH; or

[0717] R4" = H and R5" = methyl and R6" = sulfonyl; or

[0718] R4"=H and R5"=O-methyl and R6"=H; or

[0719] R4"=H and R5"=O-methyl and R6"=OH; or

[0720] R4" = H and R5" = O-methyl and R6" = methyl; or

[0721] R4"=H and R5"=O-methyl and R6"=O-methyl; or

[0722] R4"=H and R5"=O-methyl and R6"=-S(=O)2OH; or

[0723] R4" = H and R5" = O-methyl and R6" = sulfonyl; or

[0724] R4"=H and R5"=-S(=O)2OH and R6"=H; or

[0725] R4"=H and R5"=-S(=O)2OH and R6"=OH; or

[0726] R4"=H and R5"=-S(=O)2OH and R6"=methyl; or

[0727] R4"=H and R5"=-S(=O)2OH and R6"=O-methyl; or

[0728] R4"=H and R5"=-S(=O)2OH and R6"=-S(=O)2OH; or

[0729] R4"=H and R5"=-S(=O)2OH and R6"=sulfonyl; or

[0730] R4"=H and R5"=sulfonyl and R6"=H; or

[0731] R4"=H and R5"=sulfonyl and R6"=OH; or

[0732] R4" = H and R5" = sulfonyl and R6" = methyl; or

[0733] R4" = H and R5" = sulfonyl and R6" = O-methyl; or

[0734] R4"=H and R5"=sulfonyl and R6"=-S(=O)2OH; or

[0735] R4"=H and R5"=sulfonyl and R6"=sulfonyl; or

[0736] R4"=OH and R5"=H and R6"=H; or

[0737] R4"=OH and R5"=H and R6"=OH; or

[0738] R4"=OH and R5"=H and R6"=methyl; or

[0739] R4"=OH and R5"=H and R6"=O-methyl; or

[0740] R4"=OH and R5"=H and R6"=-S(=O)2OH; or

[0741] R4"=OH and R5"=H and R6"=sulfonyl; or

[0742] R4"=OH and R5"=OH and R6"=H; or

[0743] R4″=OH and R5″=OH and R6″=OH; or

[0744] R4"=OH and R5"=OH and R6"=methyl; or

[0745] R4"=OH and R5"=OH and R6"=O-methyl; or

[0746] R4"=OH and R5"=OH and R6"=-S(=O)2OH; or

[0747] R4"=OH and R5"=OH and R6"=sulfonyl; or

[0748] R4"=OH and R5"=methyl and R6"=H; or

[0749] R4"=OH and R5"=methyl and R6"=OH; or

[0750] R4" = OH and R5" = methyl and R6" = methyl; or

[0751] R4" = OH and R5" = methyl and R6" = O-methyl; or

[0752] R4"=OH and R5"=methyl and R6"=-S(=O)2OH; or

[0753] R4" = OH and R5" = methyl and R6" = sulfonyl; or

[0754] R4"=OH and R5"=O-methyl and R6"=H; or

[0755] R4"=OH and R5"=O-methyl and R6"=OH; or

[0756] R4" = OH and R5" = O-methyl and R6" = methyl; or

[0757] R4″=OH and R5″=O-methyl and R6″=O-methyl; or

[0758] R4"=OH and R5"=O-methyl and R6"=-S(=O)2OH; or

[0759] R4" = OH and R5" = O-methyl and R6" = sulfonyl; or

[0760] R4"=OH and R5"=-S(=O)2OH and R6"=H; or

[0761] R4"=OH and R5"=-S(=O)2OH and R6"=OH; or

[0762] R4"=OH and R5"=-S(=O)2OH and R6"=methyl; or

[0763] R4"=OH and R5"=-S(=O)2OH and R6"=O-methyl; or

[0764] R4"=OH and R5"=-S(=O)2OH and R6"=-S(=O)2OH; or

[0765] R4"=OH and R5"=-S(=O)2OH and R6"=sulfonyl; or

[0766] R4"=OH and R5"=sulfonyl and R6"=H; or

[0767] R4"=OH and R5"=sulfonyl and R6"=OH; or

[0768] R4" = OH and R5" = sulfonyl and R6" = methyl; or

[0769] R4" = OH and R5" = sulfonyl and R6" = O-methyl; or

[0770] R4"=OH and R5"=sulfonyl and R6"=-S(=O)2OH; or

[0771] R4"=OH and R5"=sulfonyl and R6"=sulfonyl; or

[0772] R4"=methyl and R5"=H and R6"=H; or

[0773] R4" = methyl and R5" = H and R6" = OH; or

[0774] R4" = methyl and R5" = H and R6" = methyl; or

[0775] R4" = methyl and R5" = H and R6" = O-methyl; or

[0776] R4" = methyl and R5" = H and R6" = -S(=O)2OH; or

[0777] R4" = methyl and R5" = H and R6" = sulfonyl; or

[0778] R4" = methyl and R5" = OH and R6" = H; or

[0779] R4"=methyl and R5"=OH and R6"=OH; or

[0780] R4" = methyl and R5" = OH and R6" = methyl; or

[0781] R4" = methyl and R5" = OH and R6" = O-methyl; or

[0782] R4" = methyl and R5" = OH and R6" = -S(=O)2OH; or

[0783] R4" = methyl and R5" = OH and R6" = sulfonyl; or

[0784] R4" = methyl and R5" = methyl and R6" = H; or

[0785] R4" = methyl and R5" = methyl and R6" = OH; or

[0786] R4" = methyl and R5" = methyl and R6" = methyl; or

[0787] R4" = methyl and R5" = methyl and R6" = O-methyl; or

[0788] R4" = methyl and R5" = methyl and R6" = -S(=O)2OH; or

[0789] R4" = methyl and R5" = methyl and R6" = sulfonyl; or

[0790] R4" = methyl and R5" = O-methyl and R6" = H; or

[0791] R4" = methyl and R5" = O-methyl and R6" = OH; or

[0792] R4" = methyl and R5" = O-methyl and R6" = methyl; or

[0793] R4" = methyl and R5" = O-methyl and R6" = O-methyl; or

[0794] R4" = methyl and R5" = O-methyl and R6" = -S(=O)2OH; or

[0795] R4" = methyl and R5" = O-methyl and R6" = sulfonyl; or

[0796] R4"=methyl and R5"=-S(=O)2OH and R6"=H; or

[0797] R4"=methyl and R5"=-S(=O)2OH and R6"=OH; or

[0798] R4" = methyl and R5" = -S(=O)2OH and R6" = methyl; or

[0799] R4" = methyl and R5" = -S(=O)2OH and R6" = O-methyl; or

[0800] R4" = methyl and R5" = -S(=O)2OH and R6" = -S(=O)2OH; or

[0801] R4" = methyl and R5" = -S(=O)2OH and R6" = sulfonyl; or

[0802] R4" = methyl and R5" = sulfonyl and R6" = H; or

[0803] R4" = methyl and R5" = sulfonyl and R6" = OH; or

[0804] R4" = methyl and R5" = sulfonyl and R6" = methyl; or

[0805] R4" = methyl and R5" = sulfonyl and R6" = O-methyl; or

[0806] R4" = methyl and R5" = sulfonyl and R6" = -S(=O)2OH; or

[0807] R4" = methyl and R5" = sulfonyl and R6" = sulfonyl; or

[0808] R4"=O-methyl and R5"=H and R6"=H; or

[0809] R4" = O-methyl and R5" = H and R6" = OH; or

[0810] R4" = O-methyl and R5" = H and R6" = methyl; or

[0811] R4" = O-methyl and R5" = H and R6" = O-methyl; or

[0812] R4" = O-methyl and R5" = H and R6" = -S(=O)2OH; or

[0813] R4" = O-methyl and R5" = H and R6" = sulfonyl; or

[0814] R4" = O-methyl and R5" = OH and R6" = H; or

[0815] R4"=O-methyl and R5"=OH and R6"=OH; or

[0816] R4" = O-methyl and R5" = OH and R6" = methyl; or

[0817] R4" = O-methyl and R5" = OH and R6" = O-methyl; or

[0818] R4" = O-methyl and R5" = OH and R6" = -S(=O)2OH; or

[0819] R4" = O-methyl and R5" = OH and R6" = sulfonyl; or

[0820] R4" = O-methyl and R5" = methyl and R6" = H; or

[0821] R4" = O-methyl and R5" = methyl and R6" = OH; or

[0822] R4" = O-methyl and R5" = methyl and R6" = methyl; or

[0823] R4" = O-methyl and R5" = methyl and R6" = O-methyl; or

[0824] R4" = O-methyl and R5" = methyl and R6" = -S(=O)2OH; or

[0825] R4" = O-methyl and R5" = methyl and R6" = sulfonyl; or

[0826] R4" = O-methyl and R5" = O-methyl and R6" = H; or

[0827] R4" = O-methyl and R5" = O-methyl and R6" = OH; or

[0828] R4" = O-methyl and R5" = O-methyl and R6" = methyl; or

[0829] R4" = O-methyl and R5" = O-methyl and R6" = O-methyl; or

[0830] R4" = O-methyl and R5" = O-methyl and R6" = -S(=O)2OH; or

[0831] R4" = O-methyl and R5" = O-methyl and R6" = sulfonyl; or

[0832] R4"=O-methyl and R5"=-S(=O)2OH and R6"=H; or

[0833] R4"=O-methyl and R5"=-S(=O)2OH and R6"=OH; or

[0834] R4" = O-methyl and R5" = -S(=O)2OH and R6" = methyl; or

[0835] R4" = O-methyl and R5" = -S(=O)2OH and R6" = O-methyl; or

[0836] R4" = O-methyl and R5" = -S(=O)2OH and R6" = -S(=O)2OH; or

[0837] R4" = O-methyl and R5" = -S(=O)2OH and R6" = sulfonyl; or

[0838] R4" = O-methyl and R5" = sulfonyl and R6" = H; or

[0839] R4" = O-methyl and R5" = sulfonyl and R6" = OH; or

[0840] R4" = O-methyl and R5" = sulfonyl and R6" = methyl; or

[0841] R4" = O-methyl and R5" = sulfonyl and R6" = O-methyl; or

[0842] R4" = O-methyl and R5" = sulfonyl and R6" = -S(=O)2OH; or

[0843] R4" = O-methyl and R5" = sulfonyl and R6" = sulfonyl; or

[0844] R4"=-S(=O)2OH and R5"=H and R6"=H; or

[0845] R4"=-S(=O)2OH and R5"=H and R6"=OH; or

[0846] R4"=-S(=O)2OH and R5"=H and R6"=methyl; or

[0847] R4"=-S(=O)2OH and R5"=H and R6"=O-methyl; or

[0848] R4"=-S(=O)2OH and R5"=H and R6"=-S(=O)2OH; or

[0849] R4"=-S(=O)2OH and R5"=H and R6"=sulfonyl; or

[0850] R4"=-S(=O)2OH and R5"=OH and R6"=H; or

[0851] R4"=-S(=O)2OH and R5"=OH and R6"=OH; or

[0852] R4"=-S(=O)2OH and R5"=OH and R6"=methyl; or

[0853] R4"=-S(=O)2OH and R5"=OH and R6"=O-methyl; or

[0854] R4"=-S(=O)2OH and R5"=OH and R6"=-S(=O)2OH; or

[0855] R4"=-S(=O)2OH and R5"=OH and R6"=sulfonyl; or

[0856] R4"=-S(=O)2OH and R5"=methyl and R6"=H; or

[0857] R4"=-S(=O)2OH and R5"=methyl and R6"=OH; or

[0858] R4"=-S(=O)2OH and R5"=methyl and R6"=methyl; or

[0859] R4"=-S(=O)2OH and R5"=methyl and R6"=O-methyl; or

[0860] R4"=-S(=O)2OH and R5"=methyl and R6"=-S(=O)2OH; or

[0861] R4" = -S(=O)2OH and R5" = methyl and R6" = sulfonyl; or

[0862] R4"=-S(=O)2OH and R5"=O-methyl and R6"=H; or

[0863] R4"=-S(=O)2OH and R5"=O-methyl and R6"=OH; or

[0864] R4" = -S(=O)2OH and R5" = O-methyl and R6" = methyl; or

[0865] R4"=-S(=O)2OH and R5"=O-methyl and R6"=O-methyl; or

[0866] R4"=-S(=O)2OH and R5"=O-methyl and R6"=-S(=O)2OH; or

[0867] R4" = -S(=O)2OH and R5" = O-methyl and R6" = sulfonyl; or

[0868] R4"=-S(=O)2OH and R5"=-S(=O)2OH= and R6"=H; or

[0869] R4"=-S(=O)2OH and R5"=-S(=O)2OH and R6"=OH; or

[0870] R4" = -S(=O)2OH and R5" = -S(=O)2OH and R6" = methyl; or

[0871] R4" = -S(=O)2OH and R5" = -S(=O)2OH and R6" = O-methyl; or

[0872] R4"=-S(=O)2OH and R5"=sulfonyl and R6"=H; or

[0873] R4"=-S(=O)2OH and R5"=sulfonyl and R6"=OH; or

[0874] R4" = -S(=O)2OH and R5" = sulfonyl and R6" = methyl; or

[0875] R4" = -S(=O)2OH and R5" = sulfonyl and R6" = O-methyl; or

[0876] R4"=sulfonyl and R5"=H and R6"=H; or

[0877] R4"=sulfonyl and R5"=H and R6"=OH; or

[0878] R4" = sulfonyl and R5" = H and R6" = methyl; or

[0879] R4" = -sulfonyl and R5" = H and R6" = O-methyl; or

[0880] R4" = sulfonyl and R5" = H and R6" = -S(=O)2OH; or

[0881] R4" = sulfonyl and R5" = H and R6" = sulfonyl; or

[0882] R4"=sulfonyl and R5"=OH and R6"=H; or

[0883] R4"=sulfonyl and R5"=OH and R6"=OH; or

[0884] R4" = sulfonyl and R5" = OH and R6" = methyl; or

[0885] R4" = sulfonyl and R5" = OH and R6" = O-methyl; or

[0886] R4" = sulfonyl and R5" = OH and R6" = -S(=O)2OH; or

[0887] R4" = sulfonyl and R5" = OH and R6" = sulfonyl; or

[0888] R4" = sulfonyl and R5" = methyl and R6" = H; or

[0889] R4" = sulfonyl and R5" = methyl and R6" = OH; or

[0890] R4" = sulfonyl and R5" = methyl and R6" = methyl; or

[0891] R4" = sulfonyl and R5" = methyl and R6" = O-methyl; or

[0892] R4" = sulfonyl and R5" = methyl and R6" = -S(=O)2OH; or

[0893] R4" = sulfonyl and R5" = methyl and R6" = sulfonyl; or

[0894] R4" = sulfonyl and R5" = O-methyl and R6" = H; or

[0895] R4" = sulfonyl and R5" = O-methyl and R6" = OH; or

[0896] R4" = sulfonyl and R5" = O-methyl and R6" = methyl; or

[0897] R4" = sulfonyl and R5" = O-methyl and R6" = O-methyl; or

[0898] R4" = sulfonyl and R5" = O-methyl and R6" = -S(=O)2OH; or

[0899] R4" = sulfonyl and R5" = O-methyl and R6" = sulfonyl; or

[0900] R4"=sulfonyl and R5"=-S(=O)2OH and R6"=H; or

[0901] R4"=sulfonyl and R5"=-S(=O)2OH and R6"=OH; or

[0902] R4" = sulfonyl and R5" = -S(=O)2OH and R6" = methyl; or

[0903] R4" = sulfonyl and R5" = -S(=O)2OH and R6" = O-methyl; or

[0904] R4"=sulfonyl and R5"=sulfonyl and R6"=H; or

[0905] R4"=sulfonyl and R5"=sulfonyl and R6"=OH; or

[0906] R4" = sulfonyl and R5" = sulfonyl and R6" = methyl; or

[0907] R4" = sulfonyl and R5" = sulfonyl and R6' = O-methyl.

[0908] In formula (V), (VI), (VII), (VIII), (IX), (X) and their variants, the substituted benzene ring bonded to the imino functional group is preferably selected from the group consisting of:

[0909]

[0910] The dotted line indicates the binding site to the cyclohexene imine ring.

[0911] In a further more preferred variant according to the first aspect of the invention, in the general formula (V), (VII), (VIII) and their variants, the substituents R4', R5' and R6' may be identical or different and are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl; provided that, if the substituted phenyl ring is monosubstituted, the substituent is located in the ortho or meta position but not in the para position to the imino function of the general formula (V), (VI) and (VIII).

[0912] In a further more preferred variant according to the first aspect of the invention, in the general formula (VI), (IX), (X) and their variants, the substituents R4', R5' and R6' may be identical or different and are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl; provided that, if the substituted phenyl ring is monosubstituted, the substituent is located in the ortho or meta position but not in the para position to the imino function of the general formula (VI), (IX), (X).

[0913] Still more preferably according to the first aspect of the present invention, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises at least one mycosporin-like amino acid compound selected from the group consisting of:

[0914] Table 3

[0915]

[0916]

[0917]

[0918]

[0919]

[0920]

[0921] or their tautomers or stereoisomers or salts, or any mixture of the above compounds.

[0922] Among the mycosporin-like amino acid compounds specified above, compounds MAA-1 and MAA-13 are particularly preferred because they have a significant SPF and UVA light protection promoting effect. Most preferred are acid compounds MAA-20, MAA-21, MAA-22, MAA-23, MAA-24, MAA-24, MAA-26, MAA-27, MAA-28, MAA-29, MAA-30, MAA-31 and amide compounds MAA-32, MAA-33, MAA-34, MAA-35, MAA-36, MAA-37, MAA-38 and MAA-39. The compounds having acid or amide functional groups are light-stable and temperature-stable, and show stability in pH solutions or in oil-in-water emulsions and do not degrade.

[0923] In particular, mycosporin-like amino acid compounds having an acid functional group have better pH stability in a wider pH range than their corresponding hydrolyzed ester compounds, and are therefore unstable in alkaline solutions above pH 9.

[0924] Due to their better solubility in water, the mycosporin-like amino acid compounds can be incorporated into the aqueous phase of emulsions at higher concentrations, resulting in better SPF and UVA photoprotection boosting effects compared to their corresponding ester compounds and thus improving the sun protection efficacy in sunscreen products, cosmetic or pharmaceutical preparations or home care products.

[0925] Most preferably according to the first aspect of the present invention, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises at least one mycosporin-like amino acid compound selected from the group consisting of:

[0926] MAA-A:

[0927]

[0928] MAA-B:

[0929]

[0930] MAA-C:

[0931]

[0932] or their tautomers or salts, or any mixture of the above compounds, wherein the alkyl group is preferably methyl, or ethyl, or propyl, or isopropyl, or butyl, or isobutyl, or tert-butyl, and most preferably methyl.

[0933] The mycosporin-like amino acid compounds according to the invention and defined herein are used as single substances or in mixtures with one, two or more different mycosporin-like amino acid compounds as defined herein.

[0934] Particularly preferred are mixtures of two mycosporin-like amino acid compounds according to the invention and defined herein. Such mixtures show a particularly enhanced promoting effect, as demonstrated in the following examples.

[0935] The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the present invention is further characterized in that it does not contain one or more of the following mycosporin-like amino acid compounds:

[0936] Compound 1:

[0937]

[0938] Compound 2:

[0939]

[0940] Compound 3:

[0941]

[0942] Compound 4:

[0943]

[0944] Compound 5:

[0945]

[0946] Compound 6:

[0947]

[0948] Compound 7:

[0949]

[0950] Compound 8:

[0951]

[0952] As described herein, various mycosporin amino acid compounds (b) contain one or more chiral centers and may therefore exist as racemic mixtures of enantiomers, mixtures of diastereomers, or enantiomerically or optically pure compounds. It should also be noted that the compounds of the present invention include E and Z isomers or mixtures thereof, as well as cis and trans isomers or mixtures thereof.

[0953] Therefore, the chemical structures and mycosporin-like amino acid compounds of general formula (V) to (X) and variations thereof expressly disclosed herein include all possible enantiomers and diastereomers or stereoisomers.

[0954] In certain embodiments, the mycosporin-like amino acid compound (b) of the present invention is isolated as an E or Z isomer. In other embodiments, the compound of the present invention is a mixture of E and Z isomers.

[0955] Alternatively, stereoisomerically pure compounds are used in sunscreen products, cosmetics or pharmaceutical preparations or home care products according to the present invention. As used herein and unless otherwise indicated, the term "stereoisomerically pure" means that one stereoisomer of a compound is substantially free of other stereoisomers of the compound, or a geometric isomer (e.g., about double bonds) is substantially free of other geometric isomers. For example, a stereoisomerically pure compound with a chiral center of the present invention will be substantially free of the opposite enantiomer of the compound. A stereoisomerically pure compound or its composition with two chiral centers of the present invention will be substantially free of other diastereomers of the compound. A stereoisomerically pure compound or its composition with a double bond capable of E / Z isomerization of the present invention will be substantially free of one of the E / Z isomers.

[0956] A typical stereomerically pure compound contains greater than about 80% by weight of one stereoisomer or E / Z isomer of the compound and less than about 20% by weight of other stereoisomers or E / Z isomers of the compound, more preferably greater than about 90% by weight of one stereoisomer or E / Z isomer of the compound and less than about 10% by weight of other stereoisomers or E / Z isomers of the compound, even more preferably greater than about 95% by weight of one stereoisomer or E / Z isomer of the compound and less than about 5% by weight of other stereoisomers or E / Z isomers of the compound, and most preferably greater than about 97% by weight of one stereoisomer or E / Z isomer of the compound and less than about 3% by weight of other stereoisomers or E / Z isomers of the compound.

[0957] As used herein and unless otherwise indicated, the term "stereoisomerically enriched" means a compound of the invention, or composition thereof, which contains greater than about 60% by weight of one stereoisomer or E / Z isomer of a compound of the invention, preferably greater than about 70% by weight, more preferably greater than about 80% by weight of one stereoisomer or E / Z isomer of a compound of the invention.

[0958] Thus, it should be noted that, unless otherwise indicated, the terms mycosporin-like amino acid compounds according to general formula (V) to (X) and variations thereof, as well as the individual mycosporin-like amino acid compounds specified herein, are to be interpreted as covering racemic mixtures of enantiomers, mixtures of diastereoisomers or enantiomerically or optically pure compounds.

[0959] Due to their amino-cyclohexene-imine structure and their electron delocalization capabilities, the compounds according to the general formulae (V) to (X) and their variants are in equilibrium with their tautomeric structures, in which the hydrogen of the amino group changes its position with the double bond of the cyclohexene ring.

[0960] Tautomerism is defined as each of two or more isomers of a compound that exist together in equilibrium and are readily interchangeable by migration of atoms or groups within the molecule. A tautomeric pure or enriched system will readily exchange to an equilibrium state over time.

[0961] The tautomers of the general formula (V) are represented by the general formula (V-tau):

[0962]

[0963] The tautomers of the general formula (VI) are represented by the general formula (VI-tau):

[0964]

[0965] The above principles of tautomerism and redispersion explained based on the mycosporin-like amino acid compounds according to general formula (V) and (VI) are equally applicable to any of the mycosporin-like amino acid compounds defined by general formula (VII), (VIII), (IX), (X) and variations thereof, or to any individual mycosporin-like amino acid compound specified herein.

[0966] Therefore, hereinafter and throughout the specification, references to a mycosporin-like amino acid compound represented by any of the general formulae (V) to (X) and variations thereof, or to an individual mycosporin-like amino acid compound specified herein, also encompass tautomeric isomers thereof.

[0967] According to a first aspect of the invention, the mycosporin-like amino acid compounds according to the general formula (V) to (X) and variations thereof as well as the individual mycosporin-like amino acid compounds specified herein are used in neutral (i.e., uncharged form) or in the form of their salts (such as acid addition salts with inorganic or organic acids).

[0968] In the context of the present invention, the term "salt" refers to a salt of a compound that has the desired effect or pharmacological activity of the parent compound. Such salts include:

[0969] (1) an acid addition salt formed with an inorganic acid or with an organic acid (preferably a monovalent or polyvalent carboxylic acid); or

[0970] (2) Salts formed when an acidic proton present in the starting compound is replaced by a metal ion (eg, an alkali metal ion, an alkaline earth metal ion, or an aluminum ion); or coordinated with an organic base.

[0971] Among the salts, acid addition salts are also particularly preferred, since the mycosporin-like amino acid compounds according to the general formulae (V) to (X) and variations thereof or the mycosporin-like amino acid compounds specified herein contain a protonatable N atom.

[0972] The inorganic acid used in accordance with the present invention to form an acid addition salt with the mycosporin-like amino acid compound is preferably selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Among the salts, hydrochloride or sulfate is most preferred. Particularly preferred is hydrochloride or sulfate or phosphate.

[0973] Even more preferred are acid addition salts with organic mono- or polycarboxylic acids. Further preferred are acid addition salts with organic mono- or polycarboxylic acids, wherein the carboxylic acids are selected from saturated or monounsaturated or polyunsaturated C1 to C30 monocarboxylic acids, saturated or monounsaturated or polyunsaturated C3 to 10 dicarboxylic acids or tricarboxylic acids. The carboxylic acids may be mono- or polysubstituted by hydroxyl groups, preferably α-hydroxycarboxylic acids, wherein the hydroxyl groups are located on carbon atoms adjacent to the carboxyl groups. Many representative substances occur naturally as so-called fruit acids. Preferred α-hydroxycarboxylic acids are: malic acid, citric acid, 2-hydroxy-4-methylmercaptobutyric acid, glycolic acid, isocitric acid, mandelic acid, lactic acid, tartronic acid or tartaric acid.

[0974] The organic acid used according to the present invention to form an acid addition salt with the mycosporin-like amino acid compound is preferably selected from the group consisting of amino acids, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, oxalic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, dodecylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, 4-hydroxybutyric acid, etc.

[0975] Suitable anionic counterions are in particular chloride, bromide, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, hydrogencarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and anions of C1 to C4 alkanoic acids, preferably formate, acetate, trifluoroacetate, propionate and butyrate, furthermore lactate, gluconate, and anions of polyacids such as succinate, oxalate, maleate, fumarate, malate, tartrate and citrate, furthermore sulfonate anions such as benzenesulfonate (phenylsulfonate), toluenesulfonate (p-toluenesulfonate), naphthenesulfonate (naphthalene-2-sulfonate), methanesulfonate (methanesulfonate), ethanesulfonate (ethanesulfonate) and edisulphonate. They can be formed by reacting the compounds according to the invention having basic functional groups with acids of the corresponding anions. Preferred salts of the compounds of formula (I) to (III) and of the individual mycosporin-like amino acid compounds specified herein are the hydrochloride salts.

[0976] The metal ion for salt formation which replaces the acidic protons present in the starting compound is selected from the group consisting of alkali metal ions (preferably Na+, K+ or Li+), alkaline earth metal ions (preferably Ca++ or Mg++, Al+++ or NH4+).

[0977] The coordinating organic base used for salt formation is selected from the group consisting of ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, triethylamine, and the like.

[0978] In the following specification and claims, unless otherwise stated, the term mycosporin-like amino acid compound includes the neutral, uncharged form of the compound / molecule as well as the salt form of the compound as well.

[0979] Mycosporin-like amino acid compounds in salt form result in lower logP OW, and thus make the compound more hydrophilic, which leads to better water solubility. In particular, due to their surface activity, i.e. co-emulsifying properties, cationic salts of mycosporin-like amino acid compounds support the emulsification process in emulsions. In addition, mycosporin-like compounds in the form of cationic salts show excellent substantivity behavior on the skin and hair: most conditioning active substances are cationic; the conditioning effect leads to a softer skin feel, which makes the final product more acceptable to consumers. In addition, mycosporin-like amino acid compounds in the form of cationic salts show antimicrobial activity.

[0980] In a particularly advantageous variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the invention comprises one of the following combinations of components (a) and (b):

[0981] at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with at least one compound according to general formula (V) as defined herein; or

[0982] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with at least one compound according to general formula (VI) as defined herein.

[0983] Such combinations of organic UV filters and mycosporin-like amino acid compounds show synergistic SPF performance and UVA photoprotection improvement of sunscreen products, cosmetic or pharmaceutical preparations or home care products.

[0984] In the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the present invention, a more preferred combination of components (a) and (b) is:

[0985] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-1; or

[0986] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-2; or

[0987] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-3; or

[0988] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-4; or

[0989] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-5; or

[0990] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-6; or

[0991] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-7; or

[0992] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-8; or

[0993] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-9; or

[0994] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-11; or

[0995] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-12; or

[0996] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-13; or

[0997] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-14; or

[0998] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-16; or

[0999] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-17; or

[1000] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-20; or

[1001] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-21; or

[1002] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-22; or

[1003] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-23; or

[1004] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-24; or

[1005] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-25; or

[1006] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-26; or

[1007] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-27; or

[1008] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-28; or

[1009] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-29; or

[1010] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-30; or

[1011] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-31; or

[1012] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyldibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-32; or

[1013] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-33; or

[1014] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-34; or

[1015] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-35; or

[1016] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-36; or

[1017] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-37; or

[1018] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-38; or

[1019] ■ at least one organic UV filter: homosalate and / or phenylbenzimidazole and / or sulfonic acid and / or butyl methoxydibenzoylmethane and / or octocrylene and / or ethylhexyl methoxycinnamate and / or isoamyl p-methoxycinnamate and / or ethylhexyl triazone and / or diethylhexyl butamido triazone and / or 4-methylbenzylidene camphor and / or ethylhexyl salicylate and / or disodium phenyl dibenzimidazole tetrasulfonate and / or bis-ethylhexyloxyphenol methoxyphenyl triazine and / or diethylaminohydroxybenzoyl hexyl benzoate and / or menthyl anthranilate, in combination with MAA-39;

[1020] In particular, the combination with the mycosporin-like amino acid compounds MAA-1 to MAA-39 and organic UV filters shows a synergistic SPF performance and UVA light protection improvement effect. This SPF performance and UVA light protection improvement effect can be particularly observed when the mycosporin-like amino acid is in its acid form or its salt form, i.e., its cationic form.

[1021] In the preparation of sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention, the compounds defined herein can be used in combination with other UV-absorbers different from the at least one primary organic UV filter (a) in order to further optimize the SPF, i.e. to obtain a high SPF in the range of 6 to 100, preferably in the range of 6 to 70, and to cover a wide UVA and UVB range.

[1022] Thus, the at least one primary organic UV filter (a) in the sunscreen product, cosmetic or pharmaceutical preparation or home care product as defined herein is advantageously combined with at least one primary inorganic UV filter and / or with at least one secondary sunscreen ingredient or secondary sunscreen UV filter.

[1023] The primary inorganic UV filter is a pigment selected from the group consisting of titanium dioxide (TiO2) (amorphous or crystalline in rutile and / or anatase form), zinc oxide (ZnO), iron oxide (Fe2O3), zirconium oxide (ZrO2), silicon dioxide (SiO2), manganese oxide (e.g. MnO), aluminum oxide (Al2O3), cerium oxide (Ce2O3), barium carbonate (BaCO3), calcium carbonate (CaCO3) and mixtures thereof.

[1024] Preferably, the inorganic UV filter is titanium dioxide, zinc oxide and mixtures thereof, more preferably, the inorganic UV filter is titanium oxide and / or zinc oxide, and most preferably, the inorganic UV filter is zinc oxide. ZnO has a broad UVA / UVB absorption curve, while TiO2 provides better UVB protection.

[1025] According to another variant, the inorganic UV filter has a weight median particle size d of 1 nm to 1000 nm, preferably 3 nm to 800 nm, more preferably 5 nm to 600 nm, and most preferably 10 nm to 400 nm. 50 in the form of particles.

[1026] Inorganic UV filters also encompass nanopigments of untreated or treated metal oxides (average size of primary particles: typically 1 nm to 100 nm, preferably 3 nm to 90 nm, more preferably 5 nm to 80 nm, and most preferably 10 nm to 70 nm), such as, for example, titanium dioxide (TiO2) (amorphous or crystalline in rutile and / or anatase form), zinc oxide (ZnO), iron oxide (Fe2O3), zirconium oxide (ZrO2), silicon dioxide (SiO2), manganese oxide (e.g. MnO), aluminum oxide (Al2O3), cerium oxide (Ce2O3), barium carbonate (BaCO3), calcium carbonate (CaCO3) or nanopigments of mixtures thereof.

[1027] Treated nanopigments and non-nanopigments are pigments that have been subjected to one or more surface treatments of a chemical, electronic, mechanochemical and / or mechanical nature with compounds such as amino acids, beeswax, fatty acids, fatty acid esters, fatty alcohols, anionic surfactants, lecithin, sodium, potassium, zinc, iron or aluminum salts of fatty acids, metal (titanium or aluminum) alkoxides, polyethylene, silicones, proteins (collagen or elastin), alkanolamines, silica, metal oxides, sodium hexametaphosphate, alumina or glycerol, hydrated silica, stearic acid, jojoba esters or glutamic acid derivatives.

[1028] The treated nano pigments and non-nanopigments can more particularly be titanium oxide treated with silica and alumina, alumina and aluminum stearate, alumina and aluminum laurate, aluminum hydroxide, iron oxide and iron stearate, silica, alumina and silicone, sodium hexametaphosphate, octyl trimethoxy silane, alumina and stearic acid, alumina and glycerol, or alumina and silicone or polyhydroxy stearic acid, hydrated silica, jojoba esters, stearoyl glutamic acid, glutamic acid, glutamic acid and derivatives, trimethoxy caprylyl silane, glycerol, polydimethylsiloxane, hydrogenated polydimethylsiloxane, dimethicone or a combination thereof. Other titanium oxide nano pigments treated with silicone are preferably TiO2 treated with octyl trimethyl silane, preferably with an average size of 25 nm to 40 nm of the basic particles; TiO2 treated with polydimethylsiloxane, preferably with an average size of 21 nm of the basic particles; or TiO2 treated with polydimethyl hydrogen siloxane, preferably with an average size of 25 nm of the basic particles.

[1029] The coated zinc oxide nanopigments and zinc oxide non-nanopigments are, for example, ZnO coated with polymethylhydrogensiloxane; ZnO dispersions in cyclomethicone / oxyethylated polydimethylsiloxane containing 30% or 80% of nano or non-nano zinc oxide coated with silica and polymethylhydrogensiloxane; ZnO coated with perfluoroalkyl phosphate and perfluoroalkylethyl-based copolymers as dispersions in cyclopentasiloxane; ZnO coated with dimethoxydiphenylsilane triethoxyoctanoylsilane crosspolymer; ZnO coated with glutamic acid; ZnO coated with octyltriethoxysilane; ZnO coated with polydimethylsiloxane; ZnO coated with silicone grafted acrylic polymers, dispersed in cyclomethicone; ZnO coated with triethoxycaprylylsilane; ZnO coated with polyhydroxystearic acid; alumina treated ZnO dispersed in a mixture of ethylhexyl methoxycinnamate / PVP-hexadecene / polymethicone copolymer; ZnO coated with silica and polymethylsilsesquioxane; ZnO dispersed in a hydroxystearic acid polycondensate; or ZnO coated with a mixture of stearoyl glutamic acid, jojoba esters, polyhydroxystearic acid, isopropyl titanium triisostearate, hydrogenated olive oil stearyl esters, cetearyl nonanoate, white beeswax, polydimethylsiloxane, dimethoxydiphenylsilane triethoxycaprylylsilane crosspolymer, octyl triethoxysilane, glutamic acid and sodium stearoyl lactylate.

[1030] Also preferred are particulate UV filters or inorganic pigments, which may optionally be hydrophobized, such as iron oxide (Fe2O3), zirconium oxide (ZrO2), silicon oxide (SiO2), manganese oxide (e.g. MnO), aluminum oxide (Al2O3), cerium oxide (e.g. Ce2O3), barium carbonate (BaCO3), calcium carbonate (CaCO3), or mixtures thereof.

[1031] The previously specified inorganic UV filters are used in sunscreen products, cosmetic or pharmaceutical preparations or household care products as single component or in mixtures with two, three, four or more of the inorganic UV filters mentioned.

[1032] The combination of different classes of effective sunscreen UV filters, such as UVA filters, UVB filters, broadband filters and / or inorganic pigments, provides reliable protection against different UV rays in the wavelength range from 290 to 400 nm.

[1033] In a further preferred variant, the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention comprise primary UV filters, i.e. in particular organic UV filters and / or inorganic pigments (UV filter pigments), in such a total amount that the products or preparations according to the invention have a sun protection factor SPF of 6 to 100, preferably 6 to 70. Such compositions according to the invention are particularly suitable for protecting the skin, hair and nails.

[1034] In addition to the abovementioned primary organic UV filters (a), secondary sunscreen ingredients of the antioxidant type can also advantageously be used in the sunscreen products, cosmetic or pharmaceutical preparations or household care products according to the invention in order to further optimize the UV protection.

[1035] Secondary sunscreen ingredients of the antioxidant type interrupt the photochemical reaction chain that is initiated when UV rays penetrate into the skin.

[1036] Typical examples of secondary sunscreen ingredients are amino acids (e.g. arginine, lysine, glycine, histidine, tyrosine, tryptophan) and their derivatives in very low compatible doses, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D,L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g. dihydrolipoic acid), aurothiocan, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine) and their derivatives. thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoxide amine compounds (e.g. buthionine sulfoxide amine, homocysteine ​​sulfoxide amine, buthionine sulfoxide ether sulfone, penta-, hexa- and heptathionine sulfoxide amine), and also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactic acid ferritin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and its derivatives (e.g. ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate), tocopherol and its derivatives (e.g. vitamin E acetate), vitamin A and its derivatives (vitamin A palmitate) and coniferyl benzoate of benzoin resin, rutinic acid and its derivatives Derivatives, glycosyl rutin, ferulic acid, furfurylidene glucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic acid, nordihydroguaiaretic acid, trihydroxybutylpropionic acid, uric acid and its derivatives, mannose and its derivatives, superoxide dismutase, sinapinic acid, sinapinic acid malate, sinapinic acid ester derivatives, selenium and its derivatives (e.g. selenomethionine), stilbene and its derivatives (e.g. stilbene oxide, trans-stilbene oxide) and derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances suitable for the purposes of the present invention.

[1037] The group of secondary sunscreen ingredients also encompasses plant-based extracts which have antioxidant and generally photoprotective properties and interrupt the photochemical reaction chain initiated when UV rays penetrate into the skin, thus effectively preventing skin aging. The plant extract with UV protection properties is selected from the group consisting of lignin / cellulose, lignin, hydrolyzed lignin, propolis and green propolis, galangal extract, macroalgae and microalgae (porphyra, red algae (Porphyra Umbilicalis, Palmaria palmata, Saccharina latissima, Corallina pilulifera, Eckloina cava, Sargassum sagamianum, Porphyra rosengurttii, Sargassum siliquastrum, Thalassiosira weissflogii), green microalgae (e.g., Interfilum and Klebsormidium), seaweed (e.g., Padina australis), Eucheuma cottonii), Pongamia Glabra seed oil, Karanja oil (Millettiapinnata), Rhatania Extrakt (Krameria lappacea), Lichen, Soybean, Capparis spinosa, Bamboo, Green Coffee Oil, Buriti Oil (Mauritiaflexuosa), Black Sea Cucumber (Holothuria atra), Cyanobacteria, Polypodiumleucotomos, Green Tea, Black Tea (Camellia sinensis), Aloe, Walnut, Borage Oil, Evening Primrose Oil, Avocado Oil, Tea Tree Oil, Red Clover (Trifolium pratense L.), Soybean (Glycine max L.), Capparis spinosa, Apricot, Flame Tree (Spathodea campanulata), milk thistle (Silybum marianum L.), cashew nut shells, grapes, blood oranges, pomegranates (Punica granatu), blueberries (Vaccinium myrtillus L.), blueberries (Vaccinium uliginosum L.), Strawberry (Fragaria ananassa), Polygonum multiflorum Thunb, Turmeric (Curcuma longa L.), Ginseng (Panax ginseng), Ivy (Hederahelix), Broccoli (Brassica oleracea var italica), Tamarind (Tamarindus indica), Prickly pear cactus, Coffee, Basil (Ocimum basilicum, Linn.), Pomegranate seed oil (Punica granatum), Wheat germ oil (Triticum vulgare), Blackcurrant seed oil (Ribes nigrum), Sesame oil (Sesamum indicum), Carrot (Daucuscarota sativa), Raspberry (Rubus idaeus), Traditional medicinal plants from Sri Lanka (Aporosalindleyana (Euphorbiaceae), Atalantia ceylanica (Rutaceae), Hibiscus furcatus (Malvaceae), Olaxzeylanica (Ironwood family), Ophiorrhiza mungos (Rubiaceae), Argyreiapopulifolia (Convolvulaceae), Ipomoea mauritiana (Convolvulaceae), Lasia spinosa.

[1038] (Araceae), Leucas zeylanica (Lamiaceae), Plectranthus zeylanicus (Lamiaceae)) and traditional medicinal plants from Brazil (D. gardneriana seeds, L. microphylla leaves, Amburana cearensis, Aspidosperma cuspa, Aspidosperma pyrifolium, Croton sonderianus, Curatella americana, Dimophandra gardneriana, Lippia microphylla, Luehea paniculata, Sidagalheirensis), and any mixtures thereof.

[1039] Preferably, the plant extract having UV protective properties is selected from the group consisting of lignin / cellulose, lignin, hydrolyzed lignin, galangal extract, laver, red algae (Porphyra umbilicus), green microalgae (e.g., Endothella and Creatia), seaweed (e.g., Padilla, Eucheuma), Pongamia glabrous seed oil, Karanja oil (Pongamia), Rhatania Extrakt (Arctium lappa), soybean, bamboo, Bridgeberry oil (Pendulum flexuosa), cyanobacteria, Polypodium leucotomos, green tea, black tea (Camellia sinensis), evening primrose oil, cashew nut shell, pomegranate (Punica granatum), and any mixture thereof.

[1040] Advantageously, the amount of secondary sunscreen substances in the sunscreen products, cosmetic or pharmaceutical preparations or household care products according to the invention is 0.005% to 5.0% by weight, preferably 0.01% to 4.0% by weight, more preferably 0.05% to 3.0% by weight, based on the total weight of the ready-to-use formulation.

[1041] The UV filters are incorporated into the aqueous part or the lipophilic part of the sunscreen products, cosmetic or pharmaceutical preparations or home care products, depending on whether they are water or oil (fat) soluble / miscible UV filters, or can even be added to the final product by standard methods known to those skilled in the art.

[1042] The primary organic UV filter (a) according to the first aspect of the invention is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.01% to 55.0% by weight, based on the total weight of the final formulation. In a preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or make-up product comprises the organic UV filter (a) in an amount of 0.1% to 50.0% by weight, based on the total weight of the final formulation. In a more preferred variant, the organic UV filter (a) is advantageously used in an amount of 0.5% to 45.0% by weight, based on the total weight of the final formulation, in the sunscreen product, cosmetic or pharmaceutical preparation or home care product. In a most preferred variant, the organic UV filter is advantageously used in an amount of 1.0% to 40.0% by weight, based on the total weight of the final formulation, in the sunscreen product, cosmetic or pharmaceutical preparation or home care product.

[1043] For mixtures of organic UV filters, the above amounts relate to the total content of organic UV filters in the mixture, ie the amount is the sum of the contents of all organic UV filters in the mixture.

[1044] The primary organic UV filter (a) and further UV filter components such as primary inorganic UV filters and / or secondary UV filters as defined herein (i.e. the total amount of UV filters) are present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention in an amount of 0.1% to 85.0% by weight, based on the total weight of the final formulation. In a preferred embodiment, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises the organic UV filter (a) and further UV filter components as defined herein in an amount of 0.3% to 80.0% by weight, based on the total weight of the final formulation. In a more preferred embodiment, the organic UV filter (a) and further UV filter components as defined herein are advantageously used in an amount of 0.5% to 75.0% by weight, based on the total weight of the final formulation, in the sunscreen product, cosmetic or pharmaceutical preparation or home care product. The abovementioned amounts therefore relate to the sum of the contents of all primary organic and inorganic UV filters present in the sunscreen, cosmetic or pharmaceutical preparation or household care product.

[1045] Based on the total weight of the final formulation, at least one mycosporin-like amino acid compound (b) according to the first aspect of the present invention is present in a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product in an amount of 0.001% to 15.0% by weight. In a preferred variation, based on the total weight of the final formulation, the sunscreen product, the cosmetic or pharmaceutical preparation or the home care makeup product contains at least one mycosporin-like amino acid compound (b) in an amount of 0.01% to 10.0% by weight. In a more preferred variation, based on the total weight of the final formulation, at least one mycosporin-like amino acid compound (b) is advantageously used in a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product in an amount of 0.05% to 7.5% by weight. In a most preferred variation, based on the total weight of the final formulation, at least one mycosporin-like amino acid compound is advantageously used in a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product in an amount of 0.1% to 5.0% by weight.

[1046] For a mixture of mycosporine-like amino acid compounds (b), the above amount relates to the total content of mycosporine-like amino acid compounds in the mixture, ie the amount is the sum of the contents of all mycosporine-like amino acid compounds (b) in the mixture.

[1047] Advantageously, the sunscreen product according to the first aspect of the present invention comprises:

[1048] (i) 0.01 wt. % to 55.0 wt. % of at least one primary organic UV filter; and

[1049] (ii) 0.001% to 15% by weight of at least one mycosporin-like amino acid compound as defined herein;

[1050] Based on total weight of final formulation.

[1051] In a preferred variant, the cosmetic or pharmaceutical preparation according to the first aspect of the invention comprises

[1052] (iii) 1.0 wt. % to 40.0 wt. % of at least one primary organic UV filter; and

[1053] (iv) 0.1% to 5.0% by weight of at least one mycosporin-like amino acid compound as defined herein;

[1054] Based on total weight of final formulation.

[1055] The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention provides broad spectrum light protection and therefore provides protection against UVA and UVB radiation. Typically, the composition of the invention has an SPF (UVB) of at least 6. However, the SPF may vary as desired. Preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention has an SPF (UVB) of at least 6, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 or even higher.

[1056] Furthermore, the sunscreen product, cosmetic or pharmaceutical preparation or household care product according to the invention has an SPF (UVA) or UVA-PF of 1 to 50, preferably at least 10, and most preferably greater than 2.

[1057] In the context of the present invention, it is also possible and in some cases advantageous to combine the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the first aspect of the invention with other conventional active substances, adjuvants or additives commonly used in sunscreen products, cosmetic or pharmaceutical compositions or home care products as described further below, to obtain ready-to-use preparations or formulations.

[1058] Other active agents and / or adjuvants and / or additives or auxiliaries are, for example, abrasives, anti-acne agents, anti-skin aging agents, anti-cellulite agents, anti-dandruff agents, anti-inflammatory agents, irritation preventives, irritation inhibitors, antioxidants, alkanediols, astringents, odor absorbers, antiperspirants, bactericides, antistatic agents, antimicrobial agents, binders, buffers, carrier materials, oil components, chelating agents, cell stimulants, cleaning agents, depilatories, surfactants, deodorants, antiperspirants, softeners, emulsifiers, enzymes, enzyme inhibitors agents, essential oils, fibers, film formers, water resistance improvers, color fixatives, foam formers, foam stabilizers, defoamers, foam boosters, gelling agents, gel formers, hair care agents, hair fixatives, hair straighteners, moisturizers, moisturizing substances, water-retaining substances, whitening agents, strengthening agents, detergents, optical brighteners, impregnants, antifouling agents, dyes, friction reducers, lubricants, moisturizing creams, ointments, sunscreens, plasticizers, covering agents, polishes, preservatives, glossing agents, green and synthetic polymers, powders, proteins and mixtures of two or more of the foregoing, as further described below.

[1059] The cosmetic or pharmaceutical excipients and / or active substances and / or additives and / or auxiliary carriers, oil components, rheological additives, hydrotropes, solubilizers, powders, film formers, water resistance improvers, skin moisturizing and / or water retention substances, demulcent substances, physiological cooling agents, alkanediols, antioxidants, anti-skin aging agents, matrix-metalloproteinase inhibitors (MMPI), anti-inflammatory agents, TRPV1 antagonists, emulsifiers, antimicrobial agents, preservatives, antibacterial or antifungal active substances, chelating agents, surfactants, fragrances / fragrances or perfume oils and any mixtures of two or more of the above substances are particularly preferred in the preparation of sunscreen products, cosmetic and pharmaceutical preparations or home care products.

[1060] Carrier: Since sunscreen products, cosmetics or medicines according to the present invention, particularly dermatological preparations or home care products are intended for topical application, such as in the form of ointments, pastes, creams and gels, they are preferably based on cosmetics or pharmaceutically acceptable carriers. The most common acceptable carrier is water. The acceptable carrier except water includes glycerol, C1-4 alcohol, organic solvent, fatty alcohol, fatty ether, fatty ester, polyol, glycol, vegetable oil, mineral oil, liposome, lamellar lipid material, water or their mixture. The non-limiting example of organic solvent includes monoalcohol and polyol, such as ethanol, isopropanol, propanol, benzyl alcohol and phenylethyl alcohol, or glycol or glycol ether, such as monomethyl ether, monoethyl ether and monobutyl ether or its ether of ethylene glycol, propylene glycol, such as monomethyl ether of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol and the alkyl ether of diethylene glycol, such as monoethyl ether or monobutyl ether of diethylene glycol. Other suitable examples of organic solvents are ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, propanediol and glycerol. The organic solvent can be a volatile or non-volatile compound. The total amount of carrier in the composition can vary, but is typically 40% to 90% by weight based on the total weight of the composition.

[1061] Composition of the present invention can comprise at least one water-soluble or organic solvent.The non-limiting example of organic solvent comprises monoalcohol and polyol, such as ethanol, isopropanol, propanol, benzyl alcohol and phenylethyl alcohol, or glycol or glycol ether, for example monomethyl ether, monoethyl ether and monobutyl ether or its ether of ethylene glycol, propylene glycol, for example alkyl ether of monomethyl ether, butylene glycol, hexylene glycol, dipropylene glycol and diethylene glycol of propylene glycol, for example monoethyl ether or monobutyl ether of diethylene glycol.Other suitable examples of organic solvent are ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, propylene glycol and glycerine.Organic solvent can be volatile or non-volatile compound.

[1062] Additional non-limiting examples of water-soluble solvents include alkanols (polyols such as diols and polyols) such as glycerol, 1,2,6-hexanetriol, trimethylolpropane, ethylene glycol, propylene glycol, diethylene glycol, butylene glycol, hexylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, dipropylene glycol, 1,3-butanediol, 2,3-butanediol, 1,4-butanediol, 3-methyl-1,3-butanediol, 1,5-pentanediol, tetraethylene glycol, 1,6-hexanediol, , 2-methyl-2,4-pentanediol, polyethylene glycol, 1,2,4-butanetriol, 1,2,6-hexanetriol, 2-butene-1,4-diol, 2-ethyl-1,3-hexanediol, 2-methyl-2,4-pentanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-decanediol and 4-methyl-1,2-pentanediol; alkyl alcohols having 1 to 4 carbon atoms, such as ethanol, methanol, butanol, propanol and isopropanol; glycol ethers such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol monomethyl ether acetate, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol mono-n-propyl ether, ethylene glycol monoisopropyl ether, diethylene glycol monoisopropyl ether, ethylene glycol mono-n-butyl ether, ethylene glycol mono-tert-butyl ether, diethylene glycol mono-tert-butyl ether, 1-methyl-1-methoxybutanol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monotert-butyl ether, butyl ether, propylene glycol mono-n-propyl ether, propylene glycol mono-isopropyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monoethyl ether, dipropylene glycol mono-n-propyl ether and dipropylene glycol mono-isopropyl ether; 2-pyrrolidone, N-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, formamide, acetamide, dimethyl sulfoxide, sorbitol, sorbitan, acetin, diacetin, triacetin, sulfolane and any mixture thereof. The total amount of water-soluble or organic solvent in the composition according to the present invention can vary, but is generally 0.1% to 50% by weight based on the total weight of the composition.

[1063] Solubilizer: The composition of the present invention may include at least one solubilizer. A solubilizer is a compound that helps dissolve the UV filters and / or other components in the composition. A particularly useful but non-limiting example of a solubilizer is a hydrotrope. Hydrotropes (or hydrotropes) are a diverse class of typically water-soluble compounds characterized by an amphiphilic molecular structure and the ability to significantly increase the solubility of poorly soluble organic molecules in water. Non-limiting examples of hydrotropes include sodium 1,3-benzenedisulfonate, sodium benzoate, sodium 4-pyridinecarboxylate, sodium salicylate, sodium benzenesulfonate, caffeine, sodium p-toluenesulfonate, sodium butyl monoglycol sulfate, 4-aminobenzoic acid HCl, sodium cumenesulfonate, N,N-diethylnicotinamide, N-pyridylmethylnicotinamide, N-allylnicotinamide, 2-methacryloyloxyethylphosphorylcholine, resorcinol, butyl urea, pyrogallol, N-methylpyridineacetamide 3.5, procaine HCl, proline HCl, nicotinamide, pyridine, 3-methylpyridinamine, sodium ibuprofen, sodium xylenesulfonate, ethyl carbamate, pyridoxal hydrochloride, sodium benzoate, 2-pyrrolidone, ethyl urea, N,N-dimethylacetamide, N-methylacetamide and isoniazid, and any mixtures thereof. In some cases, particularly useful hydrotropes include nicotinamide (nicotinamide), caffeine, sodium PCA, sodium salicylate, urea and hydroxyethyl urea, in particular nicotinamide (nicotinamide) and / or caffeine. Combinations of two or more, three or more, or four or more hydrotropes may also be used in the composition according to the invention. The total amount of solubilizer in the composition of the invention may vary, but is typically in an amount of 0.01% to 20% by weight based on the total weight of the composition.

[1064] Oil component: Sunscreen products, cosmetic or pharmaceutical preparations or home care products may include at least one oil phase or at least one oil component, wax, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicon dioxide, talc and zinc oxide or any mixture thereof. Powders include carriers such as lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate and polyamide powders or any mixture thereof. Solutions and emulsions include carriers such as solvents, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, propylene glycol, etc., or any mixture thereof. However, preparations based only on water are also possible. Oil, oil-in-water and water-in-oil emulsions, etc. are preferred.

[1065] Possible suitable oily phases or oil components in the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention are, for example, vegetable oils, hydrocarbons, fatty alcohols, fatty acid esters or mixtures of two or more of the aforementioned oil components.

[1066] The oil phase or oil component in sunscreen products, cosmetic or pharmaceutical preparations or home care products is preferably a vegetable oil, and even more preferably a liquid vegetable oil. It can also be advantageous to have a mixture of two or more vegetable oil components, in particular a liquid vegetable oil mixture.

[1067] Vegetable oil or vegetable oil is an oil extracted from seeds, or less often from other parts of the fruit. Similar to animal fats, vegetable oils are mixtures of triglycerides. Soybean oil, rapeseed oil, and cocoa butter are examples of vegetable oils from seeds. Olive oil, palm oil, and rice bran oil are examples of oils from other parts of the fruit. In common usage, vegetable oil or vegetable oil may refer only to plant fats that are liquid at room temperature or at skin temperature of 35°C to 37°C. Vegetable oils are usually edible.

[1068] The term "vegetable oil" also includes unsaturated vegetable oils. Unsaturated oils or vegetable oils can be converted into higher melting point oils by partial or complete "hydrogenation". The hydrogenation process involves "spraying" the oil with hydrogen at high temperature and pressure in the presence of a catalyst (usually a powdered nickel compound). When each carbon-carbon double bond is chemically reduced to a single bond, two hydrogen atoms each form a single bond with two carbon atoms. Eliminating double bonds by adding hydrogen atoms is called saturation; when the saturation increases, the oil gradually tends to be fully hydrogenated. The oil can be hydrogenated to increase resistance to rancidity (oxidation) or to change its physical properties. When the saturation increases, the viscosity and melting point of the oil increase.

[1069] In a preferred embodiment, the vegetable oil is selected from the group consisting of avocado oil, abies alba seed oil, acacia victoriae seed oil, kiwifruit seed oil, amaranthus hypochondriacus seed oil, peanut oil, astrocaryum murumuru seed butter, astrocaryum tucuma seed butter, astrocaryum tucuma seed oil, astrocaryum vulgare fruit oil, astrocaryum vulgare kernel oil, oat kernel oil, brassica alba seed oil, brassica campestris seed oil, shea butter, shea butter, calendula officinalis seed oil ... Officinalis Seed Oil, Calophyllum Inophyllum Seed Oil, Calophyllum Tacamahaca Seed Oil, Camellia Oleifera Seed Oil, Camellia Reticulata Seed Oil, Camellia Sinensis Seed Oil, Canola Oil, Carthamus Tinctorius Oil, Chlorella Vulgaris Oil, Citrullus Lanatus Seed Oil, Citrus Aurantifolia Seed Oil, Citrus AurantiumDulcis Seed Oil, Citrus Grandis Seed Oil, Coconut (Cocos Nucifera) Oil, Coconut Seed Butter, Coffea Arabica Seed Oil, Chlorella Oil (biotech), Corylus Americana Seed Oil, Corylus Avellana Seed Oil, Cucumis Melo seed oil, Cucumber (Cucumis Sativus) seed oil, Pumpkin (Cucurbita Pepo) seed oil, Oil palm (Elaeis Guineensis) oil, Palm (Elaeis) fruit oil, Soybean (Glycine Soja) oil, Cotton (GosSY-pium Herbaceum) seed oil, Upland cotton (GosSY-pium Hirsutum) seed oil, Sunflower (HelianthusAnnuus Seed Oil, Macadamia Integrifolia Seed Oil, Macadamia Ternifolia Seed Oil, Mangifera Indica Seed Butter, Mango Seed Butter, Melissa Officinalis Seed Oil, Microalgae Oil, Moringa Oleifera Seed Oil, Moringa Peregrina Seed Oil, Evening Primrose Oil, Olea Europaea Fruit Oil, Olus Oil, Orbignya Oleifera Seed Oil, Orbignya Speciosa Kernel Oil, Oryza Sativa Bran / Germ Oil, Rice Bran Oil, Rice Germ Oil, Rice Lipids, Rice Seed Oil, Passiflora Edulis Seed Oil, Avocado Butter, Avocado Oil, Prunus Amygdalus Dulcis Seed Oil, Dulcis Oil, Apricot (Prunus Armeniaca) Kernel Oil, Peach (Prunus Persica) Kernel Oil, Pomegranate (Punica Granatum) Seed Oil, Apple (Pyrus Malus) Seed Oil, Ricinoleic / Caproic / Caprylic / Capric Triglycerides, Castor (Ricinus Communis) Seed Oil, Rosa Canina Fruit Oil, Rosa Moschata Seed Oil, Raspberry (Rubus Idaeus) Seed Oil, Sesame (Sesamum Indicum) Seed Butter, Soybean Glycerides, Cocoa (Theobroma Cacao) Seed Butter, Theobroma Grandiflorum Seed Butter, Wheat (Triticum Vulgare) Bran Lipids, Wheat Kernel Oil, Grape (Vitis Vinifera) Seed Oil, Corn (Zea Mays) Kernel Oil and Corn Oil.

[1070] The vegetable oils specified above are the most common natural lipid components used as base substances for the manufacture of cosmetic or pharmaceutical preparations.

[1071] Hydrocarbons (mineral oils) are organic compounds composed entirely of hydrogen and carbon. As defined by IUPAC nomenclature or organic chemistry, hydrocarbons are classified as:

[1072] 1. Saturated hydrocarbons are the simplest hydrocarbon species. They consist entirely of single bonds and are saturated with hydrogen. The chemical formula for an acyclic saturated hydrocarbon (i.e., an alkane) is C n H 2n+2 The most general form of saturated hydrocarbons is C n H 2n+2(1-r), where r is the number of rings. Those with exactly one ring are cycloalkanes. Saturated hydrocarbons are the basis of petroleum fuels and are found as straight-chain or branched species.

[1073] 2. Unsaturated hydrocarbons have one or more double or triple bonds between carbon atoms. Those with double bonds are called alkenes. Those with one double bond have the formula C n H 2n (assuming a non-cyclic structure). Those containing a triple bond are called alkynes. Those with one triple bond have the formula C n H 2n-2 .

[1074] 3. Aromatic hydrocarbons (also called arenes) are hydrocarbons having at least one aromatic ring.

[1075] Hydrocarbons can be liquids (e.g., hexane and benzene), waxes or low melting point solids (e.g., paraffin and naphthalene) in particular. The term "aliphatic" refers to non-aromatic hydrocarbons. Saturated aliphatic hydrocarbons are sometimes referred to as "paraffins". Mineral oils and waxes are mixtures of saturated hydrocarbons consisting mainly of straight, branched and ring structures having a carbon chain length greater than C14. Mineral oils and waxes are chemicals prepared from naturally occurring crude oil. They are mainly composed of mineral oil saturated hydrocarbons (MOSH) and mineral oil aromatic hydrocarbons (MOAH). Due to their excellent skin tolerance and their high protection and cleaning properties and wide viscosity selection, hydrocarbons have been used in skin and lip care cosmetic products for decades. Compared with vegetable oils, mineral oils are non-allergenic because they are highly stable and not easily oxidized or rancid.

[1076] Fatty alcohols (or long-chain alcohols) are usually high molecular weight, straight-chain primary alcohols, but can also range from as few as 4-6 carbons to as many as 22-26 carbons, derived from natural fats and oils. The exact chain length varies with the source. Some commercially important fatty alcohols are lauryl alcohol, stearyl alcohol, and oleyl alcohol. They are colorless oily liquids (for smaller carbon numbers) or waxy solids, but impure samples may be yellow. Fatty alcohols usually have an even number of carbon atoms and a single alcohol group (-OH) attached to the terminal carbon. Some are unsaturated, and some are branched. Most fatty alcohols found in nature are waxes, which are esters with fatty acids and fatty alcohols. The traditional sources of fatty alcohols are mostly various vegetable oils, and these are still large-scale raw materials. Alcohols are obtained from triglycerides (triglycerides of fatty acids) that form the bulk of the oil. The process involves transesterification of triglycerides to obtain methyl esters, which are then hydrogenated to obtain fatty alcohols. Fatty alcohols are also prepared from petrochemical sources. In the Ziegler process, ethylene is oligomerized using triethylaluminum, followed by air oxidation. Alternatively, ethylene can be oligomerized to give a mixture of olefins, which are subjected to hydroformylation, a process that gives odd-numbered aldehydes, which are subsequently hydrogenated. Fatty alcohols are primarily used in the production of detergents and surfactants. They are also a component of cosmetic solvents. They are used as co-emulsifiers, emollients, and thickeners in cosmetics.

[1077] In a preferred variant, the fatty alcohol is selected from the group consisting of phenyl propanol, dimethyl benzyl butanol, hexyl decanol, octyldodecanol, octyldodecanol, tridecanol, isostearyl alcohol, phenyl isohexanol, phenyl propanol, trimethyl benzyl propanol, isopentanol, isostearyl alcohol and isotridecanol. In a more preferred variant, the fatty alcohol is selected from the group consisting of hexyl decanol, octyldodecanol, phenyl propanol, isopentanol, and a mixture of two or more of the aforementioned fatty alcohols. The fatty alcohol can be used as a single component or in a mixture with one or more further different fatty alcohols as specified above.

[1078] Fatty acid esters are a type of ester produced by the combination of fatty acids and alcohols. When the alcohol component is glycerol, the fatty acid ester produced can be a monoglyceride, a diglyceride, or a triglyceride. Fatty acid esters have a conditioning effect that softens the skin to produce a smooth feel. They are also added to cosmetics to dissolve highly polar active ingredients and UV absorbers. Esters of straight-chain fatty acids and lower alcohols are effective for dissolving slightly soluble ingredients in oils, and a light touch is sufficient during application. Isostearic acid and other liquid oils with branched fatty acids and unsaturated fatty acids are commonly used as emollients. Esters of higher fatty acids and higher alcohols with relatively high melting points are added to skin creams to adjust the feel of application.

[1079] Oil bodies and emollients: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention advantageously include one or more oil bodies or emollients. Emollients are oily or oily substances which help to smooth and soften the skin and can also reduce its roughness, cracking or irritation. In particular, in sunscreen products, emollients counteract the known stickiness of some UV filters and keep crystalline and oil-soluble organic and inorganic UV filters dissolved and prevent their recrystallization. In addition, emollients serve as wetting agents for inorganic UV filters to disperse them evenly in the formulation. Suitable oil bodies are, for example, Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10 carbon atoms, linear C6-C 22 -Fatty acids with straight or branched C6-C 22 - esters of fatty alcohols, or branched C6-C 13 -Carboxylic acid with straight or branched C6-C 22 - esters of fatty alcohols, such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, myristyl stearate, palmitostearate, stearyl stearate, isostearyl stearate, oleyl stearate, behenyl stearate, erucyl stearate, myristyl isostearate, palmitostearate, stearyl stearate, Isostearic acid ester, isostearic acid isostearic acid ester, oleic acid isostearic acid ester, behenic acid isostearic acid ester, oleic acid isostearic acid ester, myristic acid oleic acid ester, palmitic acid oleic acid ester, stearic acid oleic acid ester, isostearic acid oleic acid ester, oleic acid oleic acid ester, behenic acid oleic acid ester, erucic acid oleic acid ester, myristic acid behenic acid ester, palmitic acid behenic acid ester, stearic acid behenic acid ester, isostearic acid behenic acid ester, oleic acid behenic acid ester, behenic acid behenic acid ester, behenic acid erucic acid ester, myristic acid sinapic acid ester, palmitic acid sinapic acid ester, stearic acid sinapic acid ester, isostearic acid sinapic acid ester, oleic acid sinapic acid ester, behenic acid sinapic acid ester and erucic acid sinapic acid ester. Also suitable are straight chain C6-C 22 - Esters of fatty acids with branched alcohols, especially 2-ethylhexanol, C 18 -C 38 -alkyl hydroxycarboxylic acid with a straight or branched C6-C 22 - esters of fatty alcohols, in particular dioctyl malate, esters of linear and / or branched fatty acids with polyols (such as, for example, propylene glycol, dimer or trimer alcohols) and / or Guerbet alcohols, based on C6-C 10 Triglycerides of fatty acids, based on C6-C 18 -Liquid mono- / di- / triglyceride mixture of fatty acids, C6-C 22 - esters of fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid, C2-C 12- esters of dicarboxylic acids with straight-chain or branched alcohols having 1 to 22 carbon atoms or polyols having 2 to 10 carbon atoms and 2 to 6 hydroxyl groups, vegetable oils, branched primary alcohols, substituted cyclohexanes, straight-chain and branched C6-C 22 - fatty alcohol carbonates such as, for example, dicaprylyl carbonate ( CC), Guerbet carbonates based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, having linear and / or branched C6-C 22 -benzoic acid esters of alcohol (e.g. TN), a linear or branched, symmetrical or asymmetrical dialkyl ether having 6 to 22 carbon atoms per alkyl group, such as, for example, dioctyl ether ( OE), ring-opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicone, silicone methylsiloxane grade, etc.) and / or aliphatic or cycloparaffinic hydrocarbons such as, for example, squalane, squalene or dialkylcyclohexanes and mixtures thereof.

[1080] Powder: The composition as defined herein may optionally comprise a powder. The optional powder provides a smoother and softer formulation on the skin. Representative powders include talc, mica, magnesium carbonate, calcium carbonate, magnesium silicate, magnesium aluminum silicate, silicon dioxide, titanium dioxide, zinc oxide, red iron oxide, yellow iron oxide, black iron oxide, polyethylene powder, methacrylate powder, polystyrene powder, silk powder, preferred solid powder materials that can be used as components of the composition according to the present invention are hydrocolloids, such as starch, degraded starch, chemically or physically modified starch, dextrin, (powdered) maltodextrin (preferably having a dextrose equivalent value of 5 to 25, preferably 10 to 20), lactose, silicon dioxide, glucose, modified cellulose, gum arabic, gum ghatti, traganth, gum karaya, carrageenan, pullulan, curdlan, xanthan gum, gellan gum, guar flour, carob flour, alginates, agar, pectin, inulin, and mixtures of two or more of these solids, in particular maltodextrin (preferably having a dextrose equivalent value of 15 to 20), lactose, silicon dioxide and / or glucose.

[1081] Rheology modifier: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the present invention advantageously include one or more thickeners and / or rheology modifiers. The rheology modifier is present in an amount to prevent the composition from dripping or pooling significantly after application to the skin. Preferably, the rheology modifier is a carbomer. In some embodiments, the rheology modifier is selected from stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, polyethylene glycol ethers of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, polyethylene glycol ethers of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.

[1082] Additional examples of rheology modifiers include thickeners or gelling agents, including materials that can increase the viscosity of the composition. Thickeners include those thickeners that can increase the viscosity of the composition without substantially changing the efficacy of the active ingredient in the formulation. Thickeners can also increase the stability of the formulation of the present application. In certain aspects of the present application, thickeners include hydrogenated polyisobutylene or trihydroxystearin, or a mixture of the two. Additional non-limiting examples of additional thickeners that can be used in the context of the present application include carboxylic acid polymers, cross-linked polyacrylate polymers, polyacrylamide polymers, polysaccharides and gums. Examples of carboxylic acid polymers include cross-linked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acid, and salts and esters of these acrylic acid and substituted acrylic acid, wherein the cross-linking agent contains two or more carbon-carbon double bonds and is derived from polyols (see CTFA International Cosmetic Ingredient Dictionary, Fourth Edition, 1991, pages 12 and 80). Examples of commercially available carboxylic acid polymers include carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerythritol (e.g., Carbopol from BF Goodrich). TM 900 Series). Non-limiting examples of cross-linked polyacrylate polymers include cationic and nonionic polymers.

[1083] Non-limiting examples of polyacrylamide polymers (including nonionic polyacrylamide polymers, including substituted branched or unbranched polymers) include polyacrylamide, isoparaffin and laureth-7, multi-block copolymers of acrylamide and substituted acrylamides with acrylic acid and substituted acrylic acid.

[1084] The non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethyl cellulose, cellulose acetate propionate carboxylate, hydroxyethyl cellulose, hydroxyethyl ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl hydroxyethyl cellulose, microcrystalline cellulose, sodium cellulose sulfate and mixtures thereof. Another example is alkyl-substituted cellulose, in which the hydroxyl groups of the cellulose polymer are hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form hydroxyalkylated cellulose, which is then further modified by ether bonds with C10-C30 straight or branched alkyl groups. Typically, these polymers are ethers of C10-C30 straight or branched alcohols and hydroxyalkyl cellulose. Other useful polysaccharides include scleroglucan, which comprises a straight chain of glucose units connected (1-3), with glucose connected to (1-6) for every three units.

[1085] Non-limiting examples of gums that can be used with the compositions of the present invention include gum arabic, agar, algin, alginic acid, ammonium alginate, pullulan, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar gum, karaya gum, seaweed ash, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof. In one embodiment, the thickener is an extract of Chondrus crispus.

[1086] Film formers: The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention may advantageously comprise one or more film formers or film-forming agents. Film formers are hydrophobic materials which impart water resistance and film-forming properties to the sunscreen product, cosmetic or pharmaceutical preparation or home care product. Standard film formers are preferably chitosan, microcrystalline chitosan, quaternized chitosan, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives, collagen, hyaluronic acid and their salts and similar compounds. Preferred film formers for improving the water resistance of the composition are selected from the group consisting of polyamide-8 (such as Oleocraft LP20PA (MV)), polyamide-3 (such as Oleocraft MP 32PA (MV)), trimethylpentanediol / adipic acid / glycerin crosspolymer (such as WetFilm), octyldodecyl citrate crosspolymer (such as CosmoSurf CE 100), polyglyceryl-3 methylglucose distearate (such as TegoCare 450), C28-52 olefin / undecenoic acid copolymer (such as Performa V6112), hydrolyzed jojoba esters, jojoba esters, water agents (such as Floraester Jojoba K100), cyclopentasiloxane acrylate / dimethicone copolymer (such as KP545), acrylates / beheneth-25 methacrylate copolymer (such as Volarest), styrene / acrylates copolymer (such as Dermacryl E polymer), polyurethanes (such as Baycusan C1001), polyurethane-2 and polymethyl methacrylate (such as Hybridur 875 polymer), acrylates / octylacrylamide copolymer (such as Dermacryl 2.0 polymer), beeswax (Cera alba) (and) sodium stearoyl lactylate (such as SymEffect Sun), pullulan, xanthan gum, hydrogenated palm oil, sugar cane extract (SymEffect TMUV), microcrystalline cellulose (and) Sphingomonas ferment extract (and) cellulose gum (such as PemuPur TM START polymers), gum arabic and xanthan gum (such as SOLAGUA™ AX), microcrystalline cellulose (and) cellulose gum (such as SOLAGUM TM AX), microcrystalline cellulose (and) cellulose gum (such as Natpure Cellgum Plus), sodium stearoyl glutamate (such as HS-11P), hydrogenated polycyclopentadiene (and) caprylic / capric triglyceride (such as 5400CCT), Hydrogenated Rosin Glycerides (and) Caprylic / Capric Triglycerides (and) Tocopherol (such as NATURAL 2063-CCT), galactoarabinan (such as A 200), C26-28 alkyl dimethicone (such as Wacker CDM 3526VP), caprylyl methicone (such as Silsoft 034), stearyl dimethicone (and) octadecene (such as Dowsil 2503 Cosmetic Wax), VP / hexadecene copolymer (such as Antaron TM V 216), triacontanyl PVP (such as Antaron TM WP-660), caprylylglycerol / sebacic acid copolymer (such as LexFilm TM Sun Natural MB), poly C10-30 alkyl acrylate (such as Tego SP 13 Sun Up), microcrystalline cellulose (such as Sunspheres TM BIO SPFBooster) and any mixture thereof. The aforementioned film forming agents are used in sunscreens, cosmetics or pharmaceutical preparations or home care products as a single component or preferably in a mixture with two or more of the film forming agents specified above. The film forming agent is used in an effective amount that allows the final formulation to remain on the skin or surface after being exposed to circulating water for at least 40 minutes, preferably 80 minutes. Based on the total weight of the final formulation, the film forming agent is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.01% to 10.0% by weight, preferably 0.05% to 8.0% by weight.

[1087] Water resistance improver: The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the present invention may advantageously include one or more agents for improving water resistance. The agent for improving water resistance is a hydrophobic material that imparts film-forming and water-resistant properties to the emulsion. Typical suitable water resistance improvers include copolymers derived from the polymerization of octadecene-1 and maleic anhydride. Preferred water resistance improvers are polyanhydride resins. Another preferred water resistance improver is a copolymer of vinyl pyrrolidone and eicosene monomers. The water resistance improver is used in an effective amount that allows the final formulation to remain on the skin or surface after being exposed to circulating water for at least 40 minutes, preferably 80 minutes. Based on the total weight of the final formulation, one or more water resistance improvers may optionally be included in the final formulation in an amount in the range of 0.01% by weight to 10.0% by weight, preferably 0.05% by weight to 8.0% by weight.

[1088] Silicones: In order to impart a silky, spreadable and luxurious texture and to make the skin look and feel smoother, and in addition to improve processability (defoaming), the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention preferably comprise one or more silicones or silicone derivatives. The total amount of silicone compounds in the composition according to the invention may vary, but is generally from 0.1% to 35.0% by weight, based on the total weight of the composition.

[1089] Dry feel modifiers: The sunscreen product or cosmetic or pharmaceutical formulation according to the present invention is preferably combined with a dry feel modifier. A dry feel modifier is an agent that, when incorporated into an emulsion, imparts a "dry feel" to the skin when the emulsion dries. Dry feel modifiers may also reduce the migration of sunscreens on the skin. Dry feel modifiers may include starch, talc, kaolin, chalk, zinc oxide, hydroxyapatite (such as Tinomax CC), silicone fluids, inorganic salts such as barium sulfate and sodium chloride, C6 to C12 alcohols such as octanol; sulfonated oils; surface treated silica, precipitated silica, fumed silica, such as available from Degussa Inc. of New York, NY USA or mixtures thereof; polydimethylsiloxane, a mixture of methylated linear siloxane polymers, available from Dow Corning, Midland, Mich. USA under the trade name DC200 fluid. One or more dry feel modifiers may optionally be included in the final formulation in an amount ranging from 0.01 wt % to 20 wt %, more preferably from 0.1 wt % to 10.0 wt %.

[1090] Emollient substances: The sunscreen products or cosmetic or pharmaceutical preparations according to the invention may also advantageously contain one or more emollient substances, wherein any emollient substance suitable or customary in cosmetic or pharmaceutical application may be used, such as alpha-bisabolol, azulene, guaiac, 18-beta-glycyrrhetinic acid, allantoin, aloe juice or gel, extracts of witch hazel, Echinacea species, Centella asiatica, chamomile, Arnica montana, Glycyrrhiza species, algae, seaweed and Calendula officinalis, and vegetable oils such as sweet almond oil, baobab oil, olive oil and panthenol, laureth-9, trideceth-9 and 4-tert-butylcyclohexanol.

[1091] Physiological coolants: The sunscreen products or cosmetic or pharmaceutical preparations according to the invention can be combined with one or more physiological coolants in a particularly advantageous manner. The use of coolants can relieve itching. Preferred individual coolants for use within the scope of the present invention are listed below. A person skilled in the art can add many other coolants to this list; the listed coolants can also be used in combination with one another, and these coolants are preferably selected from the following list: menthol and menthol derivatives (e.g. L-menthol, D-menthol, racemic menthol, isomenthol, neoisomenthol), menthyl ethers (e.g. (1-menthoxy)-1,2-propanediol, (L-menthoxy)-2-methyl-1,2-propanediol, l-menthyl-methyl ether), menthone glycerol acetal, menthone glycerol ketal or a mixture of the two, menthyl esters (e.g. menthyl formate, menthyl acetate, menthyl isobutyrate, menthyl hydroxyisobutyrate, menthyl lactate, L-menthyl acetate, menthyl acetate, menthyl isobutyrate, menthyl hydroxyisobutyrate, menthyl lactate, menthyl lactate, menthyl hydroxyisobutyrate ... Menthyl-L-lactate, L-menthyl-D-lactate, menthyl-(2-methoxy)acetate, menthyl-(2-methoxyethoxy)acetate, menthyl pyroglutamate), menthyl carbonates (e.g. menthyl propylene glycol carbonate, menthyl ethylene glycol carbonate, menthyl glycerol carbonate or mixtures thereof), half esters of menthol with dicarboxylic acids or their derivatives (e.g. monomenthyl succinate, monomenthyl glutarate, monomenthyl malonate, O-menthyl succinate-N,N-(dimethyl)amide, O-menthyl succinate amide), menthanecarboxylic acid amides (in this case preferably menthanecarboxylic acid-N-acetamide [WS3] or N-(dimethyl)amide [WS4]), α-(menthanecarbonyl)glycidyl ester [WS5], menthanecarboxylic acid-N-(4-cyanophenyl)amide or menthanecarboxylic acid-N-(-4-cyanomethylphenyl)amide, menthanecarboxylic acid-N-(alkoxyalkyl)amide), menthone and menthone derivatives (such as L-menthone glycerol ketal), 2,3-dimethyl-2-(2-propyl)-butyric acid derivatives (such as 2,3-dimethyl-2-(2-propyl)-butyric acid-N-methylamide [WS23]), isopulegol or its ester (I-(-)-isopulegol, I-(-)-isopulegol acetate), menthane derivatives (such as p-menthane-3,8-diol), cubebol or cubebol containing Synthetic or natural mixtures of cycloalkyldione derivatives, pyrrolidone derivatives of cycloalkyldione derivatives (e.g. 3-methyl-2 (1-pyrrolidinyl) -2-cyclopentene-1-one) or tetrahydropyrimidin-2-one (e.g. icilin or related compounds), further carboxamides (e.g. N- (2- (pyridin-2-yl) ethyl) -3-p-menthanecarboxamide or related compounds), (1R, 2S, 5R) -N- (4-methoxyphenyl) -5-methyl-2- (1-isopropyl) cyclohexanecarboxamide [WS12], oxalates and [(1R, 2S, 5R) -2-isopropyl-5-methylcyclohexyl] 2- (ethylamino) -2-oxo-acetate (X cooling). Preferred cooling agents due to their particular synergistic effect are l-menthol, d-menthol, racemic menthol, menthone glycerol acetal (trade name: MGA), menthyl lactate (preferably l-menthyl lactate, especially l-menthyl lactate (trade name: ML)), substituted menthyl-3-carboxamides (such as menthyl-3-carboxylic acid N-ethylamide), 2-isopropyl-N-2,3-trimethylbutyramide, substituted cyclohexanecarboxamides, 3-menthoxypropane-1,2-diol, 2-hydroxyethyl menthyl carbonate, 2-hydroxypropyl menthyl carbonate and isopulegol. Particularly preferred cooling agents are l-menthol, racemic menthol, menthone glycerol acetal (trade name: MGA), menthyl lactate (preferably l-menthyl lactate, especially l-menthyl lactate (trade name: ML)), 3-menthoxypropane-1,2-diol, 2-hydroxyethyl menthyl carbonate and 2-hydroxypropyl menthyl carbonate. Very particularly preferred cooling agents are l-menthol, menthone glycerol acetal (trade name: MGA) and menthyl lactate (preferably l-menthyl lactate, especially l-menthyl lactate (trade name: ML).

[1092] Alkanediol: In a further preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises one or more linear alkanediols having a carbon chain of 5 to 12 carbon atoms. Preferably, the one or more linear alkanediols are selected from the group consisting of 1,2-alkanediol, 2,3-alkanediol, 3,4-alkanediol and 1,3-alkanediol, more preferably 2,3-alkanediol and 1,3-alkanediol. Most preferably, the linear alkanediol is selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol and 2,3-dodecanediol.

[1093] Surprisingly, it has been found that by adding the above-mentioned alkanediols, the SPF and UVA photoprotection boosting effect is improved.

[1094] Initial observations by the inventors surprisingly showed that compositions according to the invention comprising one or more linear alkanediols having a carbon chain of 5 to 12 carbon atoms, preferably as defined herein, show particularly advantageous emulsifying properties. In particular, it was surprisingly found that one or more of the linear alkanediols (if not the emulsion itself) supports the formation of water or oil droplets having a particularly small average size in the emulsion, or (if the emulsion itself) comprises water or oil droplets having a particularly small average size.

[1095] In addition, it was found that the presence of alkanediols, in particular 1,2-alkanediol or 2,3-alkanediol, improves the solubility of oil components, such as one or more oil bodies or waxes, in the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention. Preferably, the one or more oil bodies or waxes are selected from the group consisting of natural fats and oils, fatty alcohols and alcohols, glycerides and their derivatives, esters, ethers, silicones and silanes, waxes and cycloalkanes, preferably from the group consisting of squalene, dialkylcyclohexanes, tetradecane, isohexadecane, dodecane, docosane, paraffins and mineral oils, and are further described below.

[1096] The combination of one or more of the alkanediols and 4-hydroxyacetophenone, typically in an amount of 0.1 to 2 wt %, more preferably 0.1 to 1 wt %, even improves the solubility of the oil component in a synergistic manner.

[1097] Preferably, the composition comprises 0.01% to 10% by weight, more preferably 0.1% to 5% by weight, still more preferably 0.3% to 3% by weight, most preferably 0.5% to 1% by weight of said linear alkanediol having a carbon chain of 5 to 12 carbon atoms as defined herein, based on the total weight of the composition.

[1098] Antioxidants: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention advantageously include one or more antioxidants. Suitable antioxidants include amino acids (preferably glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (preferably urocanic acid) and their derivatives, peptides (preferably D,L-carnosine, D-carnosine, L-carnosine) and their derivatives (preferably anserine), carnitine, creatine, matrikine peptides (preferably lysyl-threonyl-threonyl-lysylserine) and palmitoylated pentapeptides, carotenoids, carotenes (preferably α-carotene, β-carotene, lycopene) and their derivatives, lipoic acid and its derivatives (preferably dihydrolipoic acid), aurothioglucose, propylthiouracil pyridine and other thiols (preferably thioredoxin, glutathione, cysteine, cystine, cystamine and glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl, glyceryl and oligoglycerols thereof) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (preferably esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoxide amine compounds (preferably buthionine sulfoxide amine, homocysteine ​​sulfoxide amine, buthionine sulfoxide ether sulfone, penta-, hexa- and heptathionine sulfoxide amine), also (metal) chelators (preferably α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin, α-hydroxy Acids (preferably citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, tannic acid, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof), unsaturated fatty acids and derivatives thereof (preferably γ-linoleic acid, linoleic acid, oleic acid), folic acid and derivatives thereof, ubiquinone and derivatives thereof, vitamin C and derivatives (preferably ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate, ascorbyl glucoside), tocopherol and derivatives (preferably vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) and coniferyl benzoate of benzoin resin, rutinic acid and derivatives thereof, flavonoids and glycosylated precursors thereof, in particular quercetin and its derivatives, preferably α-glucosylrutin, rosmarinic acid, carnosol, carnosic acid, resveratrol, caffeic acid and its derivatives, sinapinic acid and its derivatives, ferulic acid and its derivatives, curcumin, chlorogenic acid and its derivatives, retinoids, preferably retinyl palmitate, retinol or retinoic acid, ursolic acid, levulinic acid, butylated hydroxytoluene, butylated hydroxyanisole, dedihydroguaiac acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (preferably ZnO, ZnSO4), selenium and its derivatives (preferably selenomethionine), superoxide dismutase, stilbene and its derivatives (preferably stilbene oxide, trans-stilbene oxide),And derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these cited active ingredients are suitable according to the invention, or extracts or fractions of plants having an antioxidant effect, preferably green tea, rooibos, honeybush, grape, rosemary, sage, lemon balm, thyme, lavender, olive, oat, cocoa, ginkgo, ginseng, liquorice, honeysuckle, sophora japonica, kudzu root, pine, citrus, emblica or St. John's wort, grape seed, wheat germ, emblica, coenzymes, preferably coenzyme Q10, plastoquinone and menaquinone. Preferred antioxidants are selected from the group consisting of vitamin A and derivatives, vitamin C and derivatives, tocopherol and derivatives, preferably tocopherol acetate and ubiquinone.,

[1099] Emulsifier: In addition, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the present invention may also advantageously contain one or more emulsifiers in order to keep the sunscreen product, cosmetic or pharmaceutical preparation or home care product stable. Emulsifiers include amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture. The emulsifier is selected in a suitable manner depending on the emulsion to be obtained. Preferred examples include:

[1100] - Add 2 mol to 30 mol of ethylene oxide and / or 0 mol to 5 mol of propylene oxide to the linear C 8-22 Fatty alcohol, C 12-22 Products of fatty acids and alkylphenols containing 8 to 15 carbon atoms in the alkyl group;

[1101] - C of the product of adding 1 mol to 30 mol of ethylene oxide to glycerol 12 / 18 Fatty acid monoesters and diesters;

[1102] - mono- and di-glycerides, mono- and di-sorbitol esters and ethylene oxide addition products thereof of saturated and unsaturated fatty acids containing from 6 to 22 carbon atoms;

[1103] - products of the addition of 15 to 60 mol of ethylene oxide onto castor oil and / or hydrogenated castor oil;

[1104] - polyol esters, and in particular polyglycerol esters, such as, for example, polyglycerol polyricinoleate, polyglycerol poly-12-hydroxystearate or polyglycerol dimethyl isostearate. Mixtures of compounds from several of these classes are also suitable;

[1105] - products of the addition of 2 to 15 mol of ethylene oxide onto castor oil and / or hydrogenated castor oil;

[1106] Based on straight chain, branched, unsaturated or saturated C 6 / 22Fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucosides (e.g. cellulose);

[1107] - mono-, di- and tri-alkyl phosphates and mono-, di- and / or tri-PEG-alkyl phosphates and their salts;

[1108] -Wool wax alcohol;

[1109] - polysiloxane / polyalkyl polyether copolymers and corresponding derivatives;

[1110] - pentaerythritol, fatty acids, citric acid and fatty alcohols and / or C 6-22 Mixed esters of fatty acids, methyl glucose and polyols, preferably glycerol or polyglycerol,

[1111] -polyalkylene glycol and

[1112] -Glyceryl carbonate.

[1113] Products of the addition of ethylene oxide and / or propylene oxide to fatty alcohols, fatty acids, alkylphenols, glycerol monoesters and diesters and sorbitan monoesters and diesters of fatty acids or to castor oil are known products which are commercially available. They are homologous mixtures whose average degree of alkoxylation corresponds to the ratio between the amount of ethylene oxide and / or propylene oxide and the amount of substrate subjected to the addition reaction. The C of the addition products of ethylene oxide onto glycerol is 12 / 18 Fatty acid monoesters and diesters are known as lipid layer enhancers for cosmetic formulations. Preferred emulsifiers are described in more detail as follows:

[1114] Partial glycerides: Typical examples of suitable partial glycerides are hydroxystearic acid monoglyceride, hydroxystearic acid diglyceride, isostearic acid monoglyceride, isostearic acid diglyceride, oleic acid monoglyceride, oleic acid diglyceride, ricinoleic acid monoglyceride, ricinoleic acid diglyceride, linoleic acid monoglyceride, linoleic acid diglyceride, linolenic acid monoglyceride, linolenic acid diglyceride, erucic acid monoglyceride, erucic acid diglyceride, tartaric acid monoglyceride, tartaric acid diglyceride, citric acid monoglyceride, citric acid diglyceride, malic acid monoglyceride, malic acid diglyceride and technical mixtures thereof, which may still contain small amounts of triglycerides from the production process. Also suitable are products of the addition of 1 to 30 mol and preferably 5 to 10 mol of ethylene oxide to the abovementioned partial glycerides.

[1115] Sorbitan esters: Suitable sorbitan esters are sorbitan monoisostearate, sorbitan sesquiisostearate, sorbitan diisostearate, sorbitan triisostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan hemierucate, sorbitan glycerol dierucate, sorbitan monoricinoleate, sorbitan sesquiricinoleate, sorbitan diricinoleate, sorbitan triricinoleate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan hemierucate, sorbitan glycerol dierucate, sorbitan monoricinoleate, sorbitan sesquiricinoleate, sorbitan diricinoleate, sorbitan triricinoleate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan Sugar alcohol monohydroxystearate, sorbitan sesquihydroxystearate, sorbitan dihydroxystearate, sorbitan trihydroxystearate, sorbitan monotartrate, sorbitan sesquitartrate, sorbitan ditartrate, sorbitan tritartrate, sorbitan monocitrate, sorbitan sesquicitrate, sorbitan dicitrate, sorbitan tricitrate, sorbitan monomaleate, sorbitan sesquimaleate, sorbitan dimaleate, sorbitan trimalate and technical mixtures thereof. Also suitable are products of the addition of 1 to 30 mol and preferably 5 to 10 mol of ethylene oxide to the abovementioned sorbitan esters.

[1116] Polyglycerol esters: A typical example of a suitable polyglycerol ester is polyglyceryl-2 dipolyhydroxystearate ( PGPH), Polyglyceryl-3 Diisostearate ( TGI), polyglyceryl-4 isostearate ( GI 34), Polyglyceryl-3 Oleate, Polyglyceryl-3 Diisostearate ( PDI), polyglyceryl-3 methyl glucose distearate (Tego 450), Polyglyceryl-3 Beeswax (Cera )、Polyglyceryl-4 Caprate (Polyglyceryl Caprate T2010 / 90), Polyglyceryl-3 Cetyl Ether ( NL), polyglyceryl-3 distearate ( GS32) and polyglyceryl polyricinoleate ( WOL 1403), polyglyceryl dimethyl ether isostearate and mixtures thereof. Other examples of suitable polyol esters are monoesters, diesters and triesters of trimethylolpropane or pentaerythritol with lauric acid, coconut fatty acid, tallow fatty acid, palmitic acid, stearic acid, oleic acid, behenic acid, etc., optionally reacted with 1 mol to 30 mol of ethylene oxide.

[1117] Anionic emulsifiers: Typical anionic emulsifiers are aliphatic C12-C22 fatty acids, such as, for example, palmitic acid, stearic acid or behenic acid, and C12-C22 dicarboxylic acids, such as, for example, azelaic acid or sebacic acid, potassium cetyl phosphate, and hydrogenated palm glycerides (Emulsiphos / Emulsiphos F).

[1118] Amphoteric emulsifiers: Other suitable emulsifiers are amphoteric or zwitterionic surfactants. Zwitterionic surfactants are surface-active compounds which contain at least one quaternary ammonium group and at least one carboxylate and one sulfonate group in the molecule. Particularly suitable zwitterionic surfactants are the so-called betaines, such as N-alkyl-N,N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinates, N-acylaminopropyl-N,N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinates, and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines containing 8 to 18 carbon atoms in the alkyl or acyl group, and cocoacylaminoethyl hydroxyethylcarboxymethylglycinate. Fatty acid amide derivatives with the CTFA name cocamidopropyl betaine are particularly preferred. Amphoteric surfactants are also suitable emulsifiers. Amphoteric surfactants are, except C 8 / 18 A surface-active compound which contains at least one free amino group and at least one -COOH- or -SO3H- group in addition to the alkyl or acyl group and is capable of forming internal salts. Examples of suitable amphoteric surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycine, N-alkyltaurine, N-alkylsarcosine, 2-alkylaminopropionic acids and alkylaminoacetic acids containing about 8 to 18 carbon atoms in the alkyl group. Particularly preferred amphoteric surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C 12 / 18 Acylsarcosine.

[1119] Anti-aging active substances: The composition according to the invention is preferably combined with one or more anti-aging active substances. In the context of the present invention, anti-aging agents or biogenic agents are, for example, antioxidants, matrix metalloproteinase inhibitors (MMPIs), skin moisturizers, glycosaminoglycan stimulators, anti-inflammatory agents, TRPV1 antagonists and plant extracts.

[1120] Matrix-metalloproteinase inhibitors (MMPI): The composition according to the invention is preferably combined with one or more matrix-metalloproteinase inhibitors, in particular those which inhibit the enzymatic cleavage of collagen by matrix-metalloproteinases, selected from the group consisting of ursolic acid, retinyl palmitate, propyl gallate, antijuvenile hormone, 6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran, 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran, benzamidine hydrochloride, cysteine ​​protease inhibitors N-ethylmaleimide and ε-amino-n-hexanoic acid of serine protease inhibitors: phenylmethylsulfonyl fluoride, collhibin (Pentapharm; INCI: hydrolyzed rice protein), oenotherol (Soliance; INCI: propylene glycol, water, evening primrose root extract, ellagic acid and ellagitannins, such as from pomegranate), hinokitiol phosphate, EDTA, MGDA (trisodium dicarboxymethyl alanine), galadine, EquiStat (Collaborative Group; apple fruit extract, soybean seed extract, ursolic acid, soy isoflavones and soy protein), sage extract, MDI (Atrium; INCI: glycosaminoglycans), fermiskin (Silab / Mawi; INCI: water and shiitake extract), actimp 1.9.3 (Expanscience / Rahn; INCI: hydrolyzed lupine protein), lipobelle soy aglycone (Mibelle; INCI: alcohol, polysorbate 80, lecithin and soy isoflavones), extracts from green and black tea and further plant extracts, proteins or glycoproteins from soy, hydrolyzed proteins from rice, pea or lupine, plant extracts inhibiting MMPs, preferably extracts from shiitake, extracts from leaves of the family Rosaceae, subfamily Rosoideae, very particularly extracts from blackberry leaves, such as, for example, SymMatrix (Symrise, INCI: maltodextrin, blackberry (Rubus Fruticosus) leaf extract). Preferred active substances are selected from the group consisting of retinyl palmitate, ursolic acid, extracts from leaves of the family Rosaceae, subfamily Rosoidea, genistein and daidzein.

[1121] Skin moisturizing and / or water-retaining substances: The sunscreen product or cosmetic or pharmaceutical preparation according to the present invention advantageously comprises one or more skin moisturizing and / or water-retaining substances. Preferred skin moisturizing and / or water-retaining substances are selected from the group consisting of: alkanediols or alkanetriols containing 3 to 12 carbon atoms, preferably C3-C 10 -Alkanediol and C3-C 10More preferably, the skin moisturizer is selected from the group consisting of glycerol, 1,2-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol and 1,2-decanediol. Other skin moisturizing and / or water-retaining substances include sodium lactate, urea, urea derivatives, alcohols, glycerol, glycols such as propylene glycol, hexylene glycol, collagen, elastin or hyaluronic acid, diacyl adipate, petrolatum, urocanic acid, lecithin, panthenol, phytantriol, lycopene, (pseudo)ceramides, glycosphingolipids, cholesterol, phytosterols, chitosan, chondroitin sulfate, lanolin, lanolin esters, amino acids, α-hydroxy acids (such as citric acid, lactic acid, malic acid) and their derivatives, monosaccharides, disaccharides and oligosaccharides such as glucose, galactose, fructose, mannose, fructose and lactose, polysaccharides such as R-glucans, in particular 1,3-1,4-β-glucans from oats, α-hydroxy fatty acids, triterpene acids such as betulinic acid or ursolic acid, and algae extracts.

[1122] Glycosaminoglycan stimulators: Preferred compositions according to the invention comprise one or more substances stimulating the synthesis of glycosaminoglycans selected from the group consisting of: hyaluronic acid and derivatives or salts, Subliskin (Sederma, INCI: Sinorhizobium meliloti ferment filtrate, cetyl hydroxyethylcellulose, lecithin), Hyalufix (BASF, INCI: water, butylene glycol, Alpinia galanga leaf extract, xanthan gum, caprylic / capric triglyceride), Stimulhyal (Soliance, INCI: calcium ketogluconate), Syn-Glycan (DSM, INCI: tetradecylaminobutyryl valinyl aminobutyric acid urea trifluoroacetate, glycerol, magnesium chloride), Kalpariane (Biotech Marine), DC Upregulex (Unique Cosmetic Ingredient, INCI: Water, Butylene Glycol, Phospholipids, Hydrolyzed Sericin), Glucosamine, N-acetyl Glucosamine, Retinoids, preferably Retinol and Vitamin A, Burdock Fruit Extract, Loquat Extract, Genkwanin, N-Methyl-L-Serine, (-)-α-Bisabolol or synthetic α-bisabolol, such as, for example, Dragosantol and Dragosantol 100 from Symrise, Oat Glucan, Echinacea Extract and Soy Protein Hydrolysate. Preferred active substances are selected from the group consisting of hyaluronic acid and derivatives or salts, retinol and derivatives, (-)-α-bisabolol or synthetic α-bisabolol, such as Dragoantol and Dragoantol 100 from Symrise, oat glucan, Echinacea extract, Sinorhizobium meliloti ferment filtrate, calcium ketogluconate, Alpinia galanga leaf extract and tetradecylaminobutyrylvalylaminobutyric acid urea trifluoroacetate.

[1123] Anti-inflammatory agents: The compositions according to the invention are preferably combined with anti-inflammatory and / or anti-redness and / or itch-relieving ingredients, in particular steroids of the corticosteroid type selected from the group consisting of hydrocortisone, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone, advantageously used as anti-inflammatory active ingredients or active ingredients for reducing redness and itching, the list of which can be expanded by adding other steroidal anti-inflammatory agents. Non-steroidal anti-inflammatory agents can also be used. More specifically:

[1124] (i) steroidal anti-inflammatory substances of the corticosteroid type, in particular hydrocortisone, hydrocortisone derivatives such as hydrocortisone 17-butyrate, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone,

[1125] (ii) non-steroidal anti-inflammatory substances, in particular oxicams such as piroxicam or tenoxicam; salicylates such as aspirin, disalicylate, solprin or fendosal; acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac; fenamate esters such as mefenamic acid, meclofenamic acid, flufenamic acid or niflumic acid; propionic acid derivatives such as ibuprofen, naproxen or benoxaprofen; pyrazoles such as phenylbutazone, oxyphenylbutazone, feprazone or azapropazone,

[1126] (iii) natural or naturally occurring anti-inflammatory substances or substances which relieve redness and / or itching, in particular extracts or fractions from chamomile, aloe vera, myrrh substances, madder substances, willow, willow herb, oats, calendula, arnica, St John's wort, honeysuckle, rosemary, passion flower, witch hazel, ginger or echinacea, or their single active compounds,

[1127] (iv) Histamine receptor antagonists, serine protease inhibitors (e.g., soybean extracts), TRPV1 antagonists (e.g., 4-tert-butylcyclohexanol), NK1 antagonists (e.g., aprepitant, hydroxyphenylpropionamide benzoic acid), and TRPV3 antagonists.

[1128] Examples that may be cited here are oxicams, such as piroxicam or tenoxicam; salicylates, such as aspirin, disalicylate, solprin or fendosal; acetic acid derivatives, such as diclofenac, fenclorac, indomethacin, sulindac, tolmetin or clindanac; fenamate esters, such as mefenamic acid, meclofenamic acid, flufenamic acid or niflumic acid; propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, or pyrazoles, such as phenylbutazone, oxyphenylbutazone, feprazone or azapropazone. Anthranilic acid derivatives are preferred antipruritic ingredients in the composition according to the invention.

[1129] Also useful are natural or naturally occurring anti-inflammatory substance mixtures or mixtures of substances that relieve redness and / or itching, in particular extracts or fractions from chamomile, aloe, myrrh substances, madder substances, willow, willowherb, oats, calendula, arnica, St. John's wort, honeysuckle, rosemary, passion flower, witch hazel, ginger or echinacea; preferably selected from the group consisting of extracts or fractions from chamomile, aloe, oats, calendula, arnica, honeysuckle, rosemary, witch hazel, ginger or echinacea, and / or pure substances, preferably alpha-bisabolol, apigenin, apigenin-7-glucoside , gingerol, shogaol, gingerdiol, dehydrogingerdione, gingerol, natural or naturally occurring avenant alkaloids, preferably tranilast, avenant alkaloid A, avenant alkaloid B, avenant alkaloid C, non-natural or non-naturally occurring avenant alkaloids, preferably dihydroavenant alkaloid D, dihydroavenant alkaloid E, avenant alkaloid D, avenant alkaloid E, avenant alkaloid F, boswellic acid, phytosterols, glycyrrhizin, glabridin and licorice chalcone A; preferably selected from the group consisting of α-bisabolol, natural avenant alkaloids, non-natural avenant alkaloids, preferably dihydroavenant alkaloid D (such as WO 2004 047833A1), boswellic acid, phytosterols, glycyrrhizin and licoricechalcone A, and / or allantoin, panthenol, lanolin, (pseudo)ceramides [preferably ceramide 2, hydroxypropyl bispalmitamide MEA, hexadecyloxypropyl glyceryl methoxypropyl myristamide, N-(1-hexadecyl)-4-hydroxy-L-proline (1-hexadecyl) ester, hydroxyethyl palmityloxyhydroxypropyl palmitamide], glycosphingolipids, phytosterols, chitosan, mannose, lactose and β-glucans, in particular 1,3->1,4-β-glucans from oats.

[1130] TRPV1 antagonists: Preferred compositions according to the invention comprise one or more TRPV1 antagonists. Suitable compounds that reduce skin nerve hypersensitivity based on their action as TRPV1 antagonists include, for example, trans-4-tert-butylcyclohexanol, or compounds that indirectly modulate TRPV1 by activating μ-receptors (e.g., acetyl tetrapeptide-15) are preferred.

[1131] Antimicrobial agents: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention can advantageously be combined with an antimicrobial agent, which acts primarily against microorganisms, in particular bacteria, yeasts and / or fungi, and includes one or more antimicrobial agents such as capryloyl hydroxamic acid, o-cymene-5-ol, isopropyl paraben, capryloyl glycine, phenylpropanol, tropolone, PCA cocoyl arginine ethyl ester, 2-methyl 5-cyclohexylpentanol, phenoxyethanol, disodium EDTA, methyl paraben. and its salts, sodium benzoate, benzyl alcohol, potassium sorbate, benzyl salicylate, propylparaben, sodium methylparaben, methylchloroisothiazolinone, methylisothiazolinone, ethylhexylglycerin, butylparaben, ethylparaben, sodium propylparaben, DMDM ​​hydantoin, dehydroacetic acid, salicylic acid, chlorphenesin, isobutylparaben, sodium ethylparaben, diazolidinyl urea, diazolidinyl urea, farnesol, bisabolol, caprylic acid glyceryl, sodium phytate or phytic acid, sodium levulinate or levulinic acid and its esters and / or ketals, chlorhexidine , lauric acid glyceryl, anisic acid and its salts, chlorhexidine digluconate, TEA salicylate, phenethyl alcohol, glyceryl caprate, sorbitan caprylate, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate, hydroxyethoxyphenyl butanone, hydroxyethoxyphenyl butanol, itaconic acid, hydroxymethyl octopirox, propylene glycol caprylate, climbazole, undecylenyl glycine, thymol, 4-hydroxyacetophenone, lactic acid, sodium lactate, trisodium dicarboxymethyl alanine, raspberry ketone, ditoluene caprylate, 3-hydroxypropyl benzoate, anisic acid 3-hydroxypropyl ester, 3-hydroxypropyl 2-hydroxybenzoate, 1,3-propylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol, and any mixture thereof.

[1132] Preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises one or more antimicrobial agents selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol, 2-benzylheptanol, 2-hydroxyacetophenone, 2-methyl 5-cyclohexylpentanol, 3-hydroxypropyl 2-hydroxybenzoate, 4-hydroxyacetophenone, and any mixtures thereof. More preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises one or more antimicrobial agents selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 1,2-tridecanediol, 4-hydroxyacetophenone, and any mixture thereof.

[1133] In order to further enhance the antimicrobial efficacy, the sunscreen product, cosmetic or pharmaceutical preparation or household care product as defined herein is advantageously combined with at least one additional antimicrobial agent different from the antimicrobial agent specified above. The combination with additional antimicrobial agents provides reliable protection against microbial degradation and deterioration of the preparation, particularly during storage. In addition, different antimicrobial agents provide reliable protection to other microorganisms as described above, such as Corynebacterium, Anaerococcus, Finegoldia, Moraxella, Porphyromonas, Fusobacterium, Malassezia, Peptoniphilus, Streptococcus, Lactobacillus, Gardnerella, Fannyhessea, Epidermophyton, Trichophyton, Cutibacterium. Therefore, the combination with different antimicrobial agents allows the antimicrobial protection of different microbial groups, and therefore the antimicrobial protection of a wider spectrum of microorganisms. In the context of the present invention, the further different antimicrobial agents are preferably selected from the group consisting of 2-benzylheptanol, alkyl (C12-22) trimethylammonium bromides and chlorides, ascorbic acid and its salts, benzalkonium bromide, benzalkonium chloride, benzalkonium saccharinate, benzethonium chloride, benzoic acid, camphor, cetylpyridinium chloride, chlorhexidine diacetate, chlorhexidine dihydrochloride, chlorocresol, chloroxylenol, cyclohexylglycerol, dimethylphenylbutanol, dimethylphenylpropanol, ethanol, lauroyl Arginine ethyl ester HCl, lauroyl arginine ethyl ester laurate, eucalyptol, gluconic acid and its salts, glycerol, hexamidine, hexamidine disalt, hexylglycerol, iodopropynyl butylcarbamate, jasmone, lauryl alcohol, levulinic acid and its esters and / or ketals, mannitol, menthol, methyl salicylate, octenidine HCL, polyarginine, polyglyceryl-10 laurate, polyglyceryl-2 caprate, polyglyceryl-3 caprylate, polylysine, sage (Salvia Officinalis) oil, silver chloride, silver citrate, sodium caproyl lactylate, sodium caproyl / lauroyl lactylate, sodium lauroyl lactylate, sorbic acid, sorbitol, Tetraselmisia extract, triclocarban, triclosan, triethyl citrate, xylitol sesquioctanoate, zinc citrate, zinc pyridone, zinc ricinoleate, and any mixture thereof.

[1134] The aforementioned antimicrobial agents are used in sunscreens, cosmetic or pharmaceutical preparations or home care products as single component or preferably in mixtures with two or more of said antimicrobial agents as specified above.

[1135] The antimicrobial agent is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.01 to 25.0 wt. %, preferably 0.02 to 15.0 wt. %, most preferably 0.05 to 6.0 wt. %, based on the total weight of the final formulation.

[1136] Advantageously, the at least one antimicrobial alkanediol is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.1% to 5% by weight, based on the total weight of the final formulation and / or the 4-hydroxyacetophenone is present in an amount of 0.01% to 2% by weight, based on the total weight of the final formulation.

[1137] Preservatives: For preservation purposes, the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention preferably comprise one or more preservatives which are suitable or customary in sunscreen products, cosmetic or pharmaceutical preparations or home care products. Suitable and advantageous preservatives are, for example, benzoic acid, sodium benzoate, ammonium benzoate, butyl benzoate, calcium benzoate, ethyl benzoate, isobutyl benzoate, isopropyl benzoate, magnesium benzoate, mea benzoate, methyl benzoate, phenyl benzoate, potassium benzoate, propyl benzoate, propionic acid, ammonium propionate, calcium propionate, magnesium propionate, potassium propionate, sodium propionate, salicylic acid, calcium salicylate, magnesium salicylate, mea salicylate, sodium salicylate, potassium salicylate, tea salicylate, sorbic acid, calcium sorbate, sodium sorbate, potassium sorbate, o-phenylphenol, sodium sulfite, ammonium bisulfite, ammonium sulfite, potassium sulfite, potassium bisulfite, sodium bisulfite, Sodium metabisulfite, potassium metabisulfite, chlorobutanol, 4-hydroxybenzoic acid, methylparaben, potassium ethylparaben, potassium paraben, sodium methylparaben, sodium ethylparaben, ethylparaben, sodium paraben, potassium methylparaben, calcium paraben, butylparaben, propylparaben, sodium propylparaben, sodium butylparaben, potassium butylparaben, potassium propylparaben, dehydroacetic acid, sodium dehydroacetate, formic acid, sodium formate, dibromohexamidine isethionate, thimerosal, phenylmercuric acetate, phenylmercuric benzoate, undecylenic acid, potassium undecylenate, sodium undecylenate, calcium undecylenate, mea undecylenate, tea undecylenate, hexamidine, 5-bromo-5 -1,3-nitro-dioxane, 2-bromo-2-nitropropane-1,3-diol, dichlorobenzyl alcohol, triclocarban, para-chloro-meta-cresol, triclosan, chloroxylenol, imidazolidinyl urea, polyaminopropyl biguanide, phenoxyethanol, hexamethylenetetramine, climbazole, DMDM ​​hydantoin, benzyl alcohol, 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, piroctone olamine salt, bromochlorfen, o-cymene-5-ol, methylchloroisothiazolinone and methylisothiazolinone, chlorhexidine, chlorhexidine diacetate, chlorhexidine digluconate, chlorhexidine dihydrochloride, phenoxyisopropanol, behenyltrimethylammonium chloride ( 1), cetrimonium bromide, cetrimonium chloride (2), lauryl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, stearyl trimethyl ammonium chloride (2), dimethyl oxazolidine, diimidazolidinyl urea, hexamidine, hexamidine disalt, diparaben hexamidine, paraben hexamidine, glutaraldehyde, 7-ethylbicyclic oxazolidine, chlorphenesin, sodium hydroxymethylglycinate, silver chloride, benzethonium chloride, benzalkonium chloride, benzalkonium bromide, benzalkonium saccharinate, formaldehyde benzyl alcohol hemiacetal, iodopropynyl n-butylamine formate, methylisothiazolinone, citric acid, silver citrate, hydroxyethoxyphenyl butyric acid (HEPB), and any mixture thereof.

[1138] Drugs: The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the present invention is preferably combined with one or more drugs. In certain such embodiments, the pharmaceutically active agent is selected from the group consisting of anti-acne agents, agents for treating rosacea, analgesics, anesthetics, anorectics, antihistamines, anti-inflammatory agents (including non-steroidal anti-inflammatory drugs), antibiotics, antifungal agents, antiviral agents, antimicrobial agents, anticancer active agents, antiscabies agents, pediculicides, antitumor agents, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cautery agents, depilatory agents, Coloring agents, depilatories, diaper rash treatments, enzymes, hair growth stimulants, hair growth retardants (including ilonicet and its salts and analogs), hemostatics, keratolytics, oral ulcer treatments, cold sore treatments, dental and periodontal treatments, photosensitizers, skin protectants / barrier agents, steroids (including hormones and corticosteroids), sunburn treatments, sunscreens, transdermal actives, nasal actives, vaginal actives, wart treatments, wound treatments, wound healing agents, etc.

[1139] Particularly useful are natural or naturally occurring anti-inflammatory substance mixtures, in particular extracts or fractions from chamomile, aloe, myrrh substances, madder substances, willow, willow herb, oats, calendula, arnica, St. John's wort, honeysuckle, rosemary, passion flower, witch hazel, ginger or echinacea; preferably selected from the group consisting of extracts or fractions from chamomile, aloe, oats, calendula, arnica, honeysuckle, rosemary, witch hazel, ginger or echinacea, and / or pure substances, preferably alpha-bisabolol, apigenin, apigenin-7-glucoside, gingerols, shogaols, gingerdiols, dehydrogingerdione, shogaols, natural or naturally occurring avenant alkaloids, preferably tranilast, avenant alkaloid A, avenant alkaloid B, avenant alkaloid C, non-natural or non-naturally occurring avenant alkaloids, preferably dihydroavenant alkaloid D, dihydroavenant alkaloid Alkaloids E, avenant alkaloids D, avenant alkaloids E, avenant alkaloids F, boswellic acid, phytosterols, glycyrrhizin, glabridin and licoricechalcone A; preferably selected from the group consisting of α-bisabolol, natural avenant alkaloids, non-natural avenant alkaloids, preferably dihydroavenant alkaloids D, boswellic acid, phytosterols, glycyrrhizin and licoricechalcone A, and / or allantoin, panthenol, lanolin, (pseudo)ceramides, preferably ceramide 2, hydroxypropyl bispalmitamide MEA, hexadecyloxypropyl glyceryl methoxypropyl myristamide, N-(1-hexadecyl)-4-hydroxy-L-proline (1-hexadecyl) ester, hydroxyethyl palmityloxyhydroxypropyl palmitamide, glycosphingolipids, phytosterols, chitosan, mannose, lactose and β-glucans, in particular 1,3->1,4-β-glucans from oats.

[1140] Besides the substances mentioned above, it is also possible to use further ingredients customary in sunscreen products, cosmetic or pharmaceutical preparations or household care products which are suitable or customary in the compositions according to the invention.

[1141] The sunscreen product or cosmetic or medicament, in particular dermatological preparation according to the first aspect of the invention is intended for topical application. The term "topical" is understood to mean external application on the skin or mucous membrane of a mammal, in particular for the protection, treatment, care and cleaning of the skin, scalp, eyelashes, eyebrows, nails, mucous membranes and hair. The mammal is preferably a human.

[1142] For topical application, the cosmetic or pharmaceutical preparations are either rinse-off or leave-on preparations.

[1143] The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention may be in the form of an aqueous solution, dispersion, hydroalcoholic carrier, stick, ointment, gel, aerosol (foam, spray, propeller pump) or the like.

[1144] The sunscreen product, cosmetic or pharmaceutical, in particular dermatological preparation or home care product according to the first aspect of the invention can be present in different forms, for example in the form of a dispersion, in the form of an anhydrous formulation, or in the form of an aqueous, aqueous / alcoholic solution, in particular an aqueous / ethanolic, aqueous / glycolic or alcoholic / glycolic solution, in particular an ethanolic / glycolic solution.

[1145] In a preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the invention is a dispersion. The term "dispersion" in the context of the present invention means that the sunscreen product, cosmetic or pharmaceutical preparation or home care product is a dispersed two-phase system consisting of colloidal particles (dispersed phase) and a medium (dispersion medium) in which they are suspended. The two phases are immiscible with each other and are only miscible with emulsifiers. Such dispersions, such as emulsions, contain at least one oil component (without UV filters) in an amount preferably ≥1% by weight, more preferably ≥3% by weight.

[1146] Preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the invention takes various forms, such as emulsions, in particular O / W emulsions, W / O emulsions, multiple emulsions, water-dispersible gels, balms, multiple emulsions of the water-in-oil type (W / O / WO) or oil-in-water type (O / W / O), PIT emulsions, Pickering emulsions, microemulsions, liquids, lotions, suspensions, emulsions, ointments, pastes, gels, cream-based, oil-based or liposome-based formulations or aerosols such as foams and sprays, including all types of silicone-based emulsions.

[1147] In a most preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention is in the form of an emulsion as defined herein, advantageously an oil-in-water (O / W) emulsion comprising an oily phase dispersed in an aqueous phase in the presence of an O / W or polymeric emulsifier.

[1148] If the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention is a dispersion, preferably an emulsion, the oil component (without UV filters) is present in the cosmetic or pharmaceutical preparation in an amount of 0.01% to 50.0% by weight, based on the total weight of the composition. In a preferred embodiment, the cosmetic or pharmaceutical preparation contains the oil component in an amount of 0.1% to 45.0% by weight, based on the total weight of the composition. In a particularly preferred embodiment, the oil component is advantageously used in the cosmetic or pharmaceutical preparation in an amount of 1.0% to 40% by weight, based on the total weight of the composition.

[1149] In a further variant, the sunscreen product, cosmetic or pharmaceutical, preferably dermatological preparation or home care product according to the first aspect of the invention is an anhydrous formulation, ie an oil formulation.

[1150] If the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention is an anhydrous formulation, i.e. an oil formulation, the oil component is present in the cosmetic or pharmaceutical preparation in an amount of ≥60% by weight, preferably in an amount of ≥75% by weight, more preferably in an amount of ≥90% by weight, based on the total weight of the composition.

[1151] Such anhydrous formulations include, for example, oils, skin fats, powders, lipsticks, antiperspirant / deo sticks and decorative cosmetics.

[1152] Furthermore, further anhydrous formulations are likewise ethanol / diol / triol / glycol-based formulations, such as sprays or gels.

[1153] Alternatively, the sunscreen product, cosmetic or pharmaceutical preparation or home care product as disclosed herein is based on an aqueous or aqueous / alcohol solution, preferably based on an aqueous / ethanol or aqueous / glycol or alcohol / glycol solution, preferably based on an ethanol / glycol solution. Typically, this can be glycerol in a water or alcohol composition. The solution is a homogeneous single-phase system of water / alcohol / glycol and additional components. Based on the total weight of the solution, the aqueous / alcohol or aqueous / glycol or alcohol / glycol solution contains 0.1 wt % to 70.0 wt %, preferably 0.5 wt % to 60.0 wt %, more preferably 1.0 wt % to 50.0 wt % of an aliphatic alcohol or glycol. The aliphatic alcohol is preferably selected from the group consisting of ethanol, isopropanol, and n-propanol. Glycol is preferably selected from the group consisting of glycerol, propylene glycol, 1,3-propylene glycol, 1,2-propylene glycol, 1,2-C5 to C10 alkanediol, butylene glycol or dipropylene glycol.

[1154] Preferably, the total water content in the final aqueous-based solution may be ≥ 30 wt%, more preferably ≥ 40 wt%, most preferably ≥ 50 wt%.

[1155] Such aqueous or aqueous / alcohol or aqueous / glycol or alcohol / glycol based solutions include, for example, deo / antiperspirant preparations, aftershaves, cleansing preparations or anti-acne preparations.

[1156] In a preferred variant, the composition of the invention is an impregnation solution in the form of an emulsion spray or an alcohol / oil spray for wet wipes.

[1157] The above-mentioned formulations or compositions are prepared according to customary and known methods.

[1158] Cosmetic preparations are preparations for cosmetic and / or non-therapeutic use in personal care, skin protection, skin care, scalp protection, scalp care, hair care, nail care, in particular for the prevention and treatment of skin disorders, intolerances or sensitive skin, skin irritations, skin redness, rashes, pruritus (itching), skin aging, wrinkle formation, loss of skin volume, loss of skin elasticity, pigment spots, pigment abnormalities, dry skin, flaking, oiliness, hypopigmentation and / or hyperpigmentation of the skin; or preparations for animal care.

[1159] Examples of personal care products are preferably anti-aging preparations, skin care lotions, body oils, body washes, cleansing lotions, face or body balms, aftershave balms, after sun balms, deo lotions, cationic lotions, body gels, treatment creams, skin protection ointments, moisturizing gels, face and / or body moisturizers, photoprotective preparations (sunscreens), micellar waters, hair sprays, color-protecting hair products, skin lightening products, anti-dark spot repair agents, etc.

[1160] Cosmetic preparations also include make-up, eye care preparations, eye shadow, mascara, eyeliner, lip care preparations such as lipstick, lip gloss, nail care preparations such as nail polish, nail polish remover,

[1161] Alternatively, the preparation according to the invention is a preparation for medical use.

[1162] The pharmaceutical composition, in particular the dermatological composition according to the present invention is preferably a preparation for the prevention and treatment of skin or mucosal disorders.

[1163] Preferably, the pharmaceutical formulation according to the first aspect of the invention is used for the prevention and / or treatment of functional disorders of human hair, skin and / or nails, in particular dermatological or keratological diseases, wherein the dermatological or keratological diseases are selected from the group consisting of atopic dermatitis (neurodermatitis), psoriasis, acne-type rashes, decreased activity of sebaceous glands, xerosis, eczema, hyper- and hyposeborrhea, dermatitis, rosacea, erythema, wheal, pruritus (itch), inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune bullous diseases, urticaria, angioedema, allergic skin reactions, wound healing, tissue regeneration, and for the treatment of inflammatory diseases.

[1164] For use, the sunscreen product or cosmetic or pharmaceutical, in particular dermatological preparation according to the first aspect of the invention is applied to the skin, hair, scalp and / or nails in a sufficient amount in the manner customary for sunscreen products or cosmetic and dermatological products.

[1165] Furthermore, the products and formulations according to the invention are home care products. Home care products typically include laundry detergents (powders, liquids and tablets), fabric conditioners, dishwashing detergents (liquids and tablets), hard floor and surface cleaners, glass cleaners, carpet cleaners, oven cleaners, air fresheners, disinfectants, stain removers, car wash products. These products are typically manufactured in the form of liquids, powders, sprays, granules, etc.

[1166] Surprisingly, it has been found that the addition of a mycosporin-like amino acid compound or a salt thereof as defined herein has the effect of improving SPF and boosting UVA light protection. The higher the SPF or UVA-PF, the more protective the sunscreen is.

[1167] Furthermore, by adding mycosporin-like amino acid compounds or salts thereof, the critical wavelength of sunscreen products, cosmetic or pharmaceutical preparations, or home care products can be increased to provide broad spectrum coverage with a critical wavelength greater than 370 nm.

[1168] The advantage of these effects is that sunscreen products or cosmetic or pharmaceutical products can be provided with a broader spectrum protection covering UVA and UVB. In addition, the improved UV filter properties, in particular UVA photoprotection, allow to reduce the amount of organic UV filters without affecting the envisaged SPF.

[1169] As demonstrated in the examples below, SPF and UVA photoprotection are highly improved, i.e. increased, by the addition of a mycosporin-like amino acid compound as defined therein. Control samples not containing a mycosporin-like amino acid compound exhibited average or lower SPF.

[1170] When a mycosporin-like amino acid compound according to formula (V) or formula (VI) as defined herein is added to a sunscreen product, cosmetic or pharmaceutical preparation or home care product comprising organic UV filters or mixtures thereof, an improvement in SPF and UVA photoprotection may be observed.

[1171] Particularly pronounced SPF and UVA photoprotection boosting effects can be obtained by adding mycosporin-like amino acid compounds according to the general formula (VI), wherein X is S, SO or SO2.

[1172] Surprisingly, the mycosporin-like amino acid compounds are particularly effective in improving the SPF and UVA photoprotection of sunscreen products, cosmetic or pharmaceutical preparations or home care products when they are in acid form or in salt form as described in detail above.

[1173] By adding a mycosporin-like amino acid compound as defined herein, the SPF of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising an organic UV filter or a mixture of organic UV filters can be increased by at least 5%, preferably by at least 10%, and more preferably by at least 10%, as demonstrated in the following examples.

[1174] The addition of MAA-1 in an amount of 1.0% by weight to a sunscreen composition comprising a modern UV filter mixture results in an in vitro SPF of 53.4, which is 68.5% higher than the in vitro SPF of the reference sample (i.e. the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 1.0% to the sunscreen composition results in an in vitro SPF of 34.4, which is 8.52% higher than the in vitro SPF of the reference sample (i.e. the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-1 in an amount of 3.0% by weight to the sunscreen composition even results in an in vitro SPF of 86.1, which is 171.6% higher than the in vitro SPF of the control sample (i.e. the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0% by weight results in an in vitro SPF of 39.8, which is 25.6% higher than the in vitro SPF of the reference sample (i.e. the sample without the addition of a mycosporin-like amino acid compound).

[1175] Furthermore, the addition of certain mycosporin-like amino acid compounds in sunscreen products, cosmetic or pharmaceutical preparations or home care products containing a mixture of organic UV filters not only results in an improved SPF, but also in an enhanced UVA-PF. In particular, the addition of MAA-13 in an amount of 1.0% results in an improvement of 14.8% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0% even results in an improvement of 30.75% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). MAA-1 in an amount of 3.0% also enhances the UVA-PF by 9.35%.

[1176] The addition of MAA-13 at 3.0% also increases the broad spectrum protection of the modern sunscreen composition from the critical wavelength of 378 nm to the critical wavelength of 379 nm.

[1177] Thus, as demonstrated by the test samples, the addition of MAA-1 and MAA-13 leads to a significant improvement in the SPF and / or UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or household care products comprising modern organic UV filter compositions.

[1178] The addition of MAA-20 in an amount of 1.0 wt. % to a sunscreen composition comprising a modern UV filter mixture results in an increased SPF. The control example without a mycosporin-like amino acid compound exhibits an SPF of 52.4. However, the addition of MAA-20 in an amount of 1.0 wt. % results in an in vitro SPF of 57.1, which is 9% higher than the in vitro SPF of the control example.

[1179] Furthermore, the addition of MAA-20 not only resulted in improved SPF, but also enhanced UVA-PF. In particular, the addition of MAA-20 at 1.0% resulted in an 18.2% improvement in UVA-PF compared to the control sample (ie, without the mycosporin-like amino acid compound).

[1180] Thus, as demonstrated by the test samples, the addition of MAA-20 leads to an improvement in the SPF and / or UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or household care products comprising classic organic UV filter compositions.

[1181] The addition of MAA-1 in an amount of 1.0% by weight to a sunscreen composition comprising a classic organic UV filter or a mixture of classic organic UV filters resulted in an in vitro SPF of 35.4, which is 5.0% higher than the in vitro SPF of the reference sample (i.e., a sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-1 in an amount of 3.0% by weight to the sunscreen composition even resulted in an in vitro SPF of 54.4, which is 61.4% higher than the in vitro SPF of the control sample (i.e., without the addition of a mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 1.0% to the sunscreen composition resulted in an in vitro SPF of 36.3, which is 7.7% higher than the in vitro SPF of the reference sample (i.e., a sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0% by weight to the sunscreen composition even resulted in an in vitro SPF of 63.1, which is 87.2% higher than the in vitro SPF of the reference sample (i.e., a sample without the addition of a mycosporin-like amino acid compound).

[1182] Furthermore, the addition of certain mycosporin-like amino acid compounds to sunscreen products, cosmetic or pharmaceutical preparations or home care products containing organic UV filters not only results in an improved SPF, but also in an enhanced UVA-PF. In particular, the addition of MAA-13 in an amount of 1.0% results in an improvement of 3.2% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0% even results in an improvement of 5.2% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound) compared to a control sample (i.e., without mycosporin-like amino acid compound).

[1183] The addition of MAA-13 at 1.0% and 3.0% also increases the broad spectrum protection of the classic sunscreen composition from the critical wavelength of 380 nm to the critical wavelength of 381 nm.

[1184] Thus, as demonstrated by the test samples, the addition of MAA-1 and MAA-13 leads to an improvement in the SPF and / or UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or household care products comprising classic organic UV filter compositions.

[1185] The addition of MAA-20 in an amount of 1.0 wt.-% to sunscreen formulations comprising classical organic UV filters or mixtures of classical organic UV filters also resulted in improved A and / or UVA-PF compared to reference samples (i.e. samples without added mycosporin-like amino acid compound), as demonstrated by the test samples.

[1186] Thus, as demonstrated by the above-mentioned test samples, the addition of MAA-20 leads to an improvement in the SPF and / or UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising classic organic UV filter compositions.

[1187] Similar SPF and UVA photoprotection improvement effects can be shown for the mycosporin-like amino acid compounds MAA-2, MAA-3, MAA-4, MAA-5, MAA-6, MAA-7, MAA-8, MAA-11, MAA-12, MAA-13, MAA-14, MAA-16, MAA-17 and MAA-20 to MAA-39. The compounds show an SPF increase of at least 10% compared to the SPF of a sunscreen product, cosmetic or pharmaceutical preparation or household care product not combined with the mycosporin-like amino acid compound.

[1188] For the mycosporin-like amino acid compounds MAA-A, MAA-B and MAA-C, a significant SPF and UVA photoprotection improvement effect can be demonstrated. The compounds show an SPF increase of at least 10% compared to the SPF of a sunscreen product, cosmetic or pharmaceutical preparation or household care product not combined with the mycosporin-like amino acid compound.

[1189] Thus, the addition of a mycosporin-like amino acid compound as defined herein results in an improvement in the SPF as well as the UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters.

[1190] Thus, with the formulations according to the invention it is possible to provide sunscreen products or cosmetic or pharmaceutical products with significantly increased SPF, significantly increased UVA-PF and increased critical wavelength and thus providing broad spectrum protection with a minimum critical wavelength well above 370 nm compared to products or formulations without the addition of the specified mycosporin-like amino acid compound.

[1191] Improved UV filter performance in terms of SPF and UVA-PF allows a reduction in the amount of primary organic UV filter without affecting the envisaged sun protection factor.

[1192] Therefore, the present invention provides a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product, wherein the SPF is increased by at least 5%, preferably at least 10%, and more preferably at least 20% compared to a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product without a mycosporin-like amino acid compound (b).

[1193] In addition, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the present invention provides at least 5% UVA-PF increase relative to the otherwise identical formulation without the mycosporin-like amino acid compound (b). In some cases, the sunscreen product, cosmetic or pharmaceutical preparation or home care product provides at least 10%, more preferably at least 15% UVA-PF increase relative to the otherwise identical formulation without the mycosporin-like amino acid compound.

[1194] Due to this beneficial effect as described above, the present invention relates in a further aspect to the use of a mycosporine-like amino acid compound (b) or a mixture thereof as defined herein for improving the SPF and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a household care product comprising at least one inorganic UV filter.

[1195] By mixing a mycosporin-like amino acid compound or a mixture thereof as defined herein, the SPF of a sunscreen product, cosmetic or pharmaceutical preparation or home care product containing an inorganic UV filter can be enhanced by at least 5%, preferably at least 10%, and more preferably even at least 20% relative to a sunscreen product, cosmetic or pharmaceutical preparation or home care product that does not contain mycosporin-like amino acid compounds. In addition, the UVA-PF in a sunscreen product, cosmetic or pharmaceutical preparation or home care product containing an inorganic UV filter can be enhanced by at least 5%, preferably at least 10%, and most preferably at least 15% relative to an otherwise identical formulation that does not contain mycosporin-like amino acid compounds.

[1196] In a further aspect, the present invention relates to a method for enhancing or boosting the SPF performance and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product. In this method, an effective amount of at least one mycosporin-like amino acid as defined herein or a mixture thereof is added to said sunscreen product, cosmetic or pharmaceutical preparation or home care product comprising an inorganic UV filter.

[1197] The invention in a further aspect relates to a method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin by topically applying a sunscreen product, cosmetic or pharmaceutical formulation or home care product according to the invention due to its enhanced SPF and UVA photoprotection.

[1198] The present invention will now be described in detail with reference to the following examples, which are merely provided to illustrate the present invention, so that the contents of the present invention are not limited to the following examples.

[1199] Example

[1200] Determination of in vitro SPF and UVA-PF

[1201] The SPF Boost and UVA-PF Boost tests are performed as an in vitro determination of SPF.

[1202] Principle: The formulation to be tested (emulsion, solution) is weighed on a PMMA plate with the aid of an analytical balance. The formulation is distributed and bound on the plate using a method corresponding to the formulation. The plate thus prepared is then measured on a Labsphere device and the result is calculated as SPF using suitable software.

[1203] 1. Sample preparation:

[1204] A PMMA plate (polymethyl methacrylate) measuring 3 cm×8.5 cm (WW5 plate with a roughness of 5 μ based on ISOethA 24443:2012 “Determination of UVA photoprotection in vitro”, GmbH & Co. AG) ​​for SPF measurement.

[1205] 1.1 Preparation of reference samples:

[1206] A reference sample is obtained by spreading 25 to 28 mg of glycerol (99.5%) on the roughened side of a PMMA plate with the index finger. The glycerol film must be very thin and uniform. The plate is then stored for at least 2 hours.

[1207] The reference plate was measured with the following transmission values:

[1208] 290nm>60% transmission;

[1209] 300nm>69% transmission; and

[1210] 320nm>82% transmission.

[1211] 1.2 Application of samples to be measured:

[1212] The sample to be measured should be mixed evenly with a spatula before application. 1.2 mg / cm2 of the sample is evenly distributed in several rows of dots on the PMMA plate. In order to minimize the evaporation of the sample during the weighing process, this process must be carried out quickly. The sample is then evenly distributed by hand with fingers pre-soaked with the sample material. This distribution is carried out in two stages:

[1213] Phase 1: Spread quickly and evenly with light pressure until the emulsion breaks.

[1214] Phase 2: Massage the sample into the rough surface with strong pressure, and the process should last for 30 seconds. In this context, under strong pressure means when massaging on a scale, which means at least 200m.

[1215] exception:

[1216] Sunscreen: Product quantity is usually 1.3mg / cm 2 For strongly spreading oils, apply less product as the amount of oil cannot be "absorbed" from the plate. The application rate should then be reduced to 1.0 mg / cm 2 -0.75mg / cm 2 The application method here is also the 30s fast / light and 30s strong method.

[1217] Sunscreen spray: The "30 / 30 method" applies here (especially with thicker sprays).

[1218] For a very liquid spray (similar to water):

[1219] Distribute quickly and evenly with slight pressure until the emulsion "breaks".

[1220] This process should take 45s.

[1221] The finished sample plates were stored dust-free and the measurements were taken after 15 minutes at the earliest.

[1222] 2. Measurement on Labsphere:

[1223] The samples were measured using the UV-200S unit using the specified Colipa method. The Labsphere user manual also applies.

[1224] 2.1 Basic settings in the software:

[1225] Open a new "Study" via File and select the "Colipa Guide 2011" method under the heading "Study". In the new window "Colipa Method Options", enter the number of panels (3 panels), the number of measurement points per panel (5 measurement points) and the in vivo SPF, and if required), the irradiance of the external irradiator (Solar Simulator Irradiance).

[1226] As standard, the irradiance set on the external device is 765W / m2. Complete naming of the sample via "Study", "Study Information".

[1227] 2.2 Sample measurement:

[1228] At the beginning of the measurement, a blank value of the glycerol reference sample is measured ("Scan Blank Plate"). In order to determine the SPF of the sample, a total of 15 measurement points (5 measurement points for 3 plates) are then generated ("Scan Positions"). The already scanned plates and measurement points are checked in the upper right window, while the absorbance of the currently measured plate is displayed in the middle window.

[1229] With irradiation:

[1230] After the first measurement run, the device calculates the irradiation dose (irradiation dose / J / cm2) and duration (exposure time) for each plate. The plates are irradiated in an external irradiation device (irradiation duration=average value of 3 plates).

[1231] The calculation of the radiation dose and exposure time is based on the irradiance set on the external device (765W / m 2 ).

[1232] No irradiation:

[1233] If no irradiation device was available or irradiation was not desired, the first plate was started again after 15 individual scans were completed and the measurement was repeated (background: no second measurement, no UVA / UVB balance calculation by the software).

[1234] After the measurement is completed, the "study" is recorded and the data can be printed / exported as a "report".

[1235] 3. Tested samples:

[1236] Example 1: Sunscreen product with modern organic UV filter combinations:

[1237] Formulation Samples A to E specified in Table 4 below were prepared as follows:

[1238] Phase A: Will not contain CG-BT and Heat the ingredients of phase A to 85°C to dissolve the ingredients. After the ingredients are dissolved, add CG-BT and And the solution is homogenized in a short time (Ultra T25: 15,000rpm / 10sec).

[1239] Phase B: Mix the ingredients of Phase B while stirring until the ingredients are dissolved. The aqueous phase combined with the sodium hydroxide solution will be cloudy. Then, heat the aqueous Phase B to 80°C. Then, add the hot Phase B to the hot Phase A and homogenize (Ultra T25: 13,000 rpm / 3 min). Finally, the mixture was cooled to ambient temperature while stirring.

[1240] The results of in vitro SPF and UVA-PF determinations are shown in Table 4.

[1241] Table 4

[1242]

[1243]

[1244] Results: As can be retrieved from Table 4, the in vitro SPF is highly improved, i.e. increased, by the combination of the sunscreen formulation with certain mycosporin-like amino acid compounds. The control example without mycosporin-like amino acid compound exhibits an SPF of 31.7. However, the addition of MAA-1 in an amount of 1.0% by weight results in an in vitro SPF of 53.4, which is 68.5% higher than the in vitro SPF of the reference sample (i.e. the sample without the addition of mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 1.0% results in an in vitro SPF of 34.4, which is 8.52% higher than the in vitro SPF of the reference sample (i.e. the sample without the addition of mycosporin-like amino acid compound). The addition of MAA-1 in an amount of 3.0% by weight even results in an in vitro SPF of 86.1, which is 171.6% higher than the in vitro SPF of the control sample (i.e. the sample without the addition of mycosporin-like amino acid compound). Addition of MAA-13 in an amount of 3.0 wt% resulted in an in vitro SPF of 39.8, which was 25.6% higher than the in vitro SPF of the reference sample (ie, the sample without the addition of the mycosporin-like amino acid compound).

[1245] Furthermore, the addition of certain mycosporin-like amino acid compounds in sunscreen products, cosmetic or pharmaceutical preparations or home care products containing a mixture of organic UV filters not only results in an improved SPF, but also in an enhanced UVA-PF. In particular, the addition of MAA-13 in an amount of 1.0% results in an improvement of 14.8% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0% even results in an improvement of 30.75% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). MAA-1 in an amount of 3.0% also enhances the UVA-PF by 9.35%.

[1246] The addition of MAA-13 at 3.0% also increases the broad spectrum protection of the modern sunscreen composition from the critical wavelength of 378 nm to the critical wavelength of 379 nm.

[1247] Thus, as demonstrated by the above-mentioned test samples, the addition of MAA-13 leads to a significant improvement in the SPF and / or UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising modern organic UV filter compositions.

[1248] Example 2: Sunscreen product with m...

Claims

1. A sunscreen product, cosmetic or pharmaceutical preparation or household care product comprising or consisting of: (a) at least one primary organic UV filter; and (b) at least one mycosporine-like amino acid compound, It is represented by the general formula (V) in -Z is selected from the group consisting of O-R2' or amide'; -R1' is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), CR7'R8', C=O, halogen, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), and unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro; -R2' is selected from the group consisting of H, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl; -amide' is selected from the group consisting of NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10', unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid); -R3' is selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9'R10', and unsubstituted or substituted C-spiro; - the substituents R4', R5' and R6', which can be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, -S(=O)2OH, sulfonyl, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9'R10', and unsubstituted or substituted C-spiro; - R7' and R8', which can be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10'; - R9' and R10', which can be the same or different, are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, and unsubstituted or substituted heteroaryl; -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and -R is unsubstituted or substituted alkyl; or a tautomer or stereoisomer or salt of the above compounds; Or represented by general formula (VI) in -R1" is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, halogen, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro; -R2" is selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -C(=O)-amide", unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted hetero Aryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro; -X is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro; - the substituents R4", R5" and R6", which can be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, -S(=O)2OH, sulfonyl, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro; - R7" and R8", which can be the same or different, are independently selected from the group consisting of H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9"R10"; -amide" is selected from the group consisting of NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid); - R9" and R10", which can be the same or different, are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, and unsubstituted or substituted heteroaryl; -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and -R is unsubstituted or substituted alkyl; or a tautomer or stereoisomer or salt of the above compounds; or any mixture of the foregoing compounds; The following compounds are waived / excluded: Compound 1: Compound 2: Compound 3: Compound 4: Compound 5: Compound 6: Compound 7: as well as Compound 8:

2. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to claim 1, wherein the mycosporin-like amino acid compound (b) is represented by the general formula (VII): wherein R1′, R2′, R3′, R4′, R5′ and R6′ have the same meanings as defined for formula (V); Or represented by general formula (VIII) wherein R1′, Amide′, R3′, R4′, R5′ and R6′ have the same meanings as defined for formula (V).

3. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to claim 1 or claim 2, wherein in the general formula (VI), X is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro.

4. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 3, wherein in the general formula (V) -Z is -O-R2' or amide'; and / or - R1' is selected from the group consisting of CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formula (V); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; Or wherein in the general formula (VII) or (VIII) - R1' is selected from the group consisting of CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formulae (VII) and (VIII); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; Or wherein in the general formula (VI) -R1" is selected from the group consisting of CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or -R2" is selected from the group consisting of -CH2-OH, -C(=O)-OY and -C(=O)-amide"; and / or -X is selected from the group consisting of CH2, C=O, O, S, SO, SO2, NH and N(alkyl); and / or -Y is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethylhexyl) and phenyl; and / or -amide" is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

5. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 4, wherein in the general formula (V) -Z is -O-R2' or amide'; and / or - R1' is selected from the group consisting of CH2 and C(methyl)2; and / or -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formula (V); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; Or wherein in the general formula (VII) or (VIII) -R1' is selected from the group consisting of CH2 and C(methyl)2; -R2' is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formulae (VII) and (VIII); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; and / or Or wherein in the general formula (VI) -R1" is selected from the group consisting of CH2 and C(methyl)2; and / or -R2" is selected from the group consisting of -CH2-OH, -C(=O)-OY and -C(=O)-amide"; and / or -X is selected from the group consisting of CH2, C=O, O, S, SO, SO2, NH and N(alkyl); and / or -Y is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, The group consisting of (2-ethylhexyl) and phenyl; and / or -amide" is selected from the group consisting of NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

6. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 5, wherein the mycosporin-like amino acid compound (b) is selected from the group consisting of the following compounds I-1 to I-128 according to the general formula (V) and compounds II-1 to II-192 according to the general formula (VI): wherein in the above-mentioned mycosporin-like amino acid compound, the benzene ring may be unsubstituted or substituted, and R4′, R5′, R6′, R4″, R5″, R6″, amide′, Y, amide″ and alkyl have the same meanings as defined in any one of the preceding claims, or a tautomer or stereoisomer or salt of the above-mentioned compound; or wherein the mycosporin-like amino acid is selected from the group consisting of: MAA-A: MAA-B: and MAA-C: wherein alkyl is methyl, or ethyl, or propyl, or butyl, preferably methyl, or a tautomer or salt thereof; or any mixture of the above compounds.

7. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 6, wherein in the general formulae (VI), (IX) and (X), X is S, SO or SO2, and / or wherein in the general formulae (V) to (X), n=1.

8. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 7, wherein in the general formulae (V), (VII) and (VIII), the substituents R4', R5' and R6', which can be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, - S(=O)2OH and sulfonyl; or Wherein in the general formula (VI), (IX) and (X), the substituents R4", R5" and R6" which may be the same or different are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl.

9. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 8, wherein in the general formulae (V) to (X), the substituted phenyl group bonded to the imino functional group is selected from the group consisting of: The dotted lines indicate the binding sites.

10. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 9, wherein in the general formulae (V), (VII) and (VIII), the substituents R4', R5', R6', which can be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, and alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl; provided that if the substituted phenyl ring is monosubstituted, then ... The substituent is in the ortho or meta position of the imino functional group; or wherein in the general formula (VI), (IX) and (X), the substituents R4", R5", R6", which can be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or tert-butyl, and alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl; provided that if the substituted phenyl ring is monosubstituted, the substituent is in the ortho or meta position of the imino functional group.

11. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 10, wherein the mycosporin-like amino acid compound (b) is selected from the group consisting of: or a tautomer or stereoisomer or salt of the above compounds; or any mixture of the above compounds.

12. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 11, wherein the at least one primary organic UV filter (a) is selected from the group consisting of: camphor benzalkonium methylsulfate, homosalate, benzophenone-3, phenylbenzimidazole sulfonic acid, terephthalylidene dicamphor sulfonic acid, butyl methoxydibenzoylmethane, benzalkonium camphor sulfonic acid, octocrylene, polyacrylamidomethylbenzylidene camphor, ethylhexyl methoxycinnamate, PEG-25 PABA, isoamyl p-methoxycinnamate, ethylhexyl triazone, drometrizole trisiloxane, diethylhexyl butamido triazone, 4-methylbenzylidene camphor, Ethylhexyl salicylate, dimethyl PABA ethylhexyl ester, benzophenone-4, benzophenone-5, methylene bis-benzotriazolyl tetramethylbutylphenol (nano), disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, polysilicone-15, diethylamino hydroxybenzoyl hexyl benzoate, tris-biphenyl triazine (nano), phenylene bis-diphenyl triazine, methoxypropylaminocyclohexenylene ethoxyethyl cyanoacetate, bis-(diethylamino hydroxybenzoyl benzoyl) piperazine, TEA-salicylate, benzophenone-8, PABA, dimethyl PABA ethylhexyl ester, menthyl anthranilate, and any mixture thereof.

13. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 12, further comprising at least one inorganic UV filter, wherein the inorganic UV filter is selected from the group consisting of titanium dioxide (TiO2) (amorphous or crystallized in rutile and / or anatase form), zinc oxide (ZnO), iron oxide (Fe2O3), zirconium oxide (ZrO2), silicon dioxide (SiO2), manganese oxide (e.g. MnO), aluminum oxide (Al2O3), cerium oxide (Ce2O3), barium carbonate (BaCO3), calcium carbonate (CaCO3), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, and mixtures thereof.

14. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 13, comprising the primary organic UV filter (a) or a mixture thereof in an amount of 0.01 to 55.0 wt.-%, particularly in an amount of 0.1 to 50.0 wt.-%, more particularly in an amount of 0.5 to 45.0 wt.-%, most particularly in an amount of 1.0 to 40.0 wt.-%, based on the total weight of the product or preparation.

15. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 14, comprising the mycosporin-like amino acid compound (b) or a mixture thereof in an amount of 0.001 to 15.0 wt.-%, particularly in an amount of 0.01 to 10.0 wt.-%, more particularly in an amount of 0.05 to 7.5 wt.-%, most particularly in an amount of 0.1 to 5.0 wt.-%, based on the total weight of the product or preparation.

16. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 15, further comprising at least one 1,2-alkanediol or 2,3-alkanediol having 5 to 12 carbon atoms, wherein the 1,2-alkanediol is preferably selected from 1,2-pentanediol, The invention relates to a 2,3-alkanediol comprising: 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, and wherein the 2,3-alkanediol is selected from the group consisting of 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol, and any mixture thereof.

17. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 16, further comprising one or more antimicrobial agents, preferably wherein the antimicrobial agent is selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol, 2-benzylheptanol, 2-hydroxyacetophenone, 2-methyl 5-cyclohexylpentanol, 3-hydroxypropyl 2-hydroxybenzoate, 4-hydroxyacetophenone, and any mixture thereof.

18. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 17, further comprising at least one excipient and / or cosmetic or pharmaceutical active substance selected from the group consisting of carriers, oil components, rheological additives, hydrotropes, solubilizers, powders, film formers, water resistance improvers, skin moisturizing and / or water retention substances, emollient substances, physiological cooling agents, antioxidants, anti-skin aging agents, matrix-metalloproteinase inhibitors (MMPI), anti-inflammatory agents, TRPV1 antagonists, emulsifiers, preservatives, antibacterial or antifungal active substances, chelating agents, surfactants, fragrances / fragrances or perfume oils and any mixtures of two or more of the above substances.

19. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 18 in the form of: (i) dispersions, preferably wherein the cosmetic or pharmaceutical preparation is in the form of an emulsion, in particular an O / W emulsion, a W / O emulsion, a multiple emulsion, an aqueous dispersion gel, a balm, a water-in-oil (W / O / W) or oil-in-water (O / W / O) multiple emulsion, a PIT emulsion, a Pickering emulsion, a microemulsion, a liquid, a lotion, a suspension, an emulsion, an ointment, a paste, a gel, a cream-based, an oil-based or a liposome-based formulation or an aerosol such as a foam and a spray, including all types of silicone-based emulsions; (ii) anhydrous preparations; or (iii) an aqueous or aqueous / alcoholic solution, preferably an aqueous / ethanolic solution, or an aqueous / glycolic solution, or an alcohol / glycol solution, preferably an ethanol / glycol solution.

20. A sunscreen product, cosmetic or pharmaceutical preparation or household care product according to any one of claims 1 to 19, as a cosmetic, for personal care, in particular for skin, hair, scalp or nail care, as a medicament, for animal care or household care.

21. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 20, wherein the SPF is increased by at least 5%, preferably at least 10%, more preferably at least 20% relative to a sunscreen product, cosmetic or pharmaceutical preparation or home care product not containing the mycosporin-like amino acid compound (b); and / or wherein the UVA-PF is increased by at least 5%, preferably at least 10%, and more preferably at least 15% relative to a sunscreen product, cosmetic or pharmaceutical preparation or home care product not containing the mycosporin-like amino acid compound (b).

22. Use of a mycosporin-like amino acid compound as defined in any one of claims 1 to 11 or a mixture thereof for increasing the SPF and / or UVA photoprotection (UVA-PF) of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising at least one organic UV filter.

23. A method for enhancing or boosting the SPF performance and UVA photoprotection (UVA-PF) of a sunscreen product, cosmetic or pharmaceutical preparation or home care product comprising at least one organic UV filter, said method comprising adding to said sunscreen product, cosmetic or pharmaceutical preparation or home care product an effective amount of a mycosporin-like amino acid compound as defined in any one of claims 1 to 11 or a mixture thereof.

24. A method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin by topically applying a sunscreen product, cosmetic or pharmaceutical formulation or home care product according to any one of claims 1 to 20.

Images